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ABSTRACT
Although much is now known of the cellular actions of exogenous opiate drugs and of
endogenous opioid peptides, how these compounds modify interconnecting neuronal
systems in the CNS is still poorly understood. The studies described in this thesis have
addressed the latter by employing the antibody microprobe technique (Duggan A.W. and
Hendry I.A., 1986, Neurosci. Letts. 68, 134-140) to investigate (a) the release of dynorphin
A(l-8) in the spinal cord of the rat as inflammation develops in peripheral tissues, and (b)
the release of cholecystokinin, a putative 'anti-opioid' neuropeptide, in the rat spinal cord
following the administration of morphine.
(a) A dramatic increase in the spinal synthesis of prodynorphin derived peptides has
been observed when inflammation develops in peripheral tissues. The functional
significance of this increased synthesis is unclear and there have been no reports of the
stimuli needed to produce dynorphin release in vivo nor of possible controls of such release.
Microprobes bearing immobilised antibodies to the dynorphin A(l-8) derivative of
prodynorphin, were inserted into the lumbar spinal cord of urethane anaesthetised normal
rats and those with a peripheral inflammation, to determine whether dynorphins are being
tonically released and how release is altered by manipulating the inflamed tissues. In the
absence of any active peripheral stimulus the antibody microprobes detected minimal
amounts of immunoreactive (ir)-dynorphin A(l-8) in two areas (lamina I and laminae IV-V)
in the dorsal horn of the spinal cord of normal rats. With the development of unilateral
ankle inflammation over 3 to 5 days, following subcutaneous injections of Freund's
complete adjuvant, this was extended to the ventral horn of both sides of the spinal cord.
Lateral compression of the ankles of the normal animals did not release ir-dynorphin A(l-8)
during the period of stimulation, but this neuropeptide was detected in the ventral horn
following the stimulus. By contrast, compression of inflamed ankles produced elevated
levels of ir-dynorphin A( 1 -8) during the period of stimulus application at three major sites
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in the spinal grey matter. The largest peak was in the deep dorsal horn/ upper ventral horn
(laminae VI -VII), with further sites of significant release in the mid dorsal horn (laminae
II-V) and the lower ventral horn. These levels persisted for at least one hour after the
period of stimulation. At a cellular level dynorphins reduce transmitter release from nerve
terminals, and hence the observation that ir-dynorphin A( 1 -8) is released in the ventral and
deep dorsal horn in addition to the superficial dorsal horn of the rat by manipulation of
inflamed tissues, implies that wide-spread spinal inhibitory controls of spinal neuronal
firing are evoked by such stimuli. This may ultimately affect the perception of pain, but
release in the ventral horn suggests an involvement in reducing motor responses to
peripheral noxious stimuli.
(b) Of all possible candidates at the spinal cord level, the 'anti-opioid' activity of
cholecystokinin (CCK) has been well characterised. This peptide has also been proposed to
play a role in the development of tolerance to but not dependence on opiate drugs. Although
the hypothesis that stimulation of opioid receptors may trigger a progressive compensatory
increase in the activity of CCK containing neurones at the spinal cord level has received
some indirect support, this has not been thoroughly investigated. Conflicting data have been
obtained from experiments which have examined the spinal cord content of CCK and spinal
release of CCK following the administration of opioids. Microprobes bearing immobilised
antibodies to CCK-8, were inserted into the lumbar spinal cord of urethane anaesthetised
normal rats under both basal conditions and following acute opiate administration. In the
absence of any active peripheral stimulus an extensive presence of ir-CCK was detected in
normal (drug naive) rats with three main zones. The largest peak was in the mid to deep
dorsal horn/ upper ventral horn (laminae III -VII), with further major sites in the superficial
dorsal horn (lamina I-II) and the mid/ lower ventral horn. Morphine administered
intravenously over two hours (total dose 25mg/ kg) failed to alter this basal presence of ir-
CCK. Enhanced release however, was observed in areas of the ventral horn of rats treated
acutely with morphine following lmg/ kg injections of naloxone. It is proposed that the
ii
occupation of opioid receptors by morphine triggers the increased synthesis of CCK and
predicted that following the development of tolerance to morphine, enhanced CCK release
will be observed in the absence of naloxone administration.
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Throughout this thesis the term 'opioid' has been used for all ligands (peptide and
non-peptide) producing effects at the p., 8 and k 'opioid receptors', with a distinction made
where considered necessary for the naturally occuring 'endogenous' opioid peptides. The
term 'opiate', in contrast has only been applied to those ligands with a morphine-like
structure (i.e. protonated amine juxataposed to an aromatic ring).
Additionally unless otherwise stated 'CCK' refers to CCK-immunoreactivity or the
sulphated octapeptide CCK-8, the most common derivative of procholecystokinin present in
the vertebrate brain and spinal cord, including the rat
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CHAPTER 1: General Introduction
1.1 OPIATES. OPIOID PEPTIDES AND OPIOID RECEPTORS: A HISTORICAL
PERSPECTIVE
It is indeed a reflection of the achievements of modem pharmacology that over the past 20
years the mechanism of action of a group of compounds that have been in use for thousands of
years, the 'opiates', have only now become to be significantly understood (recently reviewed by
Snyder, 1986; Brownstein, 1993).
Opium is the Greek name given to the liquid ('opos') that appears on the unripened capsule
of the poppy plant Papaver somniferum (Latin for the 'poppy that brings sleep') when it is
notched. Writings of its use date back to at least the end of the third millennium B.C., the
Sumerians of the Middle East being the first to cultivate the poppies, initially for use as a
euphoriant in religious rituals, and then later for medicinal purposes, a potent analgesic and
sedative. By the eighth century A.D., following the successful cultivation of large crops of the
poppy by the Turks, Arab merchants were trading in opium with the peoples of India and
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China. Between the tenth and thirteenth centuries opium use spread to all parts of Europe.
Opiate addition became an increasing problem, especially in China, where the practice of
smoking raw opium had begun in the mid seventeenth century after tobacco smoking was
banned. The availability of opium in Europe was limited until the eighteenth century, when
the British trade with India and the Far East increased, the trade they forced with the Chinese
culminating in the infamous 'Opium Wars'. Opium, however, only became a popular
recreational agent in Europe during the early nineteenth century. The British Romantic writer
Thomas de Quincey in his "Confessions of an English Opium Eater" (1821), provides an
informative account of addiction to laudanum, which was a popular camphorated tincture of
opium.
In 1806, a German scientist, Fredrich Serturner, isolated the active ingredient in opium.
This proved to be a potent alkaloid, which he named 'morphine' (after Morpheus, the Greek
god of dreams). This substance was to transform the practice of medicine, as well as the
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experience of drug addition, especially following the development of the hypodermic syringe
and the hollow needle in the 1850s, which meant that morphine could be injected directly into
the bloodstream to produce a much more rapid and reliable effect than when taken orally. It
began to be used for more surgical procedures, for post-operative and chronic pain, and as an
adjuvant to general anaesthesia. The widespread use of injectable morphine as a painkiller in
the American Civil War and Franco-Prussian war, resulted in so many veterans returning
home as addicts, that addiction to morphine become known as the 'soldier's disease'. Efforts
made to develop a more effective but less addictive opiate, were not successful, the Bayer
group in 1898, introducing Heroin (diacetylmorphine) as a 'non-addicting' cough medicine.
The addition of the two acetyl groups to morphine to form Heroin, increases the lipophilicity
of the drug, enabling it to cross the blood-brain barrier more quickly than morphine, and so
result in a more intense 'rush' of euphoria. In 1939, meperidine (Eisleb and Schaumann,
1939), the first opiate with a structure different from morphine was developed, atropine being
the start compound. This was followed in 1941 (Scott and Chen, 1941), by the synthesis of
methadone, which having a longer lasting effect compared to other opiates, was later used as a
substitute for heroin to treat addicts. In 1942, nalorphine (Weijlard and Erikson, 1942) the
first opiate with antagonist properties was produced, which although was later discovered to
also have agonist properties lead in 1961, to the discovery of the pure opiate antagonist
naloxone (Blumberg et al, 1961).
Endogenous opioid peptides and opioid receptors
By the late 1960's, it was becoming increasingly clear from the stereoselective
requirements of opiate agonists and mixed agonist-antagonists, that receptors for these
compounds must be present in the central nervous system (CNS). Initial attempts to
demonstrate the existence of these receptors with radiolabeled drugs were unsuccessful
(Goldstein et al, 1971). It was found that the relative affinities at which the opiate drugs
bound to nervous tissue did not parallel their relative pharmacological potencies as opiates.
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Due to the scarcity of opiate receptors in the brain, it was difficult to distinguish the binding
of an opiate drug to a specific (receptor) site from the vast 'noise' of the more numerous non¬
specific binding interactions. By relative simple modifications of the radioassay procedure to
increase the likelihood of detecting such specific binding, three groups (Pert and Synder, 1973;
Terenius, 1973; Simon et al, 1973) succeeded in demonstrating high affinity, saturable
binding sites for the opiate drugs in the CNS. These binding sites were also shown to have a
non-uniform distribution in the brain (Kuhar et al, 1973). The search for the possible
endogenous ligands of these receptors intensified.
In 1975, Hughes published that extracts of the pig brain contained activity which was
opiate-like in the sense of inhibiting stimulation-induced contractions of the guinea pig ileum,
and even more dramatically the mouse vas deferens, and that naloxone blocked these effects
(Hughes, 1975). The opiate-like substances responsible proved to be two pentapeptides, Tyr-
Gly-Gly-Phe-Leu (Leu-enkephalin) and Tyr-Gly-Gly-Phe-Met (Met-enkephalin), differing
only in one amino acid (Hughes et al, 1975). They were named 'enkephalin', (Greek for 'in the
head'), subsequently often referred to by the more general term 'endorphin' (endogenous
morphine-like substance). The enkephalins proved to be the first of a series of endogenous
opioid peptides to be isolated. In 1976, (3-endorphin, a 31 amino acid fragment of P*
lipotropin, that had been isolated from pituitary extracts several years earlier, was
demonstrated to have the Met-enkephalin sequence in its NH2-terminal, and to display high
affinity for brain opiate receptors (Li and Chung, 1976; Bradbury et al, 1976; Chretien et al,
1976). Another group of potent peptides having opioid activity by bioassay was identified
shortly afterwards and named the 'dynorphins' (from the Greek prefix 'dyn' signifying 'strength'
or'power'; Goldstein et al, 1979; 1981).
All the opioid peptides isolated were found to contain the NH2-terminal pentapeptide
amino acid sequence Tyr-Gly-Gly-Phe-X (where X = Met or Leu), and in mammals, belong to
one of three families of peptides, derived from separate precursor proteins, referred to as
proopiomelanocortin [POMC] (bovine: Mains et al, 1977; Roberts and Herbert, 1977;
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Nakanishi et al, 1979. human: Whitfield et al, 1982. rat: Drouin and Goodman, 1980),
proenkephalin [proEnk] (bovine: Noda et al, 1982; Gubler et al, 1982. human: Comb et al,
1982. rat: Rosen and Douglass, 1984.) and prodynorphin [proDyn] (porcine: Kakidani et al,
1982. human: Horikawa et al, 1983. rat: Civelli et al, 1985), encoded by individual genes, as
confirmed by the subsequent cloning of the complementary DNA (cDNA) sequences of these
opioid peptides (Weber et al, 1983).
That there were many potential ligands argued that there might be more than one opioid
receptor. This had previously been proposed earlier by Martin and co-workers on the basis
that naloxone showed different pA2 values in antagonising the effects of different opiates in
suppressing flexor reflexes in the chronic spinal dog, and that tolerance to one group did not
result in cross tolerance to another class of opiates. The existence of three types of receptor
was proposed and the types were named after the drugs that identified them; i.e. p. (morphine
sensitive), K (ethylketocyclazocine sensitive) and c (SKF10047 or /V-allylnormetazocine
sensitive) (Martin et al, 1976). From studies on the mouse vas deferens bioassay, Kosterlitz
and co-workers (Lord et al, 1977) suggested the existence of yet another receptor type, 8 (for
deferens), possessing a high affinity for the enkephalin peptides. They found that although the
enkephalins were less effective than morphine in inhibiting the electrically induced
contractions of the guinea pig ileum, they were more potent in inhibiting contractions of mouse
vas deferens, this inhibition also being comparatively insensitive to naloxone. Similar work on
the rat vas deferens led to the postulation of the £ receptor, which although has a high affinity
for (3-endorphin displayed a different pharmacological profile from the p, 8 and k receptors
(Wuster et al, 1978). Attempts to purify the opioid receptors to homogeneity were thwarted
for many years due to their paucity in most tissues and their lability after detergent
solubilization (Loh and Smith, 1990). As such the p, 8 and K opioid receptors have only
recently been cloned (p: Chen et al, 1993; Wang et al, 1993; Thompson et al, 1993. 8: Evans
et al, 1992; Kieffer et al, 1992, Knapp et al, 1994. k: Yasudaetal, 1993; Meng et al, 1993;
Minami et al, 1993; Mansson et al, 1994). These opioid receptors, as had been predicted
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from biochemical and pharmacological studies, and by inference to other more fully
characterised receptors, are guanine nucleotide binding (G)-protein coupled receptors,
members of the rhodopsin receptor superfamily with seven transmembrane spanning domains,
that appear to mediate their intracellular effects partially through the inhibition of adenylate
cyclase.
Other groups of peptides have been described to exert effects at the p, 8 and k opioid
receptors, which have been collectively referred to as 'atypical' opioid peptides
(Teschemacher, 1993). These peptides derived from precursor proteins other than POMC,
proEnk and proDyn, have only a tyrosine residue in common, and in contrast to the 'typical'
opioid peptides, often display extensions of sequence beyond this NH2-terminal tyrosine
residue, Tyr-X-X-X-X. Such 'atypical' opioid peptides include the (3-caseomorphins generated
by the proteolysis of the milk proteins (3-casein (Bront et al, 1981), and the 'dermorphins'
(dermal morphine-like substance; Montecucchi et al, 1981) and 'deltorphins' (8 specific
ligands; Kreil et al, 1989) secreted from the skin glands of Phyllomedusa amphibians. These
Phyllomedusa peptides are quite unusual in that they contain d-amino acids, which have never
before been found for natural peptides and which likely confers peptide stability. Along with
these peptide ligands, there is also evidence that morphine may be synthesised endogenously.
Initially isolated from toad skin (Oka et al, 1985), this alkaloid has also been found, though in
very low concentrations, in mammalian tissue, including parts of the brain (Goldstein et al,
1985). However, whether this morphine is of dietry origin or represents true endogenous
synthesis is unknown.
More recently the screening of genetic libraries has yielded numerous cDNA sequences
which share considerable homology to members of recognised supergene families but with no
known biological activity, the so-called 'orphan' proteins. Such screenings have notably
identified a G-protein coupled receptor that is particularly abundant in the CNS, whose amino
acid sequence closely resembles that of the p., 8 and k opioid receptors, named amongst others
ORL, (Mollereau et al, 1994) and LCI23 (Bunzow et al, 1994). However, despite this
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homology and being negatively coupled to adenylate cyclase, known opioid peptides or ligands
do not appear to activate this receptor. A putative ligand for this receptor has been recently
isolated from both rat (nociceptin; Meunier et al, 1995) and porcine (orphanin FQ; Reinscheid
et al, 1995) brain. The peptide isolated displays a high degree of structural similarity to the
opioid peptides, particularly the dynorphins, but appears to be pharmacologically and
physiologically distinct, inducing hyperalgesia when administered intracerebroventricularly
(i.c.v.) in mice.
1.2. OPIOID NEURONES: OVERVIEW OF PEPTIDE SYNTHESIS AND
METABOLISM
Opioid peptides, like most peptide neurotransmitters and hormones known, are not
synthesised directly but derived by the enzymatic cleavage of larger and generally inactive
precursor polypeptides. The general stages involved in the neuronal synthesis of the opioid
peptides are illustrated on figure 1. The gene encoding a particular family of opioid peptides
is transcribed into messenger RNA (mRNA) in the nucleus of the opioid synthesising neurone,
which in turn is translated into the characteristic pre-propeptide sequence by ribosomes on the
surface of rough endoplasmic reticulum in the cell body. Each pre-propeptide sequence
contains a hydrophobic NH2-terminai signal sequence, that identifies the peptide as being
destined for secretion, and directs its passage into the lumen of the endoplasmic reticulum,
where it is then removed by a signal peptidase. The remaining propeptide is then directed to
the Golgi apparatus, where it is moves from cis- to trans- Golgi compartments and to the
rrans-Golgi network by a series of vesicle fusion and budding steps. From within the trans-
Golgi network the peptides are packaged into secretory granules (visualised as large dense
core vesicles) and transported along the axon to the nerve terminal. Further biosynthetic
processing occurs in the Golgi region as the secretory granules are forming and in the newly
formed vesicles, involving cleavage of the peptide chain and
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FIGURE 1. General stages involved in the neuronal synthesis of opioid peptides. The DNA
encoding an opioid precursor is transcribed into mRNA in the nucleus of the opioid
synthesising neurone (1). This mRNA is then translated by ribosomes on the surface of the
rough endoplasmic reticulum to form a pre-propeptide (2). The NH2"terminal signal peptide
directs the passage into the lumen of the endoplasmic reticulum, where it is subsequently
removed. The propeptide is then transported to the Golgi apparatus (3) where it is packaged
into secretory granules (large dense core vesicles) (4). These are transported along the axon to
the nerve terminal (5). During stages (4) and (5) the propeptide is subjected to various
proteolytic steps and post-translational modifications to yield one or more biologically active
peptides. These peptides are then released following an appropriate stimulus into the synaptic
cleft by exocytosis (6).
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modification of individual amino acid residues (as reviewed by Dockray, 1990; Bean et al,
1994). Sequential cleavage of the opioid family propeptide by a variety of endopeptidases
(e.g. prohormone converting (PC) enzymes PCI and PC2/PC3, adrenal trypsin-like enzyme,
furin, dynorphin converting enzyme) yields one or more biologically active peptides. These
endopeptidases selectively cleave the precursor at specific sites. Commonly, dibasic residues
such as Lys-Arg, Arg-Arg, and Lys-Lys signal specific cleavage sites. However, not all such
sites appear equally susceptible to processing indicating that the amino acids surrounding
these residues must also confer some selectivity. Additionally a single arginine residue can
often signal enzymatic cleavage, as in the case of prodynorphin processing. Following the
action of the endopeptidases, a carboxypeptidase (e.g. carboxypeptidase E/H or enkephalin
convertase) is required to remove the basic cleavage site residues from the COOH-terminus of
the peptides (as reviewed by Dockray, 1990; Fricker et al, 1993). The timing of these
cleavage events are crucial in determining whether the products will be packaged together or
separately. If the cleavage takes place before packaging the resulting peptides may reside in
distinct vesicle populations, whereas cleavage after packaging will result in colocalisation
within the same vesicle, and hence corelease (Bean et al, 1994). In addition to these
proteolytic steps some opioid peptides undergo other post-translational modifications in the
endoplasmic reticulum or Golgi apparatus that may be required for the biological activity and/
or stability of the peptide. These include glycosylation, sulphation, phosphorylation, NH2-
terminal acetylation and COOH-terminal amidation (as reviewed by Mains et al, 1983;
Dockray, 1990; Fricker et al, 1993).
Following release by exocytosis the activity of neuropeptides is terminated, in general, not
by reuptake but by membrane bound peptidases that hydrolyse the active peptide to an
inactive form. For the opioid peptides these include the ubiquitous relatively non-specific
aminopeptidases, that inactivate the peptides by removing the NH2-terminal tyrosine, as well
as endo- or carboxy-peptidases (e.g. neutral endopeptidase[E.C.3.4] 24.11 or
'enkephalinase'). In addition to this degrading process, active peptides may also be converted
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into smaller fragments with retained or changed biological activity. These so-called
neuropeptide converting enzymes, capable of releasing bioactive fragments from their
substrate peptides have been identified in various CNS tissues. For example, angiotensin
converting enzyme converts Met-enkephalin-Arg-Phe to Met-enkephalin, metallo-
endopeptidase 24.15 processes several precursors into Met- and Leu-enkephalin, and the so
called 'dynorphin converting' enzymes convert prodynorphin derivatives especially dynorphin
B( 1-13) into Leu-enkephalin-Arg6 (as reviewed by Dockray, 1990; Fricker et al, 1993;
Persson et al, 1995; Csuhai et al, 1995).
Most, if not all, these intracellular and extracellular processing stages, appear to be open
to modification, hence allow for a very 'plastic' system. The consequences of this for opioid
neurotransmission will be highlighted in the following sections that discuss the multitude of
opioid peptides synthesised and functionally active in the mammalian CNS. The extent of
proteolytic processing and the peptide products ultimately released, appears to largely depend
on the neurones in which they are localised, the physiological state of these neurones and their
recent secretory demands. Since differential processing may lead to opioid peptides with
distinct biological activity, the processing enzymes involved play a key role in opioid neuronal
systems. However, it should be noted that most of these processes have been studied by in
vitro methods using brain homogenates, and although immunocytochemical techniques have
been used to identify the putative opioid neuronal products in situ, comparatively little is
known of the extent to which these processes actually occur in vivo. Most of the enzymes
reported to be involved in the biosynthesis and metabolism of the opioid peptides are also
involved with processing other peptides.
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1.3 OPIOIDS I: MULTIPLE OPIOID PEPTIDES AND OPIOID RECEPTORS
1. MULTIPLE OPIOID PEPTIDES
The majority of mammalian opioid peptides have been found by recombinant DNA
techniques to be derived from three separate precursor polypeptides, POMC, proEnk and
proDyn. The structure of these pre-propeptides along with their putative processing products
are illustrated in figure 2. Though genetically distinct these precursors show a striking
homology both at the genomic and pre-propeptide level, suggestive of a common ancestral
gene, with translated regions being highly conserved throughout the hierarchy of species down
to amphibia (Hollt et al, 1993). Each gene encoding a family of opioid peptides appears to be
expressed uniquely, there being practically no examples of where opioid peptides from several
genes are expressed in the same cell (Terenius, 1992). All three opioid peptide precursors can
generate opioids of varying amino acid chain length. These proteolytic processing patterns
appear to be differentially regulated in different tissues (Weber et al, 1983).
Proopiomelanocortin (POMC) is unique in that it contains only one copy of an opioid
active peptide, (3-endorphin ((3-end). It is also unique in encoding other biologically active
peptides, adrenocorticotrophic hormone (ACTH), corticotropin-like intermediate lobe peptide
(CLIP), a-, (3-, y- melanocyte stimulating (MSH) and y-, P- lipotropin (LPH) hormones. The
proteolytic processing of POMC was initially analysed using pituitary tissue. It has been
shown that POMC undergoes more cleavages and its products more post-translational
modifications in the intermediate lobe than in the anterior lobe of the pituitary. In general the
processing of POMC in the brain appears to be similar to that found in the intermediate
pituitary, although less extensive in caudal brain regions. The cleavage of P-lipotropin to P-
endorphin (1-31) is virtually complete in all rostral brain regions, with further cleavage to p-
endorphin (1-27) and P-endorphin (1-26) also occurring to a significant extent in certain
regions, notably the amygdala, hippocampus and nucleus accumbens. However, the
I 1
FIGURE 2. Schematic representation of the structure of the three opioid peptide precursors.
Potential cleavage sites at dibasic amino acid residues on POMC (bovine), proEnk (bovine)
and proDyn (porcine) are indicated along with known peptide products. Adapted from Millan
et al (1986).
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NH2-terminal acetylation of (3-endorphin, which leads to a complete loss of its activity at
opioid receptors, is much less pronounced in the brain than the pituitary. There is also debate
whether other possible derivatives of (3-endorphin, a-endorphin [p-endorphin (1-16)] and y-
endorphin [P-endorphin (1-17)] are physiological cleavage products of POMC (as reviewed
by Weber at al, 1983; Khachaturian et al, 1985a; b; 1993; Hollt, 1986; 1993; Millan, 1986;
Young et al, 1993).
Proenkephalin (proEnk) in contrast, encodes for several peptides containing the opioid
active core sequence, Tyr-Gly-Gly-Phe. These include four copies of Met-enkephalin [ME],
one copy of Leu-enkephalin [LE] and one copy each of the COOH-terminally extended
peptides the heptapeptide, Met-enkephalin-Arg-Phe [MERF], and the octapeptide, Met-
enkephalin-Arg-Gly-Leu [MERGL], Other possible opioid peptides include the large
enkephalin containing peptides, peptide E and its COOH-terminal derivatives, metorphamide
[adrenorphin; Met-enkephalin-Arg-Arg-Val-NH2] and the BAM peptides [12P, 18P, 22P], as
well as peptide F and amidorphin [peptide F(1-26)NH2]. The proteolytic processing of
proEnk was initially analysed in the adrenal medulla. In general, the processing of proEnk
appears to be more complete in the brain, with free enkephalins forming the predominant
products (as reviewed by Weber et al, 1983; Petruz et al, 1985; Millan, 1986; Khachaturian et
al, 1985b; 1993; Hollt, 1986; 1993; Rossier, 1993)
Prodynorphin (proDyn) encodes several active opioid peptides, which are all COOH
terminal extensions of Leu-enkephalin. The cleavage of proDyn at Lys-Arg sites results in the
formation of dynorphin A( 1 -17), dynorphin B(l-29) [leumorphin], a- and (3-neoendorphin,
whilst additional cleavage at certain arginine sites results in the production of
dynorphin A(l-8), dynorphin B( 1-13) [rimorphin] and dynorphin AB(l-32) ['big dynorphin'].
The proteolytic processing of proDyn has been extensively analysed using brain and pituitary
tissue. Whereas dynorphin A( 1-17) and dynorphin A(l-8) occur in similar amounts in
posterior pituitary, dynorphin A(l-8) has been found to be the predominant peptide in the
brain, particularly in the striatum and midbrain. Similarly dynorphin B(l-29) appears to be
14
completely processed to give dynorphin B( 1-13). Although a-neoendorphin is a more
common cleavage product since the Pro-Lys bond at the carboxy terminus of P-neoendorphin
very resistant to proteolysis, significant quantities of P-neoendorphin are found in the
hypothalamus and posterior pituitary. Other possible dibasic cleavage sites involving lysine
and arginine do not appear to be responsible for the formation of proDyn peptides. Thus,
although there are Arg-Arg sites that if cleaved would result in the formation of Leu-
enkephalin, these sites appear to be rarely if ever used, with any Leu-enkephalin found in the
brain and pituitary being commonly also localised with Met-enkephalin (as reviewed by
Weber et al, 1983; Khachaturian et al, 1985, 1993; Hollt, 1986; 1993; Millan, 1986; Fallon
and Ciofi, 1990; Day et al, 1993)
2. MULTIPLE OPIOID RECEPTORS
Although the existence of many types of opioid peptide binding sites have been postulated,
only the p., 8 and k have been shown by ligand binding autoradiography, and more recently
studies employing antibodies to defined sequences of the cloned receptors, to exist as discrete
opioid receptors in the mammalian CNS. The postulated o receptor appears not to be an
opioid receptor in the strict sense, since its mediated effects are not reversed by even very high
concentrations of opioid antagonists, such as naloxone, and it also appears to be activated by
the phencyclidines, another class of abused drugs (Zukin et al, 1984). As for the e receptor,
the question of whether this receptor type is present in the CNS has not yet been resolved,
although it has recently been reported that such sites may have previously been classified as k
receptors (Nock et al, 1990).
Although opioid peptides were discovered due to their similarity to opiate-like compounds,
there are substantial differences. Whereas morphine and its analogues are relatively selective
for p. receptors, the endogenous opioid peptides tend to show a relatively poor preference for
any one opioid receptor type (as will be discussed in detail in section 1.4). Likewise naloxone,
whilst predominantly active at p receptors has also some affinity for the other opioid receptor
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types. A number of agonists and antagonists have been developed over recent years, that have
a high affinity and/ or degree of selectivity for each opioid receptor type, as indicated on table
1. These have proved useful tools for investigating the functions of these receptors, especially
those non-peptide ligands, which since they are relatively resistant to peptidase degradation,
display prolonged biological activity. The use of some of these compounds in ligand binding,
pharmacological and behavioural studies, have suggested that subtypes of the p., 8 and k
receptors exist (recently reviewed by Adler et al, 1990; Simon and Gioannini, 1993;
Pasternak, 1993; Wollemann et al, 1993).
The p receptor has high affinity for (a) the peptide agonists DAMGO (an analogue of
enkephalin), morphine and its analogues such as ohmefentanyl, the naturally occurring
morphiceptin and its analogue PL017, and the dermorphins; (b) the competitive antagonists:
naltrexone and its analogue naloxonazine, and CTOP; and (c) the irreversible antagonist (3-
FNA. From early pharmacological and behavioural studies a Pj subtype of receptor was
proposed that binds morphine and enkephalins with a similar high affinity, in contrast to the
P2 subtype at which enkephalins have a reduced affinity (Wolozin and Pasternak, 1981).
These receptor subtypes have also been proposed to be distinguishable using the antagonist
naloxonazine which displays some selectivity for the putative p, subtype (Pasternak and
Wood, 1986). However, the possibility that such a differentiation may simply reflect the
binding of ligands to complexes of p and 8 receptors cannot be discounted from the findings of
such studies. There is no evidence to date for such subtypes from cloning studies.
The 8 receptor has high affinity for (a) the peptide agonists DPDPE, DPLPE, DTLET,
DSLET and DSBuLET (all analogues of enkephalin), the naturally occurring deltorphins, [d-
Ala2]deltorphin I and II; and (b) the antagonists ICI-174864, BNTX (an analogue of
naltrexone), naltrindole and its analogues NTB and 5'-NTII. Subtypes of the 8 receptor have
also been proposed from behavioural and pharmacological studies. Whereas the 8, subtype
appears to be activated by DPDPE and blocked by BNTX but not NTB or 5'-NTII, the 82
16
TABLE 1. Selective ligands for opioid receptors. Agonists and antagonists developed to
study the distribution and function of the different types of opioid receptor are listed, with the
principal investigators responsible for the development of each ligand quoted in brackets (see























































































































































subtype is activated by [D-Ala2]deltorphin II, and blocked by NTB and 5'-NTII (Jiang et al,
1991; Mattia et al, 1991; Sofuoglu et al, 1991; Portoghese et al, 1993).
The K receptor has high affinity for (a) the benzeneacetamide agonists U50488H,
U69593, PD117302 and CI977; and (b) the antagonist norBNI (an analogue of naltrexone).
Subtypes of the k receptor were suggested initially from the differing binding of DADLE and
dynorphin A (Attalli et al, 1982; Morre et al, 1983), but more recently from that of the
benzeneacetamide compounds (Su et al, 1985; Zukin et al, 1988; Hunter et al, 1989). The k,
subtype binds DADLE, dynorphin A and the benzeneacetamide agonists, in contrast to the k2
and k3 sites which display a relatively low affinity for these compounds, the k3 sites being
distinguished using the naloxone derivative NalBzoH (Clark et al, 1989). However, there is
debate as to whether the k3 subtype is not simply an isoform of a p. receptor, since it also
displays a high affinity for p selective agonists (Wollemann et al, 1993)
The recently cloned p, 8 and k opioid receptors have been found to be highly homologous
to one another both at a nucleic acid and amino acid level (recently reviewed by Uhl et al,
1994; Reisine, 1995; Pasternak and Standifer, 1995). The receptors appear highly conserved,
the rodent (both mouse and rat) and human receptors that have been cloned displaying very
similar amino acid sequences and ligand selectivities. They appear to form a subclass of the
rhodopsin superfamily of seven transmembrane domained, G-protein coupled receptors, with a
high sequence similarity to the somatostatin receptors. The rodent p, 8 and K receptors are
approximately 65% identical in amino acid sequence, with the highest similarity in the
transmembrane spanning regions and intracellular loops (Reisine and Bell, 1993). The
pharmacological profiles of these cloned receptors have been shown to be very similar to that
of the endogenously expressed receptors, in particular the putative p2, 82 and
K, receptors (Raynoretal, 1994).
Further evidence to support the existence of the 8 receptor subtypes in vivo has been
provided by behavioural studies employing antisense oligodeoxynucleotides to the putative
cloned 82 receptor. Whereas the intrathecal (i.t.) administration of the antisense probes to the
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spinal cord was found to block the ability of both DPDPE and deltorphin II to induce
analgesia (Standifer et al, 1994), the administration of these oligonucleotides i.e.v. was found
to prevent only the deltorphin II induced analgesia, indicating an involvement of both the 8
receptor subtypes at supraspinal sites (Lai et al, 1994). It is likely that similar investigations
will proved fruitful to further discriminate subtypes of the p. and K receptors.
1.4 OPIOIDS II: OPIOID PEPTIDE-RECEPTQR INTERACTIONS
Despite the opioid peptides being synthesised from independent precursors, no clear
relationship between an opioid peptide family with a specific type of receptor appears to exist.
The presence of the identical NH2-terminal tetrapeptide sequence, places inherent limitations
on the receptor selectivity of endogenous opioid peptides. Although early in vitro binding and
pharmacological studies did reveal some selectivity of the p. receptors for the [3-endorphins,
the 8 receptors for the Met- and Leu-enkephalins and the K receptors for the dynorphins, these
relationships are not exclusive. The (^-endorphins derived from POMC display similar
affinities for the p and 8 binding sites, and peptides are derived from proEnk and proDyn that
can interact with all three opioid binding sites (Akil et al, 1981; Quirion and Pert, 1981;
Wuster et al, 1981; Corbett et al, 1982; Magnan et al, 1982; Oka et al, 1983; Quirion and
Weiss, 1983; Goldstein and James, 1984; Chavkin et al, 1985). Thus, any peptide selectivity
appears more intimately related to the extent of peptide processing rather than the precursor
from which it is derived.
Table 2 compares the binding relationships between some of these opioid peptides and the
p, 8 and K sites and figure 3 illustrates the peptide sequences. Since most early binding
studies employed relatively non-selective radiolabelled ligands such as [3H]-dihydromorphine,
[3H]-DADLE and [3H]-ethylketocyclazine (EKC), and a variety of different tissue
preparations, the data presented on table 2 is derived from a recent review by Corbett et al
(1993) that considered only those inhibitory binding constant (K;) values for peptide binding
to homogenates of guinea pig brain determined using more selective ligands, such as
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TABLE 2. Relative affinities of POMC. proEnk and proDyn derived peptides at |li. 8 and k
opioid binding sites. The inhibitory effects (Kj, nM) of POMC , proENK and proDyn derived
peptides on the binding at p, 8 and k binding sites in homogenates of guinea-pig brain,
obtained from a review by Corbet et al (1993), are compared. The p binding sites were
labelled with [3H]-DAMGO or [3H]-morphine, the 8 sites with [3H]-DADLE or [3H]-DADLE
in the presence of PL017, and the k sites with [3H]-bremazocine in the presence of DAMGO
and DADLE or [3H]-EKC in the presence of PL017 and DSLET. The relative affinity at each
binding site was calculated using the equation Kj'(at p, 8 and k) -s- [K4"l(at p) + Kj"'(at 8) +
Kj~'(at k)]. Kj-1 is the affinity constant, the reciprocal of the apparent dissociation constant
inhibitory binding constant Kj (cited in brackets), determined from the IC50 values obtained












































































































































FIGURE 3. Comparison of opioid peptide sequences. Amino acid alignments of the opioid
peptides derived from the POMC, proEnk and proDyn opioid peptide precursors, as illustrated
in figure 2, and whose relative affinities at |i, 8 and K opioid binding sites are displayed on






























































[3H]-DAMGO and [3H]-DPDPE. The affinity of each opioid peptide for the different opioid
binding sites are compared in such a way that if a peptide interacts with only one binding site
it will have a relative affinity of 1 at that site, whereas if it interacts equally well with all three
binding sites it will have a relative affinity of 0.33 at each site. From table 2 both the long and
short forms of P-endorphin can be seen to have similar affinities for the p and 5 binding sites
with negligible affinity for k sites, the removal of four amino acids from the COOH-terminus
of (3-endorphin(l-31) to give P-endorphin(l-27) causing only a small reduction in affinity for
all three sites. By contrast, the opioid peptides derived from proEnk can be seen to display
marked differences in their relative affinities for the p., 8 and k binding sites. Whereas the
pentapeptides Met-enkephalin and Leu-enkephalin have high affinities for the 8 binding sites,
lower affinities for the p site and negligible affinity for the k site, extensions of Met-
enkephalin at the COOH-terminus can result in higher affinities at p and/ or k sites with either
little change or a reduction in 8 binding affinity. For example, extension of Met-enkephalin by
an arginine residue with metorphamide, BAM 12, BAM 18, BAM 22, and peptide E, leads to
a reduction in the affinity for the 8 sites and an increase of that for the p and k sites. Peptide
F with its Lys6-Lys7 extension by contrast displays comparatively little affinity for all three
opioid receptors. Thus, complete processing of proEnk into Met- and Leu-enkephalins is
associated with a change in binding preference towards the 8 sites. Similarly whilst the
proDyn peptides display a high affinity for k binding sites they also bind to p and 8 sites, the
smaller derivatives of proDyn, dynorphin A(l-8) and a-/ P-neoendorphin having a lower
affinity for the k site than the longer fragments, dynorphin A( 1-17) and dynorphin B( 1-13).
These opioid peptide-receptor associations are in general agreement with those determined
from pharmacological studies using a variety of smooth muscle assay systems (as reviewed by
Hollt, 1986; Corbett et al, 1993), each with a different pharmacological profile. For example
whereas the electrically evoked contractions of the mouse vas deferens are known to be
inhibited by p, 8 and k agonists, and those of the guinea-pig myenteric plexus-longitudinal
muscle by p and k agonists, those of the rat, rabbit and hamster vas deferens appear to
25
involve only one receptor type, being inhibited by (i, k and 5 agonists respectively (Smith and
Leslie, 1993; Corbett et al, 1993).
Further support for such interactions has been provided more recently by competition
studies examining the binding affinities of the newly cloned p, S, and k opioid receptors
expressed in transfected tumour Cos-1 cells (Mansour et al, 1995c). Of the three opioid
receptors the k receptor displayed the greatest degree of selectivity with respect to the
endogenous ligands tested with approximately a 2400-fold affinity range, in contrast to the
moderate (695-fold) and low range (20-fold) range of affinities of ji and 8 receptors
respectively for the same ligands. Importantly these studies also indicated how the
endogenous opioid peptide selectivity profiles between the p7 8 and k receptors may result.
This receptor discrimination appears to reside principally, with the k receptor having
additional sequence requirements, that the p and 8 receptors do not share. Based on the
findings of the early pharmacological studies of the potencies of dynorphin fragments,
receptor selectivity was proposed to be conferred by a 'message-address' configuration, the
'message' encoded by the tetrapeptide core sequence Try-Gly-Gly-Phe- and the 'address' by the
C-terminal extensions (Chavkin and Goldstein, 1981). Mansour et al (1995) however, have
proposed that whilst the Try-Gly-Gly-Phe-Met or -Leu peptide sequence is sufficient for p and
8 receptor binding, another core peptide sequence appears necessary to account for k receptor
affinity. In agreement with earlier studies (Chavkin and Goldstein, 1981; Corbett et al, 1982;
Magnan et al, 1982; Oka et al, 1982; 1983; Yoshimura et al, 1982), they found that
dynorphin A(l-8) appears to be the minimal sequence necessary to confer k receptor affinity
and selectivity, the longer forms appearing more potent due to their increased stability to
peptidase degradation. Whereas Corbett et al (1982), had found that the extension of the
COOH terminal sequence of Leu-enkephalin by the addition of an arginine in position 6,
resulted in a marked (approximately 35-fold) increase in k receptor affinity and a decrease in
8 affinity (approximately 8-fold), further accentuated by the addition of another arginine in
position 7, Mansour et al (1995) have proposed that a Try-Gly-Gly-Phe-Leu or -Met core
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and an Arg6-X7 extension (where X = Arg or Lys) is required to achieve high affinity binding
at the k sites.
Clues as to how such receptor discrimination may result, may be gained from the findings
of chimeric hybrid and site-directed mutagenesis studies of the cloned receptors. Whereas the
cloned opioid receptors are highly homologous to one another on an amino acid level, the more
limited selectivity range of the endogenous opioid peptides for the p. and 8 receptors,
especially (3-endorphin, suggests that these receptors may be more structurally similar to one
another than the k receptors. A schematic representation of an opioid receptor is illustrated on
figure 4. As indicated in section 1.3 the most divergent regions of the cloned receptors has
been shown to be the extracellular NH2- and intracellular COOH- termini, and the
extracellular loops (EC). Studies examining the binding properties of p-k and 5-k receptor
chimeras, have shown that k agonist selectivity is derived from the interaction with the fourth
transmembrane domain (TM) and EC2 (Kong et al, 1994a; Wang et al, 1994; Xue et al,
1994; Meng et al, 1995). In contrast the agonist selectivity of the p/ 5 receptors appears to
depend on interactions in the region of TM5 to TM7 domains, the 8 receptor additionally
requiring interactions with the COOH-terminal half of TM3 to EC2, while the p receptor
binding with the NH2-terminus half of TM3 (Fukuda et al, 1995; Meng et al, 1995).
Mutagenesis studies have also shown that the negative charges found in the EC2 loop of the k
receptor play a critical role. By interacting with the positively charged amino acids in
positions 6 and 7 of COOH-terminally extended enkephalin peptides, such as dynorphin, these
negative charges possibly serve to stabilise the peptide-receptor configuration, and hence
allow the peptides to fit into the k receptor binding pocket, in alignment to the NH2-terminal
tyrosine (Meng et al, 1993). Interestingly, such chimeric studies have shown that, in contrast
to the p, 8 and most other known receptors, the k receptor selective antagonists do not bind in
the region of this agonist recognition site, but instead interact with entirely separate sites
within the NH2-terminus of the receptor (Kong et al, 1994b). Reisine (1995) has proposed
that this NH2-terminus must be able to fold upon the k receptor, to move the separate
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FIGURE 4. Schematic representation of an opioid receptor, illustrating the different




recognition sites to be in close proximity, to allow for competition of agonist and antagonist
binding.
A physiological consequence of the ability of an opioid peptide to potentially stimulate
each class of opioid receptor, is that the functional expression of the activation of opioid
synthesising neurones is dependent not only on the final peptide(s) forms that are synthesised
and the concentrations following release, but also by the relative abundance of p, 8 and K
receptors present at the site of release.
1.5 OPIOIDS III: ACTIONS AT A CELLULAR LEVEL
Overall, opioids have been demonstrated to be inhibitory to neurotransmission, through a
depression of neuronal firing rate and a reduction of neurotransmitter release. Where
excitatory effects of opioids have been observed, for example in the olfactory bulb,
hippocampus, ventral tegmental area and substantia gelatinosa of the spinal cord, they have
been proposed to be the result of disinhibition (that is inhibition of inhibitory neurones)
(Duggan and North, 1984). A number of in vitro preparations have been employed to
investigate the actions of opioids at the cellular level. These include the guinea-pig myenteric
(primarily p and K receptors) and submucous plexuses (predominantly 8 receptors), the rat
locus coeruleus (primarily p receptors), various preparations of the spinal cord and dorsal root
ganglion (DRG), and neuroblastoma derived cell lines. These studies have shown the
activation of opioid receptors to result in at least one of three G-protein linked events, namely
an increase in an outward potassium conductance, a reduction in a voltage dependent calcium
conduction and an inhibition of the enzyme adenylate cyclase, each of which will now be
considered in turn (recently reviewed by McFadzean, 1988; Loh and Smith, 1990; North,
1993; and Childers, 1993).
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1. EFFECT OF OPIOIDS ON POTASSIUM CHANNELS
An increase in membrane potassium conductance following opioid administration has been
demonstrated directly by measurement of membrane reversal potentials under voltage clamp
conditions or indirectly via membrane resistance decreases and reductions in the opioid effect
by potassium channel blockers, such as tetraethylammonium (TEA), barium or caesium.
Increased potassium conductances have been observed following (a) p. receptor activation for
example, in the guinea-pig myenteric plexus (North and Tonini, 1977), both the guinea-pig
(Pepper and Henderson , 1980) and rat (Williams et al, 1982) locus coeruleus, the substantia
gelatinosa of the rat spinal cord (Yoshimura and North, 1983), and mouse DRG cells (Werz
and MacDonald, 1983); (b) following 8 receptor activation in the guinea-pig submucous
plexus (Mihara and North, 1986) and mouse DRG cells (Werz and MacDonald, 1983); and
more recently (c) following k receptor activation in the substantia gelatinosa of the guinea-pig
spinal trigeminal nucleus (Grudt and Williams, 1993).
Potassium channels can either be affected by membrane potential, by the binding of
intracellular messengers, or by both. Studies of the potassium conductance activated by
opioid peptides in the rat locus coeruleus and guinea-pig submucous plexus, have suggested
that an 'inwardly rectifying' type of potassium current is affected, the conductance becoming
larger as the membrane is hyperpolarised (North et al, 1987). However, evidence that other
potassium conductances can be affected has also been shown (North, 1993). Thus, there
appears to be no species of potassium channel that is uniquely opened by opioid action, rather
several distinct potassium channels can be activated. Pertussis toxin sensitive G-proteins,
possibly including G0, have been found to link the opioid peptides to these potassium
channels. It has been proposed that the G-proteins might bind directly to the voltage
dependent channels (Brown and Birnbaumer, 1990). The net result on the neurone of
increasing the potassium conductance is likely to be a hyperpolarisation and reduction in the
firing rate, whilst that on the terminal a reduction in calcium influx and an inhibition of
transmitter release (North, 1993).
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In some preparations, notably the locus coeruleus slice (Williams et al, 1982) and
substantia gelatinosa of the spinal cord (Yoshimura and North, 1983), hyperpolarisations
following opioid administration have been observed in a calcium-free medium, which implies a
direct postsynaptic effect. Such postsynaptic actions of opioids have implications for the
selective effects of opioids demonstrated in various parts of the CNS. For example, in the
spinal cord opioids have been found to selectively inhibit C but not A fibre evoked neuronal
activity (as will be discussed later in section 1.7).
2. EFFECTS OF OPIOIDS ON CALCIUM CHANNELS
p, 5 and k receptors also appear to suppress calcium conductances. The most abundant
type of calcium channels found in mammalian nerve cells are voltage dependent, classified as
L, N, and T, according to whether their conductances are of a large, intermediate or transient
nature. Reductions in a voltage dependent calcium conductance (independent of actions on
potassium channels), were observed under voltage clamp conditions initially for k receptors of
cultured mouse DRG neurones (MacDonald and Werz, 1986), but have since been
demonstrated (a) for p receptors of the human neuroblastoma cell line SH-SY5Y (Seward et
al, 1991) and adult rat dissociated DRG neurones (Schroeder et al, 1991); (b) for 5 receptors
of guinea-pig submucous plexus neurones (Surprenant et al, 1990); and (c) for k receptors in
rat cultured DRG (Bean et al, 1989) and spinal cord (Sah et al, 1990) neurones. Effects on
calcium channels have also been inferred from reductions in action potential duration observed
in the presence of voltage gated potassium channel blockers (Werz and MacDonald, 1985),
although possible contributions from unblocked residual potassium receptors cannot be
disregarded (North, 1993). From such studies on cultured DRG neurones has come the
somewhat surprising observation that low concentrations (nM) of specific opioid receptor
agonists (e.g. DAMGO, DPDPE or U50488H) may actually result in an prolongation of the
action potential duration, by a mechanism distinct from that responsible for inhibiting the
action at higher doses (pM) (Crain and Shen, 1990). However, support that this phenomenon
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actually occurs in vivo is lacking. The calcium current inhibited appears to be of the N type
(Seward et al, 1991; Surprenant et al, 1990). The opioid receptors appear to produce this
effect again directly via pertussis sensitive G-proteins (Brown and Birnbaumer, 1990). It has
been suggested that this G-protein binding may change the voltage dependent state of the
calcium channel, thereby reduce the probability that it will open with membrane depolarisation
(Bean et al, 1989). Whereas it has been proposed that such an action of opioids on calcium
channels could underlie the presynaptic inhibition of neurotransmitter release, it is also as
likely that an increased potassium conductance leading to earlier repolarisation and shorter
action potential duration could also be involved in mediating such an effect, as previously
described (North, 1993).
3. EFFECTS OF OPIOIDS ON ADENYLATE CYCLASE
Of all the second messenger systems which have been implicated with opioid receptor
function, the inhibition of adenylate cyclase mediated by the G-protein G;, is the best
characterised. Although the first reports of opioid-inhibited adenylate cyclase were from brain
membranes (Collier and Roy, 1974), much progress in understanding this mechanism has
come from studies employing transformed cell lines such as the NG108-15 neuroblastoma x
glioma hybrid cells (Sharma et al, 1975). This is now recognised as a sodium and pH
dependent mechanism to which all three opioid receptors may be coupled (Schoffelmeer et al,
1987; Chrieiweiss et al, 1988; Dunman et al, 1988; Attali et al, 1989) although the evidence
for the k receptors is somewhat controversial (Childers, 1993). However, the relationship
between opioid-inhibited adenylate cyclase and opioid-inhibited neurotransmitter release is
unclear, most electrophysiological evidence to date suggesting that cyclic AMP plays no direct
role in the effect of opioids on potassium and calcium conductances (Childers, 1993; North,
1993). For example, opioid responsive potassium (North et al, 1987) and calcium (Gross et
al, 1990) currents recorded under whole cell voltage clamp conditions have been found to be
unaffected by several procedures likely to enhance or mimic the actions of cyclic AMP, such
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as the intracellular administration of forskolin or the catalytic subunits of cyclic AMP-
dependent protein kinase (protein kinase A). An exception maybe the spinal cord, since
evidence has been presented that the excitatory opioid effects on calcium conducance of mouse
DRG cultures may be mediated by phosphorylation with protein kinase A via the G-protein Gs
(Chen et al, 1988). Instead it has been proposed that opioid-inhibition of adenylate cyclase
may play more of a long term regulatory role in modulating neuropeptide synthesis and
receptor function, several neuropeptide genes, including proEnk, containing cyclic AMP-
responsive promoter elements (CRE) and most G-protein coupled receptors, including opioid
receptors, being regulated by phosphorylation (Childers, 1993).
The distinction between the opioid receptors at the cellular level is far from clear, no
class of opioid receptor appears to be uniquely associated with a given ion channel or second
messenger system, the p., 8 and K opioid receptors having now been described to have effects
on both potassium and calcium conductances. This along with evidence that these receptors
can co-exist on the same neurone (e.g. DRG neurones, Werz et al, 1987) and the lack of
ligand selectivity displayed by most opioids peptides reveals a somewhat bewildering
complexity (or simplicity, if redundancy occurs) of the opioid systems. The action of opioids
to increase membrane potassium conductance and inhibit neuronal calcium currents is shared
by other members of a subgroup of the superfamily of G-protein coupled receptors to which
the opioid receptors belong, indeed in many cases several receptors are expressed in the same
cells and their activation involves the same conductances, as shown for noradrenaline cc,,
somatostatin and 8 receptors in the guinea-pig submucous plexus (Mihara et al, 1987;
Suprenant et al, 1990). In contrast to these short term effectors, diffusible second messenger
systems like cyclic AMP may be responsible for more long term changes of opioid action.
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1.6 OPIOIDS IV: DISTRIBUTION IN THE MAMMALIAN CNS
As previously discussed (sections 1.3 and 1.4), three distinct types of opioid synthesising
neurone exist in the mammalian CNS that may release a number of opioid active peptides, to
exert their effects via at least three types of receptor. These neuronal systems have been found
to be widely distributed throughout the CNS and to influence many functions including
nociception and analgesia, cardiovascular regulation, gastrointestinal activity, respiration,
appetite and thirst, thermoregulation, motor function, neuroendocrine and neuroimmune
activity, learning and memory, reinforcement and reward behaviour (Khachaturian et al,
1993).
Some indication of the relative distribution of the opioid systems has been provided by
comparing tissue levels of distinct opioid peptides and binding sites using radiolabeled
specific antisera and ligands respectively. However, a more detailed anatomical description
has been elucidated using immunocytochemical and in situ hybridisation techniques. Opioid
peptides have been visualised to a cellular and subcellular level by light and electron
microscopy, using a variety of labelled antisera. However, these studies may be limited by the
sensitivity of the antibodies and their ability to penetrate to intracellular storage sites.
Problems with the specificity of the immunological reaction can also occur. By detecting the
mRNA for each precursor, the locations of the cell bodies of these opioid synthesising
neurones can be identified with more certainty, the levels serving as a measure of the
biosynthetic activity of the opioid system. Until recently autoradiography remained the only
method for localising opioid ligand binding sites in the CNS. These studies have been limited
by not only the availability of highly specific ligands but also on the ability to employ electron
microscopic methods and other anatomical techniques sequentially. It is hoped now that either
by using labelled antibodies raised to distinct amino acid sequences of the newly cloned
receptors or in situ hybridisation oligonucleotide probes to visualise the receptors mRNA, the
distribution of the opioid receptors will be determined to a higher degree of anatomical
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resolution, including at an ultrastructural level, and perhaps even allow the putative subtypes
to be differentiated.
The functional implications that can be derived from such anatomical studies is obviously
limited, providing no evidence of whether a localised peptide will be released or whether a
receptor site is functional. However, they do serve to highlight areas of potential interest.
Thus, following a general overview of the distribution of the opioid peptide-receptor systems
in the brain, that at the spinal cord level will be considered in greater depth.
1. DISTRIBUTION OF THE OPIOID SYNTHESISING NEURONES
POMC has been shown to be synthesised in the brain as well as the anterior and
intermediate lobes of the pituitary gland in a number of species including the rat, monkey and
man (Khachaturian et al, 1993). The pituitary is the major source of the POMC biosynthesis.
In the brain immunocytochemical and in situ hybridisation studies have shown two distinct
POMC cell groups to exist, namely in the arcuate nucleus of the hypothalamus (Bloom et al,
1978; Watson et al, 1978) and the nucleus tractus solitarus of the medulla (Joseph et al, 1983;
Schwartzberg and Nakane , 1983; Gee et al, 1983). POMC mRNA has also been detected in
the cerebral cortex, basal ganglia and amygdala (Civelli et al, 1982), and there is recent data
to suggest that some (3-endorphin containing cell bodies might be scattered caudally down the
spinal cord (Gustein et al, 1992; Plantinga et al, 1992). Lesion and deafferentation studies
have revealed the POMC cell bodies located in the arcuate have extensive projections
throughout the brain to a diverse number of forebrain and midbrain structures. The main
rostral targets include several hypothalamic nuclei, septum and preoptic area, where as the
main lateral projections innervate several amygdaloid nuclei. Caudal targets include many
areas considered to be associated with nociception, such as the periventricular nucleus of the
thalamus, and the periaqueductal gray and raphe nuclei of the brain stem. Nerve fibres from
the nucleus tractus solitarus in contrast appear to project mostly within the medulla itself and
possibly into the spinal cord. Certain areas of the medulla oblongata including the nucleus
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tractus solitarus, that are involved in respiration and cardiovascular regulation receive
innervation from POMC cells in the arcuate as well as the nucleus tractus solitarus (as
reviewed by Khatachurian et al, 1985a; b; 1993; Young et al, 1993) .
ProEnk synthesis has been shown widely throughout the neuroaxis from the cerebral
cortex to the spinal cord in a number of species including the rat, monkey and man
(Khachaturian et al, 1993). Immunocytochemical studies have found enkephalin containing
neurones to form both short and long tract projections (Hokfelt et al, 1977a; b; 1979; Sar et
al, 1978; Uhl et al, 1979; Finley et al, 1981; Conrath-Verrier et al, 1983; Standaert et al,
1986; Merchanthaler et al„ 1986; Menetrey and Basbaum, 1987; Nahin et al, 1987; Leah et
al, 1988; Arvidsson et al, 1992). The use of the neurotoxin colchicine to inhibit microtubular
axonal transport has enabled the cell bodies of smaller neurones and those synthesising
relatively low amounts of proEnk to be visualised. Thus, proenkephalin containing cell bodies
have been located in most regions of the telecephalon, including the cerebral cortex, amygdala,
hippocampus, striatum, septum and preoptic area; most hypothalamic and thalamic nuclei in
the diencephalon, such as the periventricular and lateral geniculate nuclei; in the midbrain, to
the interpeduncular nucleus, the substantia nigra, the periaqueductal grey, and the superior
and inferior colliculi; to a number brainstem nuclei including the raphe magnus, nucleus
tractus solitarius. lateral reticular and spinal trigeminal nuclei; and at the level of the spinal
cord, to the dorsal horn (as reviewed by Petrusz et al, 1985; Khachaturian et al, 1985b; 1993).
In situ hybridisation studies performed more recently are in good agreement with these
immunocytochemical results with even more proEnk containing cell bodies being observed in
regions of the neocortex, nucleus accumbens, striatum and the cerebellum (Harlan et al,
1987). Since all these regions also contain enkephalin-positive fibres and terminals, this
opioid system has the potential to influence a wide variety of CNS functions.
ProDyn, like proEnk, has been demonstrated to be synthesised in many neuronal systems
throughout the brain and spinal cord of a number of species, including the rat, monkey and
man (Khachaturian et al, 1993). In addition, proDyn is also synthesised in the anterior and
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posterior lobes of the pituitary gland. Immunocytochemical studies have found dynorphin
containing neurones to form both short and long tract projections (Vincent et al, 1982;
Khachaturian et al, 1982; Menetrey and Basbaum, 1987; Nahin et al, 1987; Leah et al, 1988).
Again the application of colchicine increased the ability to detect the presence of proDyn
peptides in neuronal cell bodies. Such studies have shown proDyn peptides to be present in
cell bodies in the cerebral cortex, amygdala, hippocampus, striatum, several hypothalamic and
thalamic nuclei, the periaqueductal grey, numerous brain stem nuclei including the nucleus
tractus solitarus, lateral reticular and spinal trigeminal nuclei, as well as in the dorsal hom of
the spinal cord. Additionally fibres and terminals containing proDyn peptides are further
found in many other regions of the CNS including the globus pallidus, substantia nigra and
raphe nuclei (as reviewed by Khachaturian et al, 1985b, 1993; Fallon and Ciofi, 1990). This
distribution has been confirmed to a limited extent by more recent in situ hybridisation studies
(Morris et al, 1986; Ruda et al, 1988; Weihe et al 1989).
Thus, whilst the expression of the POMC is restricted to just a few brain areas, that of
proEnk and proDyn appears to be widely distributed throughout the CNS. In general, the
findings of both immunocytochemistry and in situ hybridisation studies suggest that although
cells containing proEnk are more numerous than those of proDyn, their distribution
throughout the brain and the spinal cord is often in parallel, although species differences have
been found to exist. Notably considerable overlapping populations exist in regions implicated
in the processing of nociceptive information, such as the periaqueductal grey and dorsal hom
of the spinal cord. Although there is some evidence to support the coexistence of these two
opioid peptide families in the CNS (Guthrie and Basbaum, 1984; Sasek and Elde, 1986;
Weihe et al, 1988; Tuchscherer and Seybold, 1989; Fallon and Ciofi, 1990), this has still to
be satisfactorily investigated, for example using double labelling techniques at the mRNA
level. In contrast to proEnk, the distribution of the mRNA of proDyn has only been
investigated in certain areas of physiological interest. Since the Leu-enkephalin sequence can
be in both proEnk and proDyn derivatives there is the possibility of cross reactivity between
38
the two systems in immunocytochemical studies (Khatachurian et al, 1985b, 1993; Elde and
Hokfelt, 1993)
2. DISTRIBUTION OF THE OPIOID RECEPTORS
The majority of studies to date have employed radiolabelled ligands to identify opioid
binding sites which were equated with receptors. Whereas the anatomical distribution of the
multiple opioid receptor systems is very similar across mammalian species from the rat to the
monkey, the distribution and relative abundance of each opioid receptor type has been found
to sometimes vary dramatically (as reviewed by Mansour et al, 1988; Adler et al, 1990;
Mansour and Watson, 1993).
The p. receptors using relatively selective radioligands, such as [3H]-DAMGO, have been
shown to be widely distributed throughout the CNS of both the rat and monkey (Mansour and
Watson, 1993). Particularly dense binding is observed in basal ganglia and limbic structures,
thalamic and brain stem nuclei, including those associated with nociception, such as the
periventricular region, periaqueductal grey and raphe nuclei, as well as the dorsal horn of the
spinal cord. Marked species variations have been noted in the cerebral cortex and in the
hypothalamus.
The 8 receptors display the most restricted distribution of all the opioid receptors, with
binding mainly concentrated in forebrain regions. The distribution of these receptors is also
well conserved between mammalian species. For example, in both rat and monkey the overall
similarity of 8 receptor distribution using radioligands such as [3H]-DPDPE is remarkable
(Mansour and Watson, 1993). Here the 8 binding appears densest in the cerebral cortex,
striatum and amygdala, sparse to non-existent in the hypothalamus and thalamus, and poor in
most brainstem regions where the 8 binding is limited to a few structures such as the
substantia nigra and the nucleus tractus solitarus, as well as the dorsal horn of the spinal cord.
The K receptors demonstrate some of the most striking species differences in distribution
observed amongst all the opioid receptor types. For example, in the rat these binding sites
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comprise only 10% of the total number of opioid receptor sites, whilst in most other species,
such as the guinea-pig, monkey and human, these sites represent at least a third of the opioid
receptor population (Mansour and Watson, 1993). In all species examined so far, k sites
labelled with non-selective radioligands such as [3H]-bremazocine or [3H]-EKC in the
presence of unlabeled DAMGO and DPDPE, and more recently using more selective ligands
such as [3H]-U69593, have been found to be widely distributed throughout the neuroaxis.
Marked species differences are observed in forebrain areas such as the cerebral cortex,
hippocampus and basal ganglia, but not those of the midbrain and hindbrain, such as the
periaqueductal grey, superior and inferior colliculi, raphe and spinal trigeminal nuclei, and the
dorsal hom of the spinal cord.
Overall, the distribution of the opioid receptor types is well conserved across species in
brainstem and spinal cord areas, varying most notably in forebrain and midbrain structures,
although that of the 5 receptor sites appears to be well conserved throughout the entire
neuroaxis. The distributions of the p. and k receptors are parallel to some extent. Interestingly
the distribution of the opioid receptors appears to be well conserved across species within
certain functional systems. Notably aside from those regions considered important for the
processing of nociceptive information, particularly dense binding is observed on structures of
the limbic system such as the amygdala and hypothalamus, that regulate emotional behaviour
and which may be responsible for the euphoric effects of opiates (Mansour et al, 1988,
Mansour and Watson, 1993). Recent in situ hybridisation studies have visualised the
distribution of the cloned receptors mRNA, and on the whole these distributions show a good
correlation to those by autoradiography (as recently reviewed for the rat CNS; Mansour et al,
1995a). Such studies, however, allow the cell synthesising the receptors to be located but
provide no information of the final distribution of the receptors within a cell. Some
investigations using antibodies to defined sequences of the cloned opioid receptors have been
performed (Arvidsson et al, 1995a; b; Mansour et al, 1995b; 1996) but much work remains to
be done, particularly at the ultrastructural level and in combination with other anatomical
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techniques such as tract-tracing and dual labelling procedures, to explore the relationship of
the opioid receptors to other neurotransmitter systems. As discussed in section 1.4 no clear
relationship exists between an opioid peptide family and a specific type of opioid receptor.
This is further evident from the numerous reported 'mismatches' in opioid peptide-receptor
distributions found in the mammalian CNS, with no clear parallelism between the distributions
of a particular opioid peptide and receptor being found, including at the level of the spinal
cord as will now be described.
3. DISTRIBUTION AT THE SPINAL CORD LEVEL
Members of the each of the three opioid peptide families have been identified in the
mammalian spinal cord, but to a strikingly different extent. Whereas enkephalin and
dynorphin immunoreactivity has been found in numerous cell bodies and axon varicosities, no
neuronal cell bodies containing p-endorphin have been immunocytochemically labelled in the
spinal cord of the adult rat and only a few scattered axon varicosities have been found (Tsou
et al, 1986). However, more recent studies have indicated that some P-endorphin synthesis
may occur at the spinal cord level, with reports of P-endorphin immunoreactivity measured by
radioimmunoassay persisting in segments caudal to a thoracic spinal transection (Gustein et
al, 1992), and of the detection of POMC mRNA in the rat spinal cord (Plantinga et al, 1992).
Enkephalin immunoreactivity has been described in cell bodies and fibres of laminae I to
VII of the spinal cord (concentrated in lamina I-II) and in the region around the central canal,
lamina X (rat: Hokfelt et al, 1977a; b; Sar et al, 1978; Uhl et al, 1979; Hunt et al, 1980;
Finley et al, 1981; Stengaard-Pedersen and Larsson, 1981; Jansco et al, 1981; Gibson et al,
1981; Petrusz et al. 1985; Sasek and Elde, 1986; Miller and Seybold, 1987; 1989; Weihe et
al, 1988. cat: Glazer and Basbaum, 1983; Bennet et al, 1982; Conrath-Verrier et al, 1983;
Cruz and Basbaum et al 1985; Petrusz et al, 1985; Miller and Seybold, 1987; 1989. guinea-
pig: Stengaard-Pedersen and Larsson, 1981). In situ hybridisation studies have confirmed this
diffuse presence, labelled cell bodies being found in all laminae of the spinal cord except for
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the motoneuronal cell groups (rat: Harlan et al, 1987; Noguchi et al, 1992), suggestive of a
diverse role of this opioid system in spinal cord function. Although there is some evidence
that enkephalin containing fibres may descend from the brainstem (rat: Hokfelt, 1979;
Menetrey and Basbaum, 1987. cat/ monkey: Arvidsson et al, 1992) or originate from DRG
(rat: Senba et al, 1982; 1989; Pohl et al, 1994. cat: Garry et al, 1989), most of the enkephalin
immunoreactivity appears to reside in neurones intrinsic to the spinal cord. Some of these
spinal neurones, notably those located around the central canal region in laminae X, appear to
form ascending pathways to regions of the midbrain and diencephalon (rat: Standaert et al,
1986; Leah et al, 1988). There is evidence for co-localisation of enkephalin with
substance P (rat: Senba et al, 1988; Ribeiro-da-Silva et al, 1991), y-aminobutyric acid
(GABA) (rat: Todd et al, 1992); 5-hydroxytryptamine (5HT) (cat/ monkey: Arvidsson et al,
1992) and somatostatin (rat: Todd and Spike, 1992), particularly in cells and terminals in the
superficial dorsal horn .
ProDyn synthesising neurones have been found to display a considerably overlapping,
although more restricted distribution to those containing proEnk, being located in cell bodies
and fibres in laminae I-II, laminae IV-VI, and in the area around the central canal, lamina X
(as will be considered in detail in section 4.4). Like enkephalin most of dynorphin
immunoreactivity resides in neurones intrinsic to the spinal cord, with some evidence for
coexistence with substance P (Tuscherer and Seybold, 1989) and as previously indicated co-
localisation with enkephalin itself (Sasek and Elde, 1986; Weihe et al, 1988; Tuscherer and
Seybold, 1989; Fallon and Ciofi, 1990). It is of note that although most studies have been
performed at the lumbosacral level of the spinal cord, no significant rostrocaudal differences
in the distribution of these peptides have been found. The localisation of proEnk and proDyn
containing neurones in the superficical laminae and the neck of the spinal dorsal horn where
small diameter primary afferents terminate has led to the function of these peptides at the
spinal level to be discussed predominantly in context of the processing of nociceptive
information (as will be further discussed in section 1.7).
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All three types of opioid receptor have been localised to the dorsal horn of the mammalian
spinal cord (rat: Gouardares et al, 1985; Morris and Hertz, 1987. guinea-pig: Gouardares et
al, 1985). By autoradiography marked differences have been found to exist in the distribution
of the p, 6 and k binding sites in the rat lumbar spinal cord. Morris and Hertz (1987) found
that whilst p binding sites, labelled with [3H]-DAMGO, were detected to a significant extent
in the substantia gelatinosa (lamina II) and to a lesser extent laminae III-V and lamina VIII of
the ventral horn, the levels of 8 sites labelled with [3H]-DADLE (in the presence of DAMGO)
and k sites labelled with [3H]-bremazocine (in the presence of DAMGO and DADLE) were
low and notable only in lamina I and lamina II respectively. This was later confirmed by
studies employing quantitative densitometric analysis (Besse et al, 1991, Stevens et al, 1991).
These studies found a remarkable degree of homology in the respective proportions of the
three types of opioid receptor along the rostrocaudal axis of the spinal cord. For example,
Besse et al (1991) showed for the rat that there is a high percentage of p (70-74% of total
opioid binding), an intermediate percentage of 8 (18-20%), and a low percentage of k (7-10%)
binding sites at each of the spinal cord levels. Previous reports of rostrocaudal differences in
the same or other species are believed most likely due to the use of poorly selective ligands
and different tissue preparations (Lombard et al, 1995). As noted above, K receptors have
demonstrated some of the most striking species differences in the distribution of all the opioid
receptor types. For example, in human studies, Gouarderes et al (1986) reported very low
levels of the p and 8 opioid binding sites in the lumbosacral spinal cord, the only significant
sites being those of k. This is in contrast to the rat were only low levels of k opioid binding
sites are reported (Mansour et al, 1988). What this potentially means to the functioning of the
opioid systems at the spinal level is yet unknown and the possibility exists that the rat may
represent an atypical model for man with respect to the role of k mediated opioid receptor
systems. It should be noted however, for the purpose of studying the function of the
endogenous opioid peptides themselves such a caveat is unlikely to exist due to their poor
receptor selectivities and relatively minimal species variance in distribution.
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There is evidence that a proportion of the opioid binding sites in the superficial layers of
the dorsal horn are located near or on the spinal terminations of primary afferent fibres.
Earlier binding and autoradiographic studies showed a clear decrease in opioid binding at this
level following dorsal rhizotomy (monkey: La Motte et al, 1976; Ninkovic et al, 1982 rat:
Ninkovic et al, 1981), or peripheral nerve section (rat: Fields et al, 1980). Such studies,
however cannot exclude the possibility that trans-synaptic degeneration and damage to
segmental arteries during rhizotomy might have occurred to produce cell death in the dorsal
horn. However, the findings of electrophysiological studies on DRG neurones (as indicated in
section 1.5) along with the reduction in binding observed in rats treated neonatally with
capsaicin (a homovanillic acid derivative known to cause selective degeneration of small
diameter primary afferent neurones; Jansco et al, 1977; Nagy et al, 1981) have also pointed to
the preferential localisation of these receptors on a subpopulation of small diameter (mainly
unmyelinated) primary afferent fibres (Gamse et al, 1979). Besse et al (1990) used the
quantitative receptor autoradiographic technique to gauge the relative pre- and post- synaptic
locations of the p, 5 and k sites in the superficial layers of the rat cervical dorsal horn, 8 days
after a large unilateral dorsal rhizotomy (C4 to T2), corresponding to the brachial plexus.
Their results suggested a high percentage of the superficial laminae p ([3H]-DAMGO) and 5
([3H]-DTLET) sites were located presynaptically, with decreases in binding of 76% and 61%
respectively being observed at C7. However, the percentage decrease they observed for the k
sites (53%) needs to be considered with caution, since the non-selective ligand [3H]-EKC was
used to label these sites, and again the possibility of trans-synaptic degeneration cannot be
excluded. Notably more recent studies employing antibodies to the cloned opioid receptors
have reported that whereas p (rat: Arvidsson et al, 1995b; Ding et al, 1995; Mansour et al,
1995b. monkey: Honda and Arvidsson, 1995) and k (rat: Arvidsson et al, 1995c; Mansour et
al, 1996) receptors appear to be present on both primary afferent axons and cell bodies and
dendrites in the superficial dorsal hom, 5 (rat: Dado et al, 1993; Arvidsson et al, 1995a;
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Cheng et al, 1993. monkey: Honda and Arvidsson, 1995) receptors are mainly restricted to
axons of presumed primary afferent nature.
Using in situ hybridisation techniques cells expressing p., 5, and k receptor mRNA have
been detected in both the dorsal and ventral horns of the rat spinal cord, as well as DRG (as
reviewed by Mansour et al, 1995a). Notably Maekawa et al (1994; 1995) found that in the
rat lumbar spinal cord whereas the expression of p and k opioid receptor mRNAs was intense
in cell bodies of laminae I-II, with additional moderate to intense signals for the p receptor in
laminae VII-VIII and for the k receptor throughout lamina III-VIII, that of the 8 receptor
mRNA was very different. In contrast a marked expression of the 8 receptor mRNA was
found only in the ventral horn, with an intense signals observed on most of the large nuclei
(likely motoneurones) in lamina IX.
1.7 OPIOIDS V: ROLE IN SPINAL CORD FUNCTION
An integral part of opiate drug action and the major reason for opiate use by man is their
ability to alter sensations, from reducing the awareness of pain to producing states of
euphoria. Since the opioid peptides were discovered due to their 'morphine-like' effects,
considerable attention has been directed to the possible involvement of these peptides in the
central transmission of sensory information. A major focus of interest has been the
relationship of the opioids to the processing of peripheral stimuli normally perceived as
painful, especially at the level of the spinal cord, where opiates appear to act to dramatically
reduce the amount of nociceptive information reaching the brain. However, it is clear from the
unwanted side effects of opiate drugs alone, that the endogenous opioid peptides likely have
other actions. For example, the spinal administration of opiates in the intact and unaesthetised
animal has revealed powerful receptor mediated effects on motor, cardiovascular,
gastrointestinal and bladder function, suggestive of roles on somatomotor and autonomic
systems (as reviewed by Yaksh and Nouiehed, 1985; Duggan and Fleetwood Walker, 1993;
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Yaksh, 1993). Thus, in considering the role of opioids in spinal cord function although the
major focus will be the processing of sensory information especially in relation to noxious
stimuli, the association of these peptides with other spinal cord pathways must also be
addressed. To do this the findings of electrophysiological and behavioural studies employing
either systemic opiates or locally applied opioid receptor ligands will be reviewed for actions
on nociceptive and non-nociceptive pathways. First a brief overview of the basic anatomy
involved will be given.
Electrophysiological recordings of nerve fibres in animals, as well as psychophysical
studies in man, have established that information concerning potentially damaging (or noxious
stimuli), acting on cutaneous and deep tissue, is transmitted by small diameter myelinated (A8
or group III) and unmyelinated (C or group IV) afferent fibres, whose cell bodies are located
in ganglia outside the spinal cord. The central branches of these fibres run via the dorsal roots
to terminate in the spinal grey matter of the dorsal horn. Rexed (1952) divided the spinal grey
matter on a cytoarchitectonic basis into 10 laminae. A combination of electrophysiological
and neuroanatomical techniques have shown that in general whereas cutaneous derived A5 and
C afferents terminate in the superficial dorsal hom in lamina I (marginal zone) and the outer
lamina II (substantia gelatinosa) respectively (Light and Perl, 1977), the group III and IV
afferents of deeper origin (i.e. muscle, visceral and joint) terminate to a greater extent in the
deep dorsal horn laminae V-VI, as well as lamina I (Craig and Mense, 1983; Cervero and
Connell, 1984; Craig et al, 1988). The non-nociceptive large diameter myelinated (cutaneous,
AaJ P or deep tissue, group 1/ II) afferent fibres by contrast terminate in inner lamina II,
lamina III-IV (nucleus proprius) and lamina V-VI of the dorsal horn (as reviewed by Besson
and Chaoch, 1987). The dorsal horn neurones onto which the fine afferents terminate, provide
the first point for the integration of these nociceptive signals and represent the first
opportunity for modulation from intraspinal and supraspinal sources. These neurones either
project to propriospinal or supraspinal destinations, or remain intrinsic to the same spinal cord
segment, relaying the nociceptive message to higher order neurones that project to brain
46
centres involved in the perception of pain and/ or contact motoneurones that mediate spinal
reflexes. Thus, although cells which fire to peripheral noxious stimuli (either mono- or
polysynaptically) are widely distributed in the spinal cord, many are located in laminae I, II
and V near the central terminals of peripheral nociceptors. The majority of lamina II cells are
short, local circuit neurones (including the morphologically distinct 'islet' and 'stalk' cells) that
make connections with other lamina II cells and dendrites that penetrate this lamina from
neurones in laminae I, III-V, although the axons of some cells send their axons into lamina I
(Bennet et al, 1979) and into the deeper laminae III-V (Light and Kavookjian, 1988). By
contrast many lamina I and V cells are projection neurones, some lamina V cells having
dendrites that penetrate into the superficial dorsal laminae making direct contacts with both
small and large diameter primary afferents possible. Of the neurones that project
supraspinally, transmitting nociceptive information to the brain, a considerable proportion
ascend in the contralateral ventrolateral quadrant of the spinal cord. Although the origin and
destination of these tracts are to some extent species dependent, they have been found in
certain species (notably the rat, cat and monkey) to form a major part of the spinothalamic
tract (laminae I, IV-VII), and some part of the spinomesencephalic (lamina I and V),
spinoreticular (lamina VII and VIII), spinocervicothalamic (laminae III-V) tracts, as well as
that of the postsynaptic dorsal column pathway (laminae III-V) (as reviewed by Besson and
Chaoch, 1987). There is considerable evidence that nociceptive transmission is subject to
control in the spinal cord, both segmentally (Melzack and Wall, 1965) and via descending
fibres from areas of the brainstem (Reynolds, 1969), such as the periaqueductal grey matter,
rostral ventromedial medulla (including the nucleus raphe magnus) and dorsolateral
pontomesencephalic tegmentum (as reviewed by Fields and Basbaum, 1994).
1. OPIOIDS AND NOCICEPTIVE PATHWAYS
Evidence that opioids could exert direct effects on nociceptive pathways in the spinal cord
came initially from the findings of electrophysiological studies that systemic opiates reduce
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polysynaptic (flexor) but not monosynaptic (extensor) spinal reflexes in spinal animals
(Wikler, 1950), and behavioural studies that intrathecally applied opiates produce regional
analgesia without effecting voluntary motor activity (Yaksh and Rudy, 1976, 1977). The
magnitude of this effect on reflexes was found to be most pronounced on motor neuronal
activity evoked by high intensity electrical nerve stimulation or the application of noxious
stimuli to spinal animals (cat: Koll et al, 1963; Bell and Martin, 1977. rabbit: Clarke and
Ford, 1987. dog: Martin et al, 1976) and paraplegic man (Wilier, 1985). Although there is
relatively little data on the cell types affected by systemic opiates, an early study found that
analgesic doses of morphine had a greater effect in reducing the spontaneous firing of
neurones of lamina I and V, than any other laminae (Kitahata et al, 1974). Recordings in
spinal cats revealed a preferential, naloxone reversible, suppression of A5 and C fibre evoked
excitations of dorsal horn neurones responsive to both innocuous and noxious inputs,
following the systemic administration of a variety of opiates at analgesic doses (Le Bars et al,
1976; Duggan et al, 1980). Notably, such a selective inhibitory effect was demonstrated on
the firing of ventrolateral tract neurones to C fibre input in the intact cat (Jurna and
Grossman, 1976) and rat (Jurna and Heinz, 1979). In general, similar inhibitory effects have
been observed when 'natural' noxious stimuli have been employed to excite spinal neurones,
however the selectivity of this action was not always tested (as reviewed by Duggan and
Fleetwood-Walker, 1993; Yaksh, 1993).
Electrophysiological studies have been performed to investigate sites of action of each
opioid receptor type in the processing of nociceptive information at the spinal cord level.
These studies involving the local administration of opioid receptor ligands (by
microiontophoresis or pressure ejection) at defined spinal cord laminae, have revealed that p,
5 and K opioid receptors are involved in the inhibition of nociceptive transmission at
anatomically distinct sites (recently reviewed by Duggan and Fleetwood-Walker, 1993).
Overall, p preferring ligands (morphine, metorphamide, DAMGO) have been found to
produce a selective, naloxone reversible antinociceptive influence in superficial lamina 1/ II of
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the cat (Duggan et al, 1976; 1977b, 1981; Zhao et al, 1986; Fleetwood-Walker et al, 1988)
and rat (Hope et al, 1990a) spinal cord. Notably a highly selective action for morphine
iontophoretically administered into lamina II was demonstrated by Duggan and co-workers, by
simultaneously recording with a second microelectrode the nociceptive responses of neurones
in laminae IV/ V. These effects were readily reversed by naloxone either administered
systemically or iontophoresised into the substantia gelatinosa, and the specificity of the action
lost when morphine was ejected closer to the lamina IV/ V cells being recorded (Duggan et al,
1976; 1977b; 1981). Similar double microelectrode studies were performed on identified
spinocervical tract cells in laminae III-V using the highly selective p agonist DAMGO
(Fleetwood-Walker et al, 1988).
In contrast the conclusions that can be drawn form similar studies employing 5 preferring
ligands are more limited. Whereas early experiments showed that the stable enkephalin
analogues [Met^jenkephalinamide and DADLE produced similar naloxone reversible effects
to morphine, on the nociceptive activation of laminae IV/ V neurones when ejected into the
substantia gelatinosa (Duggan et al, 1977a; 1981; Davies and Dray et al, 1978; Sastry and
Goh, 1983), repeating the experiments with the more 5 selective agonists (DSLET and
DPLPE), Fleetwood-Walker et al (1988) failed to reproduce this lamina II effect indicating
that actions at p. receptors may be more responsible for the effect. However, non-selective
actions of enkephalins were also described on the activity of lamina IV/ V neurones (Duggan
et al, 1977a; Zieglgansberger and Tulloch, 1979) and identified primate spinothalamic tract
neurones (Willcockson et al, 1986), that although were readily reversed by iontophoretically
applied naloxone, were not reversed by even very high doses given systemically. This along
with the lack of effect DADLE and the highly 8 selective DPDPE had, when iontophoresised
near these deep dorsal horn neurones in the cat (Fleetwood-Walker et al, 1988) and rat (Hope
et al, 1990), indicates that these non-selective effects by the enkephalins are unlikely to be 8 or
even p receptor mediated. In contrast in the rat, lamina I cells (some of which were identified
as spinomesencephalic tract cells), were clearly inhibited by DPDPE applied in the superficial
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dorsal horn (Hope et al, 1990). Since the inhibitory actions on these neurones (both non¬
selective and selective inhibitions being displayed), were antagonised by the local application
of the 5 selective antagonist ICI178864, these effects are likely be mediated by 8 receptors.
Although few electrophysiological studies have been performed using k preferring ligands,
the relatively selective agonists, dynorphin A and U50488H, were found to produce potent,
naloxone reversible inhibition of the responses of identified cat spinocervical tract neurones
and rat neurones in lamina IV/ V, when iontophoretically administered near to these deep
dorsal hom neurones. However no effects were observed on the firing of either these lamina
IV/ V neurones or the lamina I neurones of the rat when the agonists were applied in the
substantia gelatinosa (Fleetwood-Walker et al, 1988; Hope et al, 1990).
The findings of studies employing the topical administration of opioids, although unable to
localise sites of action to discrete spinal laminae and potentially limited by lipophilicity of
drugs applied (which may result in a significant redistribution via systemic circulation),
appear to be in general agreement with the those of the above iontophoretic studies. For
example, whereas the p. receptor agonists DAMGO (Dickenson et al, 1987) and the naturally
occurring dermorphin (Sullivan and Dickenson, 1988), and the 8 receptor agonists DPDPE,
DTLET (Dickenson et al, 1987) and DSBuLET (Sullivan et al, 1989) have been reported to
partially inhibit C- but not A-fibre evoked responses in dorsal hom neurones when applied to
the spinal cord surface, the topical administration of k receptor agonists (U50488H, U69593,
dynorphin A) has resulted in variable responses, with only the highest doses producing
inhibitions that were insensitive to naloxone (Knox and Dickenson, 1987; Hylden et al, 1991)
and norBNI (Sullivan and Dickenson, 1991). Whilst this may be a reflection simply of a
deeper dorsal horn site of action, K preferring ligands have also been found to display other
'non-opioid' effects at the spinal level. These will be detailed in a discussion of the functions
of dynorphins in spinal processing in section 4.4. Overall electrophysiological and
behavioural studies following the spinal administration of opioid receptor ligands have
demonstrated clear analgesic responses (as reviewed by Millan, 1986; Millan et al, 1993).
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Although the finding of early behavioural studies implied that k preferring ligands act
exclusively against non-thermal noxious stimuli (Schmauss and Yaksh, 1984), later studies
employing 'match-intensity' stimuli revealed such modality selectivity to be artifactual (Millan
et al, 1989). This was also supported at an electrophysiological level when the noxious
thermal and mechanical stimuli were graded so as to produce equal firing in motoneurones
(Parsons and Headley, 1989) and dorsal horn neurones (Dong et al, 1991) of the spinal rat,
following the systemic administration of drugs.
The functional consequences of activating an opioid receptor in the spinal cord will differ
depending on where the receptor is located; namely on the terminals of primary afferent fibres
or descending pathways; or the dendrites/ cell bodies of local circuit neurones, projecting
neurones (propriospinal or supraspinal) or motoneurones. The selective blockade of the
nociceptive responses by the iontophoresis of (j. receptor agonists in lamina 1/ II suggests a
presynaptic site of action via receptors located on nociceptor terminals or an action on specific
local circuit neurones located in the superficial layers. In contrast, 8 receptors appear to
mediate more of a ubiquitous inhibitory mechanism on lamina I neurones, since both selective
and non-selective actions are displayed. This likely involves a more complex role of these
receptor sites in the modulation of nociceptive transmission, involving both pre- and post¬
synaptic actions. As indicated in section 1.5.1 the postsynaptic actions of opioids have
implications for their selective effects, especially if they occur on the cell body. Whilst this
could reflect a restricted distribution of the opioid receptors to certain local circuit neurones in
the substantia gelatinosa, it could also reflect actions in selective areas of the dendritic tree of
the neurone involved, or the selective 'antagonism' of a particular intracellular effect.
Although the selective action of k receptor agonists on lamina IV/ V neurones could equally
involve presynaptic actions on the deeper terminating (group III and IV) nociceptors, it likely
reflects an action at receptors on specific local circuit neurones in the deep dorsal horn.
Notably the antinociceptive effect of dynorphin A( 1-13) was effectively blocked by idazoxan
(a selective 0C2 adrenoceptor antagonist) (Fleetwood-Walker et al, 1988). Based on the
findings of previous electrophysiological studies that naloxone failed to reverse the inhibitions
produced by 5-HT and noradrenaline on the firing of laminae IV/ V spinal neurones (Headley
et al, 1978), and behavioural studies that pretreatment of the tryptophan hydroxylase inhibitor
p-chlorophenylalanine reduced the inhibition of the tail-flick response by intrathecal (i.t.)
dynorphin (Von Voigtlanderet al, 1984), it was proposed that the k receptors in laminae IV/V
region could control, by a 'disinhibition' mechanism, the inhibitory effects of these descending
monoamine pathways on spinal cord processing of nociceptive information. The lack of
antinociceptive effect displayed by the k receptor ligands in the superficial laminae, where the
majority of these K receptors are located, is suggestive that unlike p and 8 receptors, a major
role of these receptors in the spinal cord may be unrelated to the modulation of nociceptive
inputs.
As indicated in section 1.6.3, a proportion of p. and 8 receptors in the dorsal horn appear
to be located on the terminals of primary afferent fibres. However, there is limited
electrophysiological evidence to support such a presynaptic inhibitory effect of opioids, and
that reported may reflect an indirect action (Carstens et al, 1979; Sastry, 1980). Although as
previously described in section 1.5, opioids active at p, 8 and k receptors on a proportion of
cultured or dissociated DRG neurones have been shown to exert actions on potassium and
calcium channels to reduce the excitability of neurones and shorten the duration of their action
potentials, little evidence to support such effects at the central terminals of small myelinated
and unmyelinated primary afferents has been presented (Hori et al, 1992; Glaum et al, 1994).
Instead opioids (at least p receptor preferring ligands) have been reported to have direct
hyperpolarising actions on dorsal horn neurones in slices of the rat spinal cord (Murase et al,
1982; Yoshimura and North, 1983; Jeftinija et al, 1988; Hori et al, 1992; Glaum et al, 1994)
and trigeminal nucleus (Grudt and Williams, 1994), suggestive more of a postsynaptic
mechanism. In addition, despite reports that the application of opioids (mainly p and 8
preferring) can reduce the evoked release of neuropeptides present within many small diameter
primary afferents, such as substance P, when superfused onto in vitro slice preparations
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(trigeminal nucleus: Jessel and Iversen, 1977. spinal cord: Mauborgne et al, 1987; Pohl et al,
1989) and the spinal dorsal horn in vivo (Yaksh et al, 1980; Go and Yaksh, 1987; Aimone and
Yaksh, 1989), no such action has been found for analgesic doses of morphine administered
systemically in vivo using the push-pull cannuiae (substance P: Kuraishi et al, 1983) and
antibody microprobes (substance P: Morton et al, 1990. CGRP: Morton and Hutchison,
1990. neurokinin A: Lang et al, 1991), the concentrations of the drugs applied topically being
very high (10"3 to 10"^M). Notably a recent study employing antibodies to the cloned p
receptor has reported that colocalisation with substance P is only occasionally seen in rat
dorsal horn, suggestive that some nociceptive afferents do not possess p opioid receptors
(Ding et al, 1995). However, although a strong case has been presented against a presynaptic
action of p preferring ligands in mediating antinociceptive effects, this may not be equally true
of 5 preferring ligands, since immunological studies with antibodies directed against these
receptors have found them to be predominantly located on axons in the spinal cord rather than
on cell bodies or dendrites (Dado et al, 1993; Arvidsson et al, 1995a; Cheng et al, 1995). In
addition recent whole cell voltage clamp recordings of visually identified lamina II neurones of
the rat spinal cord slice appear to imply a presynaptic inhibitory role for the selective 8
agonists DPDPE and [D-Ala2]deltorphin II on excitatory glutamate mediated afferent
transmission (Glaum et al, 1994). However, the source of such an opioid input is uncertain.
Despite early proposals for axoaxonic synapses between enkephalin neurones and substance P
containing primary afferents (Jessel and Iversen, 1977), such a synaptic arrangement has not
been confirmed at the ultrastructural level (Hunt et al, 1980; Glazer and Basbaum, 1983).
Instead enkephalin immunoreactive neurones have been described to contact spinothalamic
tract neurones in lamina I and V (Ruda et al, 1984). Cho and Basbaum (1989) also failed to
detect a significant number of dynorphin B immunostained structures presynaptic to
degenerating primary afferents following dorsal rhizotomy. In a recent review Ribeiro da
Silva and Cuello (1995) have proposed that since enkephalin containing neurones are
sometimes presynaptic to the central element of synaptic glomeruli which do not display
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peptide immunoreactivity in the central bouton, such neurones could act both pre- and post-
synaptically in the modulation of non-peptidergic sensory neurones.
Studies have been performed in the cat and rat to determine whether the endogenous
opioid systems exert a tonic influence on nociceptive pathways in the spinal cord. In general
the effects of systemic naloxone on the basal and evoked firing of unidentified dorsal horn
neurones have been rarely observed and variable. However, naloxone was found to
consistently and selectively enhance the responses of ventrolateral tract neurones to electrical
stimulation of peripheral C fibres in both the spinal rat (Bernatsky et al, 1983) and cat
(Duggan et al, 1985). Additionally studies with naloxone revealed actions of the spinal
segmental opioid systems in certain of the supraspinally mediated inhibitions in the rat (such
as that evoked by electrical stimulation of the rostral ventromedial medulla; Rivot et al, 1979),
but not the cat (as reviewed by Duggan and Fleetwood-Walker, 1993)
2. OPIOIDS AND NON-NOCICEPTIVE PATHWAYS
(i) Motor function
As previously discussed early electrophysiological evidence pointed to a relatively
selective action of opioids in the suppression of nociceptive reflexes, exerting minimal
influence on monosynaptic reflexes in extensor motoneurones induced by the application of a
single stimulus to large diameter afferents. However, the reflex activity elicited by high
frequency stimulation of these afferents has been found to be reduced by analgesic doses of
opiate drugs (Jurna and Schafer, 1965; Krivoy et al, 1973), indicating that monosynaptic
pathways can be influenced by activity induced in interneurones following such repetitive
stimuli. Additionally, whereas the effects of systemic naloxone on dorsal horn neuronal
activity have proved variable, ventral horn neurones have more reliably been shown to be
under tonic control by endogenous opioids (as reviewed by Duggan and Fleetwood-Walker,
1993). This has demonstrated for both mono- and polysynaptic reflexes in the spinal cat
54
(Morton et al, 1982; Duggan et al, 1984) and rabbit (Clarke et al, 1989) following the
electrical nerve stimulation. The mechanism underlying these spinal reflex inhibitions has yet
to be established, but early intracellular studies involving the local iontophoretic
administration of naloxone found no evidence for a direct effect on motoneurones (Zhao and
Duggan, 1984). Of potential relevance to the function of such non-selective inhibitions is the
finding that certain reflexes are only apparent when the opioid receptors are blocked. Thus, it
is possible that the one of the functions of the endogenous opioid peptides at the spinal level is
to help set the threshold for withdrawal reflexes, so that they are only activated by appropriate
stimuli (Clarke et al, 1992).
(ii) Other functions
The spinal administration of opioids (mainly p. and 8 preferring ligands) has also been
observed to cause significant effects on certain genitourinary and gastrointestinal functions.
For example, naloxone reversible inhibitions of the volume evoked micturation reflex and
reductions in the velocity of intestinal transport have been observed in unanesthetised animals
and man. Additionally, whilst the intrathecal injections of opioids fails to produce any
detectable effect upon resting heart rate or blood pressure, there is a reduction of these
sympathetic signs when evoked by high threshold stimuli (as reviewed by Yaksh and
Nouiehed, 1985; Yaksh, 1993).
A full description of an 'opioid event' includes the stimuli producing the release of a
particular opioid peptide, the spread and degradation of the peptide released, the receptors
acted upon, and the functional consequences for neuronal processing following the activation
of these receptors. Viewed in this way our present knowledge of opioid events in the spinal
cord is limited. As highlighted in section 1.4 the opioid peptides do not display strong
selectivities for the p, 5 and K opioid binding sites. Thus, under physiological conditions
opioid-receptor binding depends not only on the preferential affinity of the opioid peptide for a
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given receptor but also on the amount of opioid peptide and receptor available in a given
tissue. This is especially true of the spinal cord. Thus, whilst localising the action of opioid
receptor agonists on the responses induced by defined stimuli to specific laminae of the spinal
cord may be informative, such studies may also be misleading of the physiological situation.
Instead it needs to be determined which sites are functionally active in response to a particular
stimulus and which opioid peptides mediate the effects. However, the ability to perform such
electrophysiological experiments was limited until recently by the lack of selective antagonists
which could be administered locally to spinal tissue, and few such studies have been
performed. Notably the selective K receptor antagonist norBNI was recently employed to
investigate the role of this endogenous opioid system in the spinal neuronal responses evoked
under normal conditions and following the development of a peripheral inflammation (Stiller et
al, 1993), the findings of which will be detailed in section 4.4. Whilst behavioural studies
employing antisense oligodeoxynucleotides to the cloned opioid receptors have shown a
relatively rapid turnover of receptors they have so far provided little additional insight into the
roles of the opioid systems at the spinal cord level over and above studies administering
selective opioid ligands (recently reviewed by Pasternak and Standifer, 1995). As for release
studies, the majority of investigations performed in vivo have involved spinal perfusion, which
is of obvious limited resolution in being able to detect the release of opioid peptides from the
deep laminae of the spinal cord and few studies have been performed to investigate the effects
of 'natural' stimuli (proEnk: Yaksh and Elde, 1980; 1981; Yaksh et al, 1983; Nyberg et al,
1983; Le Bars et al, 1987; Bourgoin et al, 1988. proDyn: Yaksh et al, 1983; Nyberg et al,
1983). Thus, there is a need to localise release to discrete laminae in response to physiological
stimuli. This is central to the aim to the studies performed in this thesis. As will be
subsequently described I have employed the antibody microprobe technique to study the
release of dynorphins in the rat spinal cord under conditions of peripheral inflammation, in
which this family of opioid peptides appear to play a special role.
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1.8 RESPONSE OF THE OPIOID SYSTEMS TO PERIPHERAL INFLAMMATION
The role played by the opioid peptides in spinal cord function has been further
investigated by studying the response of the endogenous opioid systems to different 'pain'
states. A number of animal models have been employed to represent the persistent or chronic
pain experienced in many clinically recognised pathological states involving inflammation and/
or trauma. In general, these models can be considered to represent two different though not
exclusive 'pain' states, those involving tissue damage (i.e. 'nociceptive pain') and those
involving nerve injury (i.e. 'neuropathic pain'). The response of opioid systems has been
mainly investigated under inflammatory conditions. Through these studies a role of the
proDyn family of peptides has been highlighted.
1. MODELS OF TISSUE INJURY AND INFLAMMATORY PAIN
These can be considered 'acute', in the sense of developing within minutes or 1-2 hours
and resolving either within hours or 1-2 days, or 'chronic', developing over a longer time scale
and maintained for days to weeks. Additionally acute inflammation may not resolve but may
proceed to a chronic phase.
Acute inflammatory lesions have been produced by the intradermal injection of formalin
(Dubuisson and Dennis, 1977) or carrageenan (Winter et al, 1962) into the plantar surface of
rat hindpaw. Injections of formalin characteristically produce a biphasic behavioural
response. This consists of an 'early transient' phase (related to the injection itself), that peaks
at 5 min to subside by 10 to 15 min, and a 'late prolonged' phase (related to the ensuing
inflammatory response), that occurs 20 to 60 min after the injection. Similar lesions have also
been induced by the injection of sodium urate crystals (Okuda et al, 1984; Coderre and Wall,
1987), or kaolin and/ or carrageenan into the cavity of a joint, the latter more specifically to
study joint 'pain' in non-recovery experiments (i.e. acute monoarthritis; Schaible and Schmidt,
1985). These lesions present histological and behavioural signs of inflammation, such as
57
oedema and hyperalgesia, within the first few hours and so allow changes of the peripheral
and central processing of sensory information arising from the injected regions to be readily
studied.
Chronic inflammatory lesions have more commonly employed the use of Freund's
complete adjuvant (FCA), typically a suspension of heat killed bacteria, Mycobacterium
tuberculosum/ butyricum in mineral oil. A diffuse persistent inflammatory state termed a
'polyarthritis' has been induced in rats by the intradermal innoculation of FCA at the tail base
(Pearson et al, 1963; De Castro Costa et al, 1981). This produces a two stage inflammatory
process characterised by an initial acute local reaction that develops within the first few hours
and subsides after 3 to 5 days, and a diffuse inflammatory reaction that appears during the
second week. This develops mainly in the hindlimbs and upper tail, peaking at 3 weeks and
often takes up to 10 weeks to resolve. These polyarthritic animals have been shown to
demonstrate characteristics typical of chronic pain in man; namely hyperalgesia, irritability,
hyperventilation, decreased motility and loss of body weight. Further the rats are observed to
self-administer opiate and inflammatory drugs (Millan et al, 1986; Colpaert, 1987; Millan,
1993). However, these animals suffer from a generalised disease state with lesions throughout
the body rather than localised at a single joint or limb, that complicates the interpretation of
data, making it difficult to relate observations to inflammatory pain alone. Thus, more limited
peripheral inflammatory states are also employed with lesions appearing to be confined to a
single joint or limb, that induce some of the neurophysiological, pharmacological and
biochemical aspects of chronic pain states without the complication of multifocal lesions.
These involve either the injection of small amounts of FCA or other inflammatory agents into
a hindpaw, the tissue around a joint or into the joint cavity itself. For example, intradermal
injections of FCA into the plantar surface of the rat hindpaw (i.e. unilateral adjuvent induced
inflammation; Hargreaves et al, 1988; Iadarola et al, 1988a) have been described to produce a
significant erythema, oedema and hyperalgesia of the injected paw (to both thermal and
mechanical stimulation) within 4 hours, that peaks at 2 to 3 days post-inoculation, and persists
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for 10 to 14 days. Other inflammatory agents, such as carrageenan, yeast or phorbol ester
into the rat hindpaw have been found to induce similar states (Iadarola et al, 1988a). The
injection of FCA into the periarticular tissue of the ankle joint of rats results a similar self-
limiting and reproducible unilateral inflammation, that pertains more directly to joint pain
(Grubb et al, 1988; Donaldson et al, 1993). More severe models involve the injection FCA
(i.e. monoarthritis; Butler et al, 1992) into the ankle joint of the cat or rat. This produces
along with the development of an arthritic joint, a much more prolonged inflammation that is
well maintained for at least 6 weeks. The use of such unilateral models has allowed the
establishment of more specific relationships between alterations in the peripheral and central
processing of sensory information in response to the induction of prolonged inflammation
states.
2. INFLAMMATION INDUCED CHANGES IN PRIMARY AFFERENT AND SPINAL
CORD NEURONES
Experimental evidence supporting the sensitisation of thin myelinated and unmyelinated
primary afferent nociceptive units following the development of a peripheral inflammation has
been well documented, especially for the mechanosensitive group III and IV afferents found in
the medial and posterior articular nerves (MAN and PAN) innervating the cat knee joint. The
nociceptors become spontaneously active, and acquire lowered thresholds and increased
responsiveness to suprathreshold stimuli as inflammation develops (Coggeshall et al, 1983;
Guilbaud et al, 1985; Schaible and Schmidt, 1985,1988; Grigg et al 1986; Grubb et al, 1991).
The recruitment of previously mechanoinsensitive afferents or 'silent nociceptors' has also
been observed (Schaible and Schmidt, 1985; 1988; Grigg et al 1986; Meyer et al, 1991). A
variety of mediators released from neighbouring inflammatory cells, as well as afferent and
efferent axons, are thought to participate in the sensitisation processes including
prostaglandins, leukotrienes, bradykinin, and 5HT amongst others (recently reviewed by
Schaible and Grubb, 1993). An increased afferent input might reasonably result in
59
hyperactivity of spinal neurones receiving such input, but it has been proposed that additional
changes occur centrally resulting in increased responses to a given input, a state called by
some investigators 'central sensitisation' (recently reviewed by Coderre et al, 1993). Since
these may contribute to the allodynia, hyperalgesia, and spontaneous or persistent pain
associated with tissue injury, by altering the processing of somatosensory information at the
spinal level and changing the message transmitted from the spinal cord to the brain, I shall
now briefly describe some of the evidence supporting this proposal.
It had long been postulated from clinical observations, that injury and noxious stimulation
of the periphery could induce changes centrally to alter pain sensitivity. Hardy et al (1950)
recognised that cutaneous injury resulted in two distinct types of hyperalgesia; primary and
secondary. The former primary zone, represented by the increased sensitivity to both thermal
and mechanical noxious stimulation at the site of an injury, they proposed was mediated by
peripheral mechanisms (i.e. neurogenic inflammation). The latter secondary zone, represented
by the increased sensitivity to mechanical but not thermal stimuli observed outside of this
region, they proposed must also involve central processes, since it was found to occur beyond
the recognised area of neurogenic induced 'flare' response (recently reviewed by Treede et al,
1992). More recently human microneurography studies involving the intradermal injection of
capsaicin have supported this classification, demonstrating how cutaneous hyperalgesia once
established requires minimal input from the injured peripheral tissue (La Motte et al, 1992).
Direct experimental evidence for enhanced central responses was initially provided by Mendell
(1966) who showed how repeated activation of C fibre afferents sequentially increased dorsal
horn activity to result in prolonged discharges in spinal neurones that lasted seconds to
minutes poststimulus, termed 'windup'. The potential importance of such 'central
hyperexcitability' to post-injury pain hypersensitivity states was popularised by Woolf and
coworkers. They demonstrated how brief 'conditioning' stimulation of afferent C fibres either
by direct electrical stimulation of cutaneous and muscle afferent nerves (Wall and Woolf,
1984) or by cutaneous and deep tissue injury (Woolf, 1983; Woolf and McMahon, 1985),
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could increase the excitability of flexor efferent motoneurones to biceps femoris/
semitendinosus muscle in response to noxious mechanical stimulation of the hindpaw, for a
period of 5-10 minutes (e.g. cutaneous/ sural nerve stimulation) to up to an hour (e.g. muscle/
gastrocnemius-soleus nerve stimulation). Notably reductions in flexion reflex thresholds to
noxious mechanical and thermal stimulation were also observed in the limb contralateral, as
well as ipsilateral to the site of tissue injury (Woolf, 1984; Cook et al, 1987), and were shown
to occur independently of changes in the excitability of the afferent terminals in the dorsal
horn and of the flexor motorneurones involved (Cook et al, 1986).
Increases in the spontaneous activity, reduced thresholds and increases in the responses to
afferent inputs of nociresponsive spinal neurones have been subsequently observed following
an intense C fibre mediated barrage of activity, elicited by the electrical stimulation of
peripheral nerves (Schouenborg and Dickenson, 1985), 'natural' stimulation (Laird and
Cervero, 1989; Woolf and King, 1990; Simone et al, 1991; Dougherty and Willis, 1992) or
tissue injury (Menetrey and Besson, 1982; Schaible et al, 1987; Neugebauer and Schaible,
1988, 1990; Doughterty et al, 1992, Grubb et al, 1993). Expansions of the cutaneous
receptive fields of these spinal neurones have also been observed beyond the focus of the
inflammatory lesion and hence the range of innervation primary afferents to adjacent
ipsilateral and even into contralateral regions (Menetrey and Besson, 1982; Calvino et al,
1987; Neugebauer and Schaible, 1988, 1990; Hyden et al, 1989; Hoheisel et al, 1993; Grubb
et al, 1993).
A variety of compounds released from the terminals of both primary afferents and
intrinsic spinal neurones have been implicated in the hyperexcitability of spinal neurones
following inflammation, including the excitatory amino acids, L-glutamate and L-aspartate.
Notably under these conditions a special role of the N-methyl-D-aspartate (NMDA) class of
glutamate receptor has been proposed from a variety of electrophysiological (kaolin and
carrageenan: Schaible et al, 1991a; Neugebauer et al, 1993. FCA: Doughterty et al 1992;
Neugebauer et al, 1994; formalin: Haley et al, 1990) and behavioural (carrageenan: Ren et al,
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1992. formalin: Coderre and Melzack, 1992) studies. These receptors along with the non-
NMDA classes of glutamate receptors (that mediate the transmission of both innocuous and
noxious stimuli under normal physiological conditions), appear to play a primary role in the
generation and maintenance of central sensitisation states in response to tissue injury, with
evidence for the enhanced spinal release of the excitatory amino acids as inflammation
develops peripherally (Skilling et al, 1988; Sorkin et al, 1992; Sluka and Westlund, 1993) .
For example, the 'wind-up' of dorsal horn neuronal activity by repetitive C fibre stimulation
has been shown to be significantly reduced following the application of either competitive
(AP5: Dickenson and Sullivan, 1987; 1990; Thompson et al, 1990. CPP: Woolf and
Thompson, 1991) and non-competitive (ketamine: Davies and Lodge, 1987. MK-801: Woolf
and Thompson, 1991) excitatory amino acid receptor antagonists. The findings of biophysical
studies (Mayer et al„ 1984) that the NMDA receptor linked ion channel, unlike that of the
other ionotrophic non-NMDA receptors, is blocked by Mg2+ at hyperpolarised resting
membrane potentials (hence unique in being both ligand and voltage gated) appears to partly
explain why these receptors require such high threshold prolonged neuronal activation to
become involved in spinal processing of sensory information.
Alterations have also been shown to occur in the synthesis (Noguchi et al, 1988; Minami
et al, 1989; Kurashi et al, 1989; Smith et al, 1992; Hanesch et al, 1993a) and release of a
number of neuropeptides contained primarily within primary afferent fibres such as the
tachykinins substance P (Oku et al., 1987; Schaible et al., 1990; Garry and Hargreaves, 1992)
and neurokinin(NK) A (Hope et al., 1990b), and CGRP (Garry and Hargreaves, 1992; Collin
et al, 1993; Schaible et al., 1994). The tachykinins via actions at NK1 and NK2 receptors
respectively have been shown to elicit slow depolarisations of dorsal horn neurones in vitro
(Murase and Randic, 1984; Urban and Randic, 1984) and to enhance excitatory nociceptive
responses of spinal neurones in vivo (Hendry et al, 1976; Fleetwood-walker et al, 1990; De
Konnick and Hendry, 1991; Dougherty et al, 1994; Neugebauer et al, 1995), resulting in
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prolonged facilitation of nociceptive flexor reflexes when applied intrathecally (Woolf and
Wiesenfeld-Hallin, 1986; Xu et al, 1991a).
Significant differences in the timing of the enhanced release of these neuropeptides as
inflammation develops, suggest that there are evolving processes influencing the spinal
processing of nociceptive information. For example, antibody microprobe studies have been
performed to study the release of some of these peptides following the induction of an acute
inflammation in the knee joint of the cat by intra-articular injections of kaolin and
carrageenan. Whereas a spinal release of immunoreactive(ir)-substance P was not observed
until 3 up to 8 hours post-inoculation, and then only after joint manipulation (Schaible et al,
1990), neurokinin A was detected immediately after joint injection (Flope et al, 1990). A more
recent antibody microprobe study also found evidence that CGRP release is enhanced within
the first few hours of an acute inflammation (Schaible et al, 1994). Interestingly nerve growth
factor has recently been implicated in the inflammation evoked increased expression of
tachykinins and CGRP (Donnerer et al, 1993), which suggests that increased neuronal activity
is not the only critical factor in the induction of hyperexcitability states. The action of
excitatory amino acids in the spinal dorsal horn has been found to be enhanced pre- and post-
synaptically by these primary afferent neuropeptides in vitro (Randic et al, 1990; Kangra and
Randic, 1990; Rusin et al, 1992; 1993) and in vivo (Dougherty and Willis, 1991; Dougherty
et al, 1993; Song and Zhao, 1993), with evidence for modulation of release by substance P
(Kangra and Randic, 1990; Sluka and Westlund, 1993). Notably there is evidence for
coexistence of substance P/ CGRP with L-glutamate in a subpopulation of primary afferent
neurones (DeBaisi and Rustioni, 1988). Although the increased involvement of NMDA under
inflammatory conditions receptors may be simply explained by a removal of the Mg2+ block
by a sustained small tachykinin-induced depolarisation, other mechanisms possibly involving
protein kinase mediated phosphorylations are proposed (as reviewed by Randic et al, 1995).
63
3. THE RESPONSE OF OPIOID SYSTEMS AT THE SPINAL CORD LEVEL
Whilst most emphasis has been focused on the facilitation of excitatory influences on
spinal cord neurones following the development of a peripheral inflammation, changes have
also been described in inhibitory systems active at the spinal cord level, both intrinsic to the
spinal cord and supraspinally located. For example, it has been shown that the effectiveness
of tonic descending inhibition on spinal cord neurones (notably in laminae IV-VIII) is
increased during the first hours of a developing inflammation in a knee joint (Schaible et al,
1991b). The inhibitory systems segmentally active in the spinal cord involve either GABA/
glycine or opioid peptide releasing neurones. Although increases have been observed in
GABA neuronal systems at the spinal cord level (Nahin and Hylden, 1991; Castro-Lopes et
al, 1994), the most dramatic changes involve the endogenous opioid peptides. Notably a
significant enhancement in the synthesis of the proDyn family of opioid peptides has been
observed, the consequences of which will be considered later in section 4.4. However, since
there is evidence that some of the dynorphin neurones project to supraspinal areas (Standaert
et al, 1986; Nahin et al, 1987; 1989; 1992; Leah et al, 1988) the consequences of activating
these opioid containing neurones appears complex, likely exerting an analgesic influence at the
spinal cord level as well as modulating the transmission of nociceptive information in certain
regions of the diencephalon and brainstem. A tonic activity of the spinal cord opioid systems
under inflammatory conditions was suggested by the increases in the spontaneous firing and
the responses of dorsal horn neurones to electrical stimulation of C fibres observed for
spinalised polyarthritic rats following the systemic administration of naloxone (Lombard and
Besson, 1989).
As previously indicated POMC synthesising neurones do not appear to exert a significant
influence in the spinal cord. In polyarthritic rats increases in the plasma levels of (^-endorphin
have been observed, that parallel an upregulation of POMC mRNA and ir-(3-endorphin in the
anterior but not intermediate lobe of the pituitary (Millan et al, 1986). However, since these
changes are not observed following the induction of a unilateral inflammation (Millan et al,
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1988) but are observed following chronic foot shock (Akil et al, 1986), they are thought to
more likely reflect a state of chronic stress than chronic pain (Millan, 1993).
The extent of the involvement of proEnk synthesising neurones in the responses of spinal
neurones to peripheral inflammation remains controversial. Early studies in polyarthritic rats
employing radioimmunoassay techniques reported enhanced levels of ir-Met-enkephalin in the
spinal cord but not brain of these animals (Cesselin et al, 1980, Millan et al, 1986). However,
this response has proved small and inconsistent, and appears unaccompanied by any obvious
elevation in the levels of proEnk mRNA (Millan, 1993). The induction of a unilateral
inflammation has similarly been shown to exert a mild influence upon proEnk neurones.
Although reports by an early radioimmunoassay study of increased enkephalin levels after the
injection of FCA into the rat hindpaw (Faccini et al, 1984) were not confirmed by
immunocytochemical studies using the same inflammatory agent (Iadarola et al, 1988b;
Millan et al, 1988), significant though variable increases in the expression of proEnk mRNA
have been found by RNA blot analysis (Iadarola and Draisci, 1988; Iadarola et al, 1988b;
Draisci and Iadarola, 1989; Draisci et al, 1991). These increases occur rapidly within 4 hours
of inducing the inflammation and persist for about 5 days post-inoculation (Iadarola et al,
1988b). More consistent changes have since been observed by in situ hybridisation (Noguchi
et al, 1992; Przewlocka et al, 1992). The response appears to involve only a subpopulation of
proEnk neurones, since the increases in proEnk mRNA observed were limited to laminae I-II,
V-VI and VII. These increases in proEnk expression parallel those previously observed
following the injection of formalin into the rat hindpaw (Noguchi et al, 1989) or high intensity
electrical stimulation of primary afferent neurones (Nishimori et al, 1989). Studies of the
spinal release of ir-Met-enkephalin into a surface perfusate following the development of such
peripheral inflammation states have likewise observed variable responses. Whereas a
reduction in the spontaneous but not evoked release of ir-Met-enkephalin was observed in the
spinal perfusate of polyarthritic rats in vitro (Cesselin et al, 1984) and in vivo (Bourgoin et
al, 1988), an initial elevation (12 to 24 hours post-inoculation) in the spontaneous but not
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evoked release of ir-Met-enkephalin-Arg-Gly-Leu has been reported using spinal cord slices of
rats with a unilateral inflammation (Przewlocka et al, 1992). In these studies release was
evoked either by raising the potassium concentration of the perfusing fluid, or (where
applicable) by manipulating the inflamed limbs. However, the release of ir-proEnk derivatives
into spinal perfusate has been consistently observed in vivo, following the high intensity
electrical stimulation of primary afferent fibres of the normal rat and cat (Yaksh and Elde,
1980; 1981; Yaksh et al, 1983; Nyberg et al, 1983).
In contrast to proEnk, a dramatic increase in the synthesis and spinal content of proDyn
derived peptides has consistently been observed following the development of a peripheral
inflammation. Pronounced elevations in the spinal cord levels of proDyn peptides have been
detected by radioimmunoassay and immunocytochemistry in polyarthritic rats (Millan et al,
1985; 1986; Weihe et al, 1988; 1989), as well as those with a developed unilateral
inflammation (Iadarola et al, 1988a; b; Ruda et al, 1988; Millan et al, 1988; Weihe et al,
1989; Takahashi et al, 1989; 1990; Nahin et al, 1989; 1992; Noguchi et al, 1991; Przewlocka
et al, 1992). These were accompanied by reports of striking increases in the levels of the
mRNA encoding proDyn as measured by RNA blot (Hollt et al, 1987; Iadarola et al, 1988a,
b; Iadarola and Draisci, 1988; Draisci and Iadarola, 1989; Draisci et al, 1991) and in situ
hybridisation (Ruda et al, 1988; Weihe et al, 1989; Noguchi et al, 1991; Przewlocka et al,
1992; Parker et al, 1993; Persson et al, 1994; Tolle et al, 1994). These changes have been
localised to neurones in the superficial (laminae I-II) and the deep (laminae IV-VI) dorsal
hom, as well as dorsolateral to the central canal in lamina VI, VII and X (as will be described
in detail in section 4.4). A time course analysis has revealed a significant enhancement of the
proDyn mRNA in the spinal cord within 24 hours of the injection of FCA into the hindpaw,
detectable by RNA blot as early as 4 hours, with a peak six- to eight-fold increase between
days 2 and 5, and approaching control levels within 10 to 14 days. This paralleled the
development and time course of the oedema and behavioural hyperalgesia in the hindpaw of
these animals. Increases in the dynorphin peptide were apparent by radioimmunassay, 2 to 3
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days post-inoculation, peaking with a three-fold increase around day 5 (Iadarola et al, 1988a;
b).
Immediate-early genes such as c-fos and c-jun, are thought to regulate initial genetic
events that lead to prolonged functional changes in the CNS (as reviewed by Hanley, 1988;
Morgan and Curran, 1989; Sheng and Greenberg, 1990; Munglani and Hunt, 1995; Herdegen
and Zimmermann, 1995; Hughes and Dragunow, 1995). These proto-oncogenes (so called
due to their homology to retroviral oncogenes) encode nuclear phosphoproteins (e.g. Fos, Jun),
that act as transcription factors by binding to specific DNA consensus sequences in the
promoter region of target genes (such as API sites), as homo- or heterodimeric complexes. In
this way these phosphoproteins are proposed to act as 'third' messengers in the stimulus-
transcriptional coupling cascade, to alter gene expression in response to protein kinases
activated by second messengers such as diacylglycerol, cyclic AMP and Ca2+. It has been
proposed that these immediate early genes play a role in the upregulation of proDyn (and also
proEnk) following the development of a peripheral inflammation. Increases in the levels of ir-
Fos have been observed in the dorsal horn of the rat, predominantly in laminae I-II and V-VI,
following the induction of an inflammatory lesion in the periphery (FCA: Menetry et al, 1989;
Hylden et al, 1992; Abbadie and Besson, 1992; Lanteri-Minet et al, 1993; Tolle et al, 1994.
carrageenan: Draisci and ladarola, 1989; Noguchi et al 1991; Chapman et al, 1995a; b.
formalin; Presley et al, 1990; Williams et al, 1990; Gogas et al, 1991; Leah et al, 1992;
Abbadie et al, 1992; Hunter et al, 1995). RNA blot analysis has revealed a rapid and
pronounced elevation in c-fos mRNA within 30 minutes after the injection of carrageenan into
the rat hindpaw. A three-fold increase was seen to remain for up to 2 hours post-injection,
decreasing to approximately half these levels by 4 hours to give nearly complete recovery to
control levels by 8 hours (Draisci and Iadarola, 1989). As well as this close temporal link,
there is also evidence to support co-localisation of c-fos and proDyn genes within single
neurones in the spinal cord (Naranjo et al, 1991; Noguchi et al, 1991; Lucas et al, 1993).
Additionally a API-like binding site has been found in the promoter region of the proDyn gene
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(Naranjo et al, 1991). Similar evidence exists that c-fos and related proteins are involved in
the increase in proenkephalin synthesis (Sonnenberg et al, 1989; Noguchi et al, 1992). Thus,
although not specifically involved in regulation of any one neuropeptide gene, these nuclear
phosphoproteins serve as good markers for activation of spinal neurones under such
conditions of peripheral inflammation. Notably the recent demonstration that pre- and post-
administration of the NMDA receptor antagonist (+)-HA966 (a partial agonist at the
strychnine-insensitive glycine site of the NMDA receptor complex) reduced spinal c-fos
expression evoked by intraplantar carrageenan into the rat hindpaw (Chapman et al, 1995a),
illustrates a contribution of NMDA receptor activation to inflammation evoked c-fos
expression (and perhaps proDyn/ proEnk expression).
Despite the upregulation in the synthesis of opioid peptides there appears to be no
significant modification in the number of opioid receptor sites, nor their binding affinity, in the
spinal cord of polyarthritic rats (Cesselin et al, 1980; Millan et al, 1986; Delay and Goyet,
1989; Besse et al, 1992) or that of rats with an inflamed hindpaw (Iadarola et al, 1988a;
Millan et al, 1988). However, complex changes, have been observed in the superficial
laminae of the rat spinal cord when the more persistent states of unilateral inflammation have
been employed, such as monoarthritis (Besse et al, 1992). Using quantitative receptor
autoradiography and the selective opioid ligands [3H]DAMGO and [3H]DPDPE bilateral
increases in the number of p and 8 binding sites were observed in laminae I-II of the lumbar
spinal level at 2 weeks, followed by a bilateral decrease in the k binding sites labelled with
[3H]U69593 at 4 weeks. Similar bilateral increases in the number of p binding sites were
observed using a model of chronic pain induced by unilateral foot rot in sheep but no change
in that of 8 binding sites (Brandt and Livingston, 1990). No alteration in the affinity of the
opioid receptors was evident in either study. These changes along with some evidence for a
reduction in the density of k receptor binding in polyarthritic rats (Millan et al, 1986), are
suggestive that opioid receptor alterations may occur only in more long-term persistent states
of noxious stimulation. In the polyarthritic rat any changes in opioid binding specifically
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related to peripheral inflammation may be masked by alterations induced by the generalised
disease state produced. The interpretation of such studies however requires that possible
binding by endogenous ligands be completely dissociated prior to incubating a tissue with the
exogenous labelled peptide. Notably a recent in situ hybridisation study found significant
increases in the expression of p and K opioid receptor mRNA in cell bodies located in laminae
I-II of the rat lumbar dorsal horn ipsilateral to a unilateral hindpaw inflammation at day 11
(one day after an additional injection of FCA), but no change in expression of 5 opioid
receptor mRNA in any laminae (Maekawa et al, 1995). However, no examination was made
of the expression of opioid receptor mRNAs in the DRG of the adjuvant injected rats.
Taken as a whole these experimental findings are indicative of a significant involvement
of the proDyn releasing neurones in spinal cord function following a peripheral inflammation.
The contribution from proEnk releasing neurones however cannot be readily dismissed. There
is evidence that a large 'constitutive' level of proEnk mRNA exists in the normal state. This
has been measured by RNA blot analysis to be approximately 4 times that of the proDyn and
so may be sufficient to meet requirements for the spinal proEnk neurones under inflamed
conditions (Ruda et al, 1995). For example, Iadarola and coworkers calculated that the pool
of proEnk derived peptides measured by RIA in the normal state is 10-20 times that of the
proDyn peptides (Iadarola et al, 1988b). In the face of such a normal high level of activity, it
is perhaps not surprising that small increases have been difficult to detect, and it is has been
suggested that those neurones that display an increase may be without such a high constitutive
expression of proEnk mRNA (Noguchi et al, 1991). Potentially relevant to the functional
consequences of such an enhancement of opioid peptide synthesis at the spinal cord level is the
reduction in the activity of a dynorphin converting enzyme in the cerebrospinal fluid (CSF)
observed in the acute phase of polyarthritis (Persson et al, 1992a) and at 2 weeks post-
injection in monoarthritc rats (Persson et al, 1992b), as well as in the spinal cord tissues of
rats with an inflamed hind paw (Silberring et al, 1992).
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As discussed previously, the enhanced excitability of spinal neurones at the spinal cord
level following inflammation may partially underlie the pain experienced in many disease
states involving such tissue damage. Whilst this may be triggered by the enhanced release of
excitatory amino acids and excitatory neuropeptides such as substance P, little is known of the
involvement of the opioid systems in the development of such states. An enhanced release is
implied from the dramatic upregulation of the synthesis of the proDyn peptides but little
information exists about the mechanisms of their spinal release. The k receptor preferring
dynorphins as already indicated have proved enigmatic peptides to study, with both facilatory
and inhibitory roles in the processing of sensory information at the spinal level having been
proposed (as will be discussed further in section 4.4). It was hoped by studying the effect of
the development of peripheral inflammation on the release of these peptides in the spinal cord,
as will be described in this thesis, that clues to the functional significance of the dynorphins
in such pain states could be obtained.
1.9 ANTI-OPIOID MECHANISMS: ROLE OF CHOLECYSTOKININ
Chronic exposure to opiate drugs, such as morphine, results in the development of
tolerance, characterised as a decline in the response to a given dose of opiate so that
progressively higher doses (or concentrations) become necessary to elicit the same intensity of
opioid effect, evident as a shift to the right on a concentration-response curve. This process is
equally seen for analgesia, respiratory depression, bradycardia and the hypotensive actions of
opiates. Following the cessation of the opiate or administration of a suitable opiate
antagonist, such as naloxone, physical dependence may also be demonstrated. This is
manifestested as a characteristic withdrawal (abstinence) syndrome, many aspects of which
appear to be a 'rebound overshoot' from the opiate depressed state (recently reviewed by
Johnson and Fleming, 1989; Cox, 1993; Way, 1993; Schulz, 1993). It is now generally
accepted that tolerance to and dependence upon opioids are reflections of cellular adaptations,
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investigations into the nature of which have ranged from cultured cell clones to whole animals.
However, despite considerable research, the mechanisms underlying these phenomena and the
relationship between them is still poorly understood.
The close coincidence observed between the development of tolerance and of physical
dependence in animals and man led many early investigators to propose mechanisms linking
the two phenomena. Notably influential amongst these was the 'adenylate cyclase' hypothesis,
that emerged from the finding by Collier and Roy (1974) that opiates in rat brain homogenates
inhibited the synthesis of cyclic AMP induced by the prostaglandins PGE( and PGE2 in a
concentration dependent, naloxone reversible, manner. They suggested that inhibition of
cyclic AMP formation was the fundamental basis of the actions of opioids, and that tolerance
and dependence could be mediated by a compensating hypertrophy of the cyclic AMP
synthesis mechanisms within the opiate sensitive neurone (Collier, 1980). This theory
received considerable support by the demonstration that NG108-15 neuroblastoma x glioma
hybrid cells cultured in the presence of an opiate (and hence chronically exposed) expressed an
increased capacity to synthesise cyclic AMP (Sharma et al, 1975). However, investigations
on isolated tissue preparations placed doubt on such 'unitary' theories, showing that tolerance
and dependence may be separable under certain circumstances (Wuster et al, 1985). For
example, the mouse vas deferens has been demonstrated to display high degrees of opioid
tolerance without any signs of dependence (Schulz et al, 1980a). Similar studies also
demonstrated a remarkable lack of cross tolerance among p., 8 and k receptor agonists (Schulz
et al, 1980b). Further, electrophysiological investigations using rat locus coeruleus slices
obtained from morphine pre-treated animals display a significant degree of tolerance to
opioids but no sign of dependence (Andrade et al, 1983). Evidence has also been presented
for the occurrence of naloxone precipitated withdrawal hyperexcitability of spinal cord
neurones of cats treated acutely with morphine in the absence of any tolerance (Johnson and
Duggan, 1984).
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The occurrence of opioid tolerance but not dependence may be explained by a reduction in
the number of functional receptors, either as a result of 'desensitisation' due to functional
uncoupling of opioid receptor-effector systems, or 'down regulation' due to intemalisation of
the opioid receptors themselves. Although the evidence for such changes are not consistent
especially from studies in vivo (as reviewed by Johnson and Fleming, 1989; Cox, 1993), they
cannot be readily dismissed. In contrast the development and expression of dependence
necessitates that some opioid receptors remain functional, and the involvement of additional
receptor system mechanisms mediating excitatory neurotransmission to allow a hypersensitive
state to develop. As an integrated circuitry appears to be essential for full expression of a
dependent state, this may due to compensatory hypertrophy of intra- or extra-cellularly
localised mechanisms which are involved in the functioning of an opioid neuronal pathway
(Wusteretal, 1985).
Since endogenous opioid peptides were discovered many physiological 'antagonists' of
their actions have been proposed, the so-called 'anti-opioid' peptides (recently reviewed by
Rothman, 1992; Bhargava, 1994; Cesselin, 1995). These include cholecystokinin,
neuropeptide FF (a Phe-Met-Arg-Phe[FMRF] -NH2-like peptide), thyrotropin-releasing
hormone and MSH release-inhibiting factor. It has been proposed that these peptides are
released in response to activation of opioid circuitry either by exogenously administered
opiates or by the endogenous opioid peptides. Of all possible candidates at the spinal cord
level, the anti-opioid activity of cholecystokinin (CCK) has been well characterised,
specifically with respect to the analgesic actions of opioids (as recently reviewed by Baber et
al, 1989). This peptide has also been proposed to play a role in the development of tolerance
to but not dependence on opiate drugs. Following a general description of the
neurotransmitter functions of CCK in the CNS, the evidence for CCK for acting as an 'anti-
opioid' at the spinal level will be considered.
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1. CHOLECYSTOKININ - A HORMONE AND A NEUROTRANSMITTER
The term 'cholecystokinin' was first used by Ivy and Olderg (1928) to describe the
hormonal factor in extracts of intestinal mucosa which mediated gall bladder contractions.
When later isolated by Mutt and Jorpes (1966) from the purified intestine of the pig, this
factor was found to also correspond to 'pancreozymin', the hormonal factor in intestinal
extracts that had been described by Harper and Roper (1943) to stimulate pancreatic
secretion. First characterised as a 33 amino acid peptide, CCK was found to share an
identical COOH-terminal pentapeptide sequence with gastrin, Gly-Trp-Met-Asp-Phe-NH2
(Mutt and Jorpes, 1968). Several longer and shorter molecular forms of cholecystokinin have
since been identified including CCK-58, CCK-39, CCK-8 and CCK-4, all of which are
amidated and except for CCK-4, sulphated (Goltermann, 1985; Rehfeld, 1985). These
peptides have been shown to arise by post-translational modification from a common
precursor molecule, pre-procholecystokinin (rat: Deschenes et al, 1984; pig: Gubler et al,
1984; human: Takahasi et al, 1985). It has been proposed that the CCK and gastrin families
of peptides share a common ancestral gene (Larsson and Rehfeld, 1977), along with the
caerulein-peptides found in the skin of amphibians, which also share the same COOH terminal
pentapeptide sequence (as illustrated on figure 5), more recent comparative studies indicating
that CCK is phylogenetically older than gastrin (Johnson and Rehfeld, 1992). Evidence that
CCK might also exist in the brain was first indicated by Vanderhaeghen et al (1975), who
described the presence of a 'brain gastrin immunoreactive peptide, BGP' within the cortex of a
number of vertebrate species from amphibians to mammals. The majority of this
immunoreactive material was subsequently demonstrated to represent CCK-8 in its
biologically active sulphated form (rat: Dockray, 1976; 1980; Beinfeld, 1981. rabbit: Straus
et al, 1977. sheep: Dockray et al, 1978. pig: Dockray, 1976; Muller et al, 1977; Rehfeld,
1978a. dog: Dockray, 1976. man: Rehfeld, 1978a; Robberecht et al, 1978).
Cholecystokinin has since been described by radioimmunoassay and immunocytochemical
studies to be widely distributed throughout the mammalian nervous system. Although species
73
♦












differences exist, a significant presence has been observed in general in the cerebral cortex,
amydala, hippocampus, olfactory lobes, basal ganglia, hypothalamus, thalamus, various
midbrain structures such as the substantia nigra, ventral tegmental area, periaqueductal grey
matter, raphe nuclei, the medulla oblongata and nucleus of tractus solitarius, and the spinal
cord (rat: Innis et al, 1979; Loren et al, 1979; Vanderhaeghen et al, 1980; Stengaard-Pedersen
and Larsson, 1981b; Beinfeld et al, 1981; Tuchscherer and Seybold, 1983; Fuji et al , 1985;
Vanderhaeghen, 1985; Falon and Seroogy, 1985; Gall et al, 1987. guinea-pig: Larsson and
Rehfeld, 1979; Stengaard-Pedersen and Larsson, 1981b. pig: Rehfeld, 1978a. man: Emson et
al, 1982; Rehfeld et al, 1978a). Moreover, in some of these brain regions (notably in the
cerebral cortex, amygdala, hippocampus, and septum of the rat), CCK has been reported to be
the most abundant peptide with levels 10 to 100 times greater than that of other peptides
studied (Crawley et al, 1985). This is in contrast to the true gastrins that were found only in
significant quantities in the neurohypophysis (pig: Rehfeld, 1978a; b. rat: Loren et al, 1979;
Vanderhaeghen et al, 1980. guinea-pig: Larsson and Rehfeld, 1979. man: Rehfeld, 1978a).
Other molecular forms of CCK if present are always found in much lower amounts than
CCK-8 (Dockray et al, 1976; Robberecht et al, 1978; Muller et al, 1977; Rehfeld, 1978a;
Larsson and Rehfeld, 1979; Beinfeld, 1981; Frey, 1985). Despite some speculation about the
specificity of COOH-terminally directed antisera to CCK-gastrin commonly employed in
immunocytochemical studies (Ju et al, 1986; 1987a, Wiliams et al, 1987; Hokfelt et al, 1988;
as will be considered in detail in section 5.4), the distribution of CCK determined in this way
has been confirmed in most areas of the CNS by biochemical methods (Rehfeld, 1978a;
Larsson and Rehfeld, 1979; Beinfeld et al, 1981), by the use of sequence specific monoclonal
or polyclonal antisera directed at NH2-terminal sites (Fuji et al, 1985; Hokfelt et al, 1985;
1988), and more recently by RNA blot (Voigt and Uhl, 1988; Iadarola et al, 1989; Lindefors
et al, 1991) and in situ hybridisation studies (Siegel and Young, 1985; Savasta et al, 1988;
Lanaud et al, 1989; Ingram et al, 1989; Schiffman and Vanderhaeghen, 1991; Lindefors et al,
1991; Rattray et al, 1992).
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Early binding studies in rat using [l25I]CCK-33, along with other CCK related peptide
fragments, demonstrated differences between brain and peripheral tissues. In the brain
CCK-8, desulphated CCK-8, CCK-4 and pentagastrin were bound with nearly equal affinity,
in comparison with binding sites in the pancreas and gut, that display a high selectivity for
CCK-8 (Innis and Synder, 1980a, b; Saito et al, 1980). Although electrophysiological studies
involving the iontophoretic administration of CCK peptides and analogues into specific brain
regions suggested that all CCK receptors within the CNS were not identical (Chiodo and
Bunney, 1983; Hommeret al, 1985), early homogenate binding and autoradiographic studies
failed to provide any evidence of receptor heterogeneity (Sankaran et al, 1980; Hays et al,
1980; Saito et al, 1991; Gaudreau et al, 1983a; b; Zarbin et al, 1983; Van Dijk et al, 1984;
Williams et al, 1985). Later however, Moran et al, (1986) in more detailed studies based on
the differential binding by sulphated and desulphated CCK-8, demonstrated by
autoradiography that binding sites existed in a few nuclei in the rat brain (namely the area
postrema, nucleus of tractus solitarius, dorsal hypothalamic nuclei and interpendunclear
nuclei), that displayed the same ligand selectivity as those in the periphery. They classified
these receptors as type A (for Alimentary i.e. pancreas and gastric) to distinguish them from
the majority found, type B (for Brain), that are more diffusely distributed and are relatively
non-selective to the multiple forms of CCK. However, the differentiation of receptor subtypes
based on agonist affinity is problematical and it was only on the development of the non-
peptide CCK receptor antagonists, such as MK329 (Devazepide or L365718) with a high
selectivity for peripheral CCK-A receptors (Chang and Lotti, 1986; Evans et al, 1986), that a
clearer differentiation between these classes of CCK receptor could be achieved in
biochemical and pharmacological studies. The development of similar antagonists for the
CCK-B receptor, such as L365260 (Bock et al, 1989; Lotti and Chang, 1989), has allowed
the locations of these CCK-A and CCK-B receptors in the CNS to be even more precisely
defined. For example, these antagonists (displayed on table 3) have confirmed the limited
presence of CCK-A receptors in the rodent (Hill et al, 1987a, b; Hill and Woodruff, 1990)
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TABLE 3. CCK receptor antagonists. Selective antagonists developed to study the
distribution and function of the different types of CCK receptor are listed, with the principal
investigators responsible for the development of each antagonist quoted in brackets (see
























































and primate (Hill et al, 1990; Hill and Woodruff, 1990) brain, and allowed differences
between species to be revealed, such as in the spinal cord where the CCK-B receptors are the
prominent type in the rodent but not the primate, including man (Hill et al, 1988; Hill and
Woodruff, 1990; Ghilardi et al, 1992). The CCK-B receptor binding sites appear the densest
in forebrain structures such as cerebral cortex, hippocampus, amygdala, septum, olfactory
bulbs, and basal ganglia and generally low in the midbrain and rest of brainstem (Hill and
Woodruff, 1990, Moran and McHugh, 1990). The CCK-A receptors, suggested to be
phylogenetically older (Vigna et al, 1984), since they are localised in the area postrema (a
chemosensitive trigger zone where the special epithelial cells of the blood-brain barrier are
absent) and the nucleus of tractus solitarius (the site of entry of vagal afferents), are likely to
play an important role in satiety following food ingestion, being possibly receptive to
peripherally circulating CCK (Moran et al, 1986; Moran and McHugh , 1990). Notably the
recent cloning of the rat CCK-A and CCK-B receptors has shown them to be members of the
G-protein coupled seven transmembrane spanning superfamily of receptors, and to be identical
in both nervous and peripheral tissue (Wank et al, 1992a, b).
From such anatomical studies, along with the finding of neuropharmacological,
electrophysiological and behavioural studies, CCK has been proposed to play a role in a wide
variety of CNS functions, including nociception and analgesia, appetite and thirst,
thermoregulation, neuroleptic activity, anxiety, arousal, motor behaviour, and neuroendocrine
activity (as reviewed by Vanderhaeghen, 1985; Baber et al, 1989; Cooper and Dourish,
1990; Harro et al, 1993; Crawley and Corwin, 1994). Aside from their potential usefulness
as adjuvants in opiate mediated analgesia (as will now be considered in detail), the main focus
of interest in developing effective CCK receptor agonists and antagonists has come from the
prominent role of CCK in satiety following food ingestion and anxiety (particularly of the
'panic-like' nature), the latter notably appearing to involve CCK-4.
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2. ROLE IN NOCICEPTION AND ANALGESIA
Cholecystokinin is localised in regions of the mammalian CNS associated with
nociception and pain modulation, notably the superficial layers of the spinal cord dorsal horn
(see references in section 5.4), the periaqueductal grey ( Maciewicz et al, 1984; Skirboll et al,
1982; 1983; Lanaud et al, 1989; Rattray et al, 1992; Liu et al, 1994) and raphe nuclei
(Mantyh and Hunt, 1984) of the brain stem, and intralaminar nuclei of the ventromedial
thalamus (Hunt et al, 1986; Lanaud et al, 1989). In these regions CCK has been described to
display a similar distribution to the opioid systems (Stengaard-Pedersen and Larsson, 1981c;
Gall et al, 1987; Pohl et al 1990), with even evidence for colocalisation with enkephalin (Gall
et al, 1987) and dynorphin (Gibbins et al, 1987). CCK has been notably also been described
as coexistent with substance P (Dalsgaard et al, 1982; Skirboll et al, 1982; 1983; Gibbins et
al, 1987;Juetal, 1987a; Tuschsherer et al, 1987).
Evidence that CCK plays a role in the processing of nociceptive information at the spinal
level, was originally proposed on the basis of early findings that CCK-8 (ng doses) produced a
powerful, naloxone reversible, analgesia when injected intrathecally (Jurna and Zetler, 1981),
and that ir-CCK was released into the spinal superfusate by bilateral electrical stimulation of
the sciatic nerve only at A8/ C fibre intensities (Yaksh et al, 1982). However, the analgesic
effect of i.t. CCK-8 appears to be dependent on the animal species, the behavioural test
performed and doses of CCK-8 administered (recently reviewed by Baber et al, 1989). These
analgesic effects are now considered to be mediated at high levels and possibly represent more
of a pharmacological than physiological effect. More potent analgesic effects were obtained
when CCK was administered supraspinally, namely in the periaqueductal grey and
ventromedial thalamus, and observed more consistently using analgesia tests such as the hot
plate, that are not simple spinal reflexes such as the tail-flick assay (Zetler, 1980; Jurna and
Zetler, 1981; Barbaz et al, 1986; Hill et al, 1987; Pittaway et al, 1987). Also even high doses
of i.t. CCK-8 (approximately 10 times the ED50 obtained in the tail flick test), failed to reduce
the activity in ascending axons in the spinal cord of rats evoked by the electrical stimulation of
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primary nociceptive afferents (Doi and Jurna, 1982). By contrast in the spinal cord
predominantly excitatory effects have been recorded electrophysiologically following the local
administration of CCK-8 (Jeftinija et al, 1981; Salt and Hill, 1982; Willetts et al, 1985), as in
many other regions of the CNS (Dodd and Kelly , 1981; Skirboll et al, 1981; Chiodo and
Bunney, 1983; Brooks and Kelly, 1985; Hommer et al, 1985; Jaffe et al, 1987; Liu et al,
1994), most of these spinal neurones being also excited by substance P (Willetts et al, 1985).
Notably it has been proposed that CCK acts as a physiological 'antagonist' of the
antinociceptive effects induced by opioids at the spinal level, the evidence for which will now
be considered in detail.
Following observations that CCK under certain conditions displays actions opposite to
those of opioids, such as food intake, Faris et al (1983) hypothesised that CCK would block
opioid mediated (naloxone reversible) analgesia. Using the tail flick test, they observed that
pre-treatment with CCK-8 significantly reduced the analgesia mediated by both exogenous
morphine (administered either intrathecally or systemically), and that induced by brief
electrical shocks to the rat forepaw ('foot shock induced analgesia', FSIA), for which there is
evidence for mediation by endogenous opioids (Watkins et al, 1982). Significantly lower
doses of CCK-8 were employed (approximately 10 times lower than those reported to elicit an
analgesic response) which alone produced no effect on the tail flick latencies to radiant heat
(Faris et al; 1983; Faris, 1985). Faris and co-workers also showed that rats immunised
against CCK-8 conjugated to bovine serum albumin (BSA), displayed heightened analgesic
responses compared to controls that had been treated with BSA alone (Faris et al, 1984; Faris,
1985). A multitude of behavioural evidence has since been presented in favour of CCK
acting as a endogenous inhibitor of opioid actions at the spinal level, determining the
magnitude of the opioid analgesic response, some of the more convincing being studies where
the effects of CCK receptor antagonists were examined. These are considered below. It is
interesting that many behavioural studies have found central effects following the peripheral
administration of CCK-8, despite reports this derivative of procholecystokinin does not cross
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the blood-brain barrier (Banks et al, 1980), although it may to a limited extent along with even
lower molecular weight forms such as CCK-4. Additionally there is also a possibility that
some of the central effects of systemic CCK could be indirect via actions in the periphery.
Early studies by Watkins and co-workers in rats using the weak non-selective CCK
receptor antagonist proglumide (co-administered either intrathecally or systemically together
with morphine), indicated that endogenous CCK can act to attenuate the analgesia induced by
morphine and forepaw shock, as well as that mediated by the injection of a stable enkephalin
analogue, as assessed by the tail flick assay (Watkins et al, 1984; 1985a; b). A potentiation
of the analgesic response was observed with low doses of the antagonist (up to 0.1 jig given
intrathecally), followed by a reduction of the response with high doses (1 and 5jig), a 'bell-
shaped' dose-response curve being produced. This phenomenon has been observed with other
CCK receptor antagonists (Dourish et al, 1988; 1990) and as yet remains unexplained,
though it may be the result of actions at multiple CCK neuronal sites or systems. The
specificity of the response to the opioid systems was supported by the lack of enhancement by
proglumide of non-opioid mediated analgesia (i.t. noradrenaline, hindpaw foot shock). Again
there was no evidence that CCK was producing an independent hyperalgesic effect, since
proglumide had no effect in the absence of opioids. Thus, the CCK pathways appear not to
be tonically involved in nociception but rather activated by opioids (endogenously released or
exogenously administered), and may function to return pain perception back to normal. A
similar reciprocal role of CCK and opioid peptides has also been revealed by studies of the
analgesia induced by i.e.v. (3-endorphin in the hot plate test (Itoh et al, 1982; Katsuura and
Itoh, 1985) found to be mediated by the spinal release of Met-enkephalin (Tseng et al, 1986;
Suh et al, 1992), and by the demonstration that proglumide administered into the
periaqueductal grey of rats potentiated analgesia from morphine given either by the same
route (Watkins et al, 1984, 1985a) or systemically (Li and Han, 1989).
Other studies with proglumide and benzotript (another weak CCK receptor antagonist)
have pointed to a role of CCK in opiate tolerance. Thus, the chronic coadministration of the
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CCK antagonists with morphine was found to inhibit the development of tolerance to
morphine analgesia in rats (Watkins et al, 1984, 1985a; b; Tang et al, 1984; Rovati et al,
1985; Panerai et al, 1987). It has been proposed that tolerance to the analgesic effect of
opiates may in part result from a progressive compensatory increase in the activity of CCK
systems in response to prolonged opiate administration. No such involvement of CCK in the
occurrence of opioid dependence was evident, as assessed by observing the withdrawal
syndrome precipitated by graded doses of acutely injected naloxone (Rovati et al, 1985;
Panerai et al, 1987).
Using the tail flick (Dourish et al, 1988; 1990) and paw pressure (O'Neill et al, 1989;
Rattray et al, 1988) tests in rats, the more potent and selective CCK-A receptor antagonists,
MK329 or L365031, given systemically have been similarly found to enhance morphine
analgesia, and prevent the development of tolerance to morphine. Even more potent effects
have been observed in rats using the CCK-B receptor selective antagonist L365260 (Dourish
et al, 1990; Zhou et al, 1993b), indicating that the CCK-opioid interaction most likely occurs
through CCK-B receptors in the rodent. Although CCK receptor antagonists alone had not
been found to produce an effect on behavioural nociceptive thresholds, this CCK-B receptor
antagonist when administered systemically into monkeys was shown to induce analgesia, as
revealed by increased tail withdrawal latencies to immersion in warm (55°C) water (O'Neill et
al, 1990). Due to the lack of CCK-B receptors in the primate spinal cord, however, this
effect is likely to be mediated at a higher CNS level, such as the periaqueductal grey. More
recently another CCK-B receptor antagonist CI988 (PD134308) has been shown to potentiate
the analgesic effect of morphine (Wiesenfeld-Hallin et al, 1990), to block the development of
tolerance to morphine (Xu et al, 1992), as well as reverse the tolerance induced (Hoffman and
Wiesenfeld-Hallin, 1994) in rats to repeated morphine administration, as assessed by the hot
plate test. There is also considerable evidence for an involvement of CCK in the
electroacupuncture analgesia reported to be mediated by the release of endogenous opioid
peptides (Han et al, 1981; 1985; 1986; Zhou et al, 1993a). It is of note that CCK has also
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been reported to exert effects on other neuronal systems implicated in antinociception at the
spinal cord level, namely GABA (Rodriguez et al, 1987), galanin (Wiesenfeld-Hallin et al,
1990) and noradrenaline (Sullivan et al, 1994), although such actions could be indirect via
actions on opioid systems.
Although behavioural research points to a possible physiological role of CCK as an
endogenous modulator of opioid analgesia, the mechanism of interaction remains obscure,
and much remains to be done at a single cell and membrane level. Electrophysiological
studies have tended to support the findings of these behavioural investigations. CCK does not
appear to play a direct role in nociceptive transmission. The spinal application of CCK-8
(Jeftinija et al, 1981; Magnuson et al, 1990; Kellstein et al, 1991; Stanfa and Dickenson,
1993; Sullivan et al, 1994) and of CCK receptor antagonists (Suberg et al, 1985; Kellstein et
al, 1991; Stanfa and Dickenson, 1993; Sullivan et al, 1994) have been shown to produce
minimal effects on C fibre evoked discharges of dorsal horn neurones, and when effects have
occurred with selective antagonists (Wiesenfeld-Hallin and Duranti, 1987; Wiesenfeld-Hallin
et al, 1990) they have been attributed to indirect opioid mechanisms, namely a blockade of the
tonic activity of the endogenous CCK system. In contrast however, CCK peptides and
antagonists have been found to reduce and enhance respectively the depressive action of
morphine on C fibre evoked responses at the spinal cord level (Suberg et al, 1985; Kellstein et
al, 1991; Stanfa and Dickenson, 1993; Sullivan et al, 1994) and on the nociceptive flexion
reflex (Wiesenfeld-Hallin and Duranti, 1987; Wiesenfeld-Hallin et al, 1990). A recent study
by Chapman et al (1995b) also revealed a reciprocal relationship between the CCK and
opioid peptides on the expression of c-fos in the spinal cord, following the development of a
peripheral inflammation. A normally ineffective dose of morphine was found to reduce the
expression c-fos in superficial and deep laminae of the spinal cord when administered
systemically with the CCK-B antagonist L365260, which alone induced no effect.
Thus, along with evidence that i.t. morphine causes the release of ir-CCK from the rat
spinal cord in vivo (Tang et al, 1984; Zhou et al, 1993b), it has been suggested that CCK
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may be released in response to opioid receptor activation in the spinal cord and act to
modulate the analgesic effects of opioids. Prolonged repetitive activation of opioid
antinociceptive pathways would then induce a compensatory increase in the activity of anti-
opioid CCK circuitry and hence cause progressively greater antagonism of opioid activity,
culminating in the development of tolerance to the analgesic effect of opioids. Standard
pharmacological texts describe such a process as a 'physiological antagonism' (Rang et al,
1991). Such an hypothesis appears to be supported by the demonstration that larger amounts
(20 fold) amounts of the CCK antagonists (proglumide and its more potent analogue
lorglumide) are required to reduce the tolerance that develops to a higher dose (10 fold) of
morphine co-administered intrathecally, than that which is induced by a lower dose (Kellstein
and Mayer, 1991).
However, the possible modulatory effects of opioid receptor activation on CCK neuronal
systems has not been thoroughly investigated. Despite an early study reporting that spinal
levels of ir-CCK are significantly increased in rats following morphine treatment (Watkins et
al, 1985b), more recent investigations have observed either no effect (Pohl et al, 1992) or
significant increases (Ding and Bayer, 1993) in the spinal cord content of CCK following
acute and chronic morphine treatment. Moreover, conflicting data have been obtained from
experiments which have examined spinal release of CCK following the administration of
opioids in vivo (Tang et el, 1984; Rogriguez and Sancristan, 1989; Zhou et al, 1993) and in
vitro (Benoliel et al, 1991; 1994a; b). It was hoped by examining the effect of acute and
chronic opiate administration on the release of CCK in the spinal cord, as will be discussed in
this thesis, that information on the mechanism of this interaction could be obtained.
1.10 PRINCIPLES OF THE ANTIBODY MICROPROBE TECHNIQUE
The antibody microprobe technique was developed by Duggan and Hendry (1986) as a
means of improving the spatial precision with which sites of neuropeptide release can be
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determined in the CNS under in vivo conditions. The principles of the antibody microprobe
technique are illustrated in figures 6 and 7.
Basically, antibody microprobes are fine glass micropipettes, with a siloxane polymer
coating on their outer surfaces, to which antibodies to a neuropeptide of interest are
immobilised. These are inserted into the brain or the spinal cord and left in situ for a defined
period of time, so that a proportion of the neuropeptide if released, may bind to the adjacent
microprobe surface. Following withdrawal from the CNS, any binding of the endogenous
peptide can be detected as the failure of regions of the microprobe to bind a radiolabeled
form of the peptide, in which it is subsequently incubated and autoradiographic images
obtained. These microprobe autoradiographs can be analysed quantitatively with a computer
assisted image analysis system, as illustrated on figure 7. The distribution of the amounts of
bound radiolabeled peptide is determined by changes in the image density (or grey scale
value) along the length of the autoradiographs, with any deficits in the tracer binding being
represented graphically as comparatively low grey scale values. A sorting program can select
groups of microprobes according to stimulus/ experimental parameters and allow pairs of
such grouped or ' mean' image analyses to be compared and the significance of their regional
differences evaluated statistically. The binding pattern of the endogenous peptide detected on
the antibody microprobes, under defined physiological conditions, can then be related back to
discrete structures in the CNS, such as the individual laminae of the spinal cord. Release is
equated with a significant increase in the extracellular levels of a compound following a
defined stimulus.
The antibody microprobe technique has so far been employed in the cat and rat spinal
cord to study the release of substance P (cat: Duggan and Hendry, 1986; Duggan et al, 1987;
1988a; b; 1991a; 1992; 1995; Hutchison and Morton, 1989; Morton et al, 1990; Schaible et
al, 1990; 1992; Zhao et al, 1992; Lang et al, 1994. rat: Lang and Hope, 1994), neurokinin A
(cat: Duggan et al, 1990; 1991b; Hopeetal, 1990 b; c; Lang et al, 1991), CGRP (cat: Morton
and Hutchison, 1989; 1990; Schaible et al, 1994. rat: Schaible et al, 1994),
87
FIGURE 6 Principles of the antibody microprobe technique for the in vivo detection of
neuropeptide release I. From antibody immobilisation to the production of autoradiographic
images.
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PRINCIPLES OF THE ANTIBODY MICROPROBE TECHNIQUE I
1. Antibodies (y) to a neuropeptide of interest are immobilised onto the outer surfaces of glass
micropipettes.
^VYY Y Y Y Y Y Y Y Y Y Y Y Y v
^AAAAAAAAAAAAAAA—
2. Locally released neuropeptide (V) binds to adjacent antibodies in vivo.
^VYY ¥ ¥ ¥ ¥ Y Y V Y Y Y Y Y Y
A A A A .A/^^AAAA A~7s 7\
3. Radiolabeled form of the peptide (v) in which microprobes are subsequently incubated
in vitro binds to free antibody sites.
^¥¥¥ ¥¥¥¥¥¥¥¥¥¥ ¥¥ ¥
4. After washing microprobes are placed on X-ray film to obtain an autoradiographic image.
5. Autoradiographs indicate sites of extracellular neuropeptide presence.
Area of reduced image = area of reduced radioligand binding
= area of endogenous ligand binding
6. Groups of microprobes present under defined physiological conditions are compared. Release is
equated with increased extracellular levels produced by a defined stimulus
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FIGURE 7 Principles of the antibody microprobe technique for the in vivo detection of
neuropeptide release II. Image analysis of the autoradiographic images to reveal sites of
endogenous peptide binding.
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PRINCIPLES OF THE ANTIBODY MICROPROBE TECHNIQUE II
1. Using a computer-assisted image analysis system, autoradiography are converted into plots of
image density (or grey scale values) v.s. length at 30pm intervals (A). The analysis system allows
data from a group of microprobes to be pooled and a plot of mean image density (+/- s.e.m.) at each
30pm interval to be produced (B). The means are joined to give a continuous line but the s.e.m. at
each analysis point is plotted separately.
2. Mean image analysis for two groups of microprobes can be statistically compared at each 30pm
interval, using multiple Students' t-tests (A). Areas of statistically significant differences (i.e.
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somatostatin (cat: Morton et al, 1989), galanin (cat: Morton and Hutchison, 1989. rat: Hope
et al, 1994), dynorphin (cat: Hutchison et al, 1990) and neuropeptide Y (rat: Mark et al,
current study) in response to a range of peripheral stimuli and systemically administered
drugs. It has also been used in the brain to measure the release of substance P (cat: Williams
et al, 1994a. rat: Furmidge et al, 1993); neurokinin A (rat: Furmidge et al, 1995), (3-
endorphin (rat: Duggan et al, 1993. cat: Williams et al, 1993), neuropeptide Y (cat: Williams
et al, 1993), thyrotrophin releasing hormone (rat: Waterfall et al, 1994), and enkephalins (cat:
Williams et al, 1994b).
The amounts of neuropeptide which can be detected on autoradiographs of microprobes,
as displacement of the radiolabeled ligand, can be extremely small. For example, complete
inhibition of the binding of [l2-''I]BoIton-Hunter substance P with a specific activity of
approximately 2000 Ci/ mmol, has been estimated to correspond to the binding of 3 x 10"'8
mole of substance P, over a lOOpm of the length of microprobe (Duggan, 1991). The
amount of time the microprobes need to remain in the CNS to detect the endogenous peptide
varies according to local neuropeptide concentrations and the sensitivity of the particular
microprobes, ranging in these previous studies from 5 to 30 minutes. A recent study showed
that 150 stimuli delivered at 0.5Hz for a 5 minute duration, resulted in just detectable release
of immunoreactive (ir)-substance P in the spinal cord by microprobes (Duggan et al, 1995).
Although more of a qualitative than quantitative technique, some estimate of the
concentrations in the vicinity which produce a given inhibition of binding is possible. With
nearly all studies performed, it has been shown in vitro that the neuropeptide to which the
immobilised antibodies have been raised, at a concentration of 10"7M for 30 minutes at 37°C,
has suppressed the binding of the radiolabelled form of the peptide by greater than 50%
(Duggan and Furmidge, 1994). With p-endorphin such suppression occurred with 10~9M
(Duggan et al, 1993). Morton et al (1989) also made some estimate of the concentrations of
somatostatin to which the microprobes were exposed to in vivo, by relating images of
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microprobes exposed to differing concentrations of the neuropeptide in vitro to those of
microprobes that had been inserted into the spinal cord.
Since the antibody microprobe technique determines peptide release with a biological
resolution of the order of 100pm, it can provide far greater insight to the role of a
neuropeptide in a particular system than is possible with non-invasive, surface perfusion
methods. Also since each microprobe has a diameter of only 5 to 10pm, the microprobes
cause minimal trauma to the tissue into which they are inserted, and hence minimal
disturbance to the structures releasing the peptide. This contrasts to the trauma associated
with the other invasive methods that attempt to localise areas of release in vivo, such as those
involving the introduction of push pull cannulae and microdialysis fibres with diameters of
300-500pm into the CNS. These other invasive techniques give poor biological resolution,
for example in the spinal cord they localise sites of release to little better than the dorsal or the
ventral horn, and have a tendency towards low recovery rates. Thus, the antibody microprobe
technique remains the least damaging invasive method for the in vivo detection of
neuropeptide release.
1.11 AIM OF THESIS
To employ the antibody microprobe technique to study release of neuropeptides, as a
means of investigating the involvement of the endogenous opioid peptide dynorphin in spinal
cord function using an inflammatory model of 'chronic' pain, and the possible role of
cholecystokinin as an endogenous opioid 'antagonist'.
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CHAPTER 2: General Methodology I: Animal Models and
Surgical Procedures
2.1 ANIMALS
Male Wistar rats (weight range 250-275g) obtained initially from Bantin and Kingman,
UK, and then later from Charles River,UK, were used in the studies described in thesis.
Charles River rats due to their higher pathogen-free status were preferred, since this likely
affords them a greater resistance to the respiratory infections which rats are particularly prone
when being housed. No other differences were observed between the animal sources.
The rats were acclimatised on arrival for at least 48 hours before being used in any
procedure/ experiment. They were kept under controlled conditions, at an ambient




Chronic ankle inflammations were initially induced under diethyl ether anaesthesia. This
involved placing a rat on a metal grid suspended in a sealed glass bell jar in a fume cupboard,
beneath which cotton wool balls soaked in diethyl ether had been positioned, until a suitable
level of anaesthesia was obtained. When the procedure was complete the animal was observed
for complete recovery before being rehoused.
Diethyl ether was later deemed as too irritant for both the rat and the handler to be used in
this procedure.
(ii) Halothane
The majority of the recovery procedures performed were carried out under halothane
anaesthesia (initially started at 4% to induce anaesthesia then reduced to between 0.5 and 1%).
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This involved placing the animal in a specifically designed chamber through which halothane
gas could be passed at a controlled concentration and any excess scavenged away into a
special storage vial. When anaesthetised the rat was removed from the chamber to allow the
induction of a chronic ankle inflammation. Anaesthesia was maintained throughout by
attaching the rat directly to the halothane supply via a mask into which both the nose and
mouth of the rat could be sealed. When the procedure was complete the halothane supply was
removed, but the oxygen supply continued until the animal had regained consciousness.
2 NON-RECOVERY PROCEDURES
Urethane (ethyl carbamate)
For all the non-recovery experiments described in this thesis, rats were anaesthetised with
urethane (25% weight/volume[w/v] solution; Sigma Chemical, UK). A single intraperitoneal
(i.p.) injection of 1 g/ kg urethane in Ringers' solution was sufficient to induce complete
anaesthesia. Following induction, the depth of the anaesthesia was assessed by direct
measurement of the mean arterial blood pressure (systolic pressure maintained at between 100
and 120mmHg), via a catheter inserted into a carotid artery and by regularly testing for
corneal blink and hindpaw withdrawal reflexes which had to be absent. Further injections of
urethane were given i.p to maintain anaesthesia sufficient to abolish both of the reflexes
measured. In addition, blood pressure levels and changes induced by peripheral stimuli were
closely monitored to ensure that noxious stimuli would induce no more than approximately a
5mmHg rise in blood pressure.
At the end of each experiment the anaesthetised animal, was killed by an intravenous (i.v.)
injection of a mixture of concentrated KC1 and urethane, which resulted in cardiac arrest
within seconds.
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2.3 INDUCTION OF PERIPHERAL INFLAMMATION
1. DEVELOPED ANKLE INFLAMMATION
For the purpose of the experiments performed in this thesis a unilateral adjuvant induced
inflammation of the periarticular tissues (Grubb et al, 1988; Donaldson et al, 1993) was
employed as a model of chronic inflammation. This was used primarily since it resulted in
reliable and reproducible unilateral inflammation that remained stable over several weeks, but
also since it probably pertains more directly to the joint 'pain' that most electrophysiological
investigations of inflammation have studied under more acute conditions (as described in
section 1.8).
To induce such an inflammation animals received 4 subcutaneous injections of a Freund's
complete adjuvant (FCA) suspension (1.0 mg/ ml heat killed and dried Mycobacterium
tuberculosis in 85% paraffin oil and 15% mannide manooleate; total volume of 0.15ml;
Sigma Chemical, UK) around one ankle joint, using a sterile 26'/2 gauge needle and a 2ml
syringe, on Hibitane (0.5% in 70% ethanol; Zeneca Ltd., UK) cleaned skin. This was
performed initially under diethyl ether and then for later experiments under halothane
anaethesia (as described in section 2.2.1). These animals were then left for between 3 to 5
days before being used in an experiment. Throughout this time the animals were monitored
for the development of swellings at other peripheral locations. On the day of the experiment
the circumferences of both ankles were measured. These injections resulted in a self-limiting
inflammation that was well developed by 3 to 5 days, the ankle region swelling from an
average diameter in normal animals of 2.7cm to a mean diameter of 4.0cm within this time
period. Injected animals showed little or no apparent discomfort, gait impairment or change
in weight gain.
Previous histological studies by Hanesch et al (1993b) have shown that the inflammation
resulting from this procedure involves both articular (capsule and cartilage) and periarticular
tissues (connective tissue, tendons and skin). Using this dose of FCA no signs indicative of a
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generalised disease state, such as the development of swellings at other peripheral sites, were
ever observed. This was in agreement with the studies of Donaldson et al (1993).
2 ACUTE ANKLE INFLAMMATION
In addition some rats received the same adjuvant injections on the morning of the
experiment, to allow study of the release of peptides at an early phase of the inflammatory
response. The injected ankle usually showed some sign of swelling over the period of the
study.
2.4 ACUTE ADMINISTRATION OF MORPHINE
Morphine was administered intravenously to rats, over a two hour period, in as high doses
as possible without causing significant respiratory depression, bradycardia or hypotension. It
was determined that for a rat of approximately 400g this could be achieved by administering
2.5 or 5 mg/ kg of morphine every 15 minutes over the two hour period, each dose being
followed by sterile Ringers' solution to flush the cannula of the drug solution. Morphine HC1
(Martindale Pharmaceuticals, UK) was dissolved from powder form in sterile Ringers'
solution into a 25mg/ml stock solution, divided into 1ml volumes in Eppendorf tubes and
stored at -20°C until use.
To block the effect of the morphine, naloxone was administered as an adequate single
injection of lmg/kg, again followed by sterile Ringers' solution to flush the cannula of the drug
solution. Naloxone HC1 (Sigma Chemical, UK) was dissolved from powder form in sterile
Ringers' solution into a lOmg/ml stock solution, divided into 1ml volumes in Eppendorf tubes
and stored at -20°C until use.
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2.5 SURGICAL PROCEDURES
Initial surgery involved the cannulation of a carotid artery, an external jugular vein and
the trachea, to permit direct measurements of arterial blood pressure, to allow the intravenous
injection of drugs and to aid unobstructed breathing respectively. The anaesthetised rat was
laid on its back on a homeothermic heating pad. The neck area was closely shaved with
electric clippers and a longitudinal incision made along the midline of the exposed skin. A
jugular and then a carotid artery were exposed using blunt dissection through the musculature,
connective tissue and fat pads. A section of each vessel was completely cleared using small
curved forceps allowing three fine silk ligatures to be positioned, one of which was tightened
rostrally to allow the vessel to be stretched slightly by attached artery forceps. An opening
was then made in each vessel, using iris scissors under a binocular microscope. The carotid
artery was first securely clamped at its caudal end. Portex cannula (3FG) attached to plastic
three way taps were filled with either sterile Ringers' solution alone for the vein, or with
Heparin (12.5units/ ml; CP Pharmaceuticals Ltd, UK) for the artery. These cannulae were
then introduced caudally into each vessel in turn, for a distance of approximately 1.5cm, and
secured in position by tightening the remaining ligatures. The trachea was then exposed and
an opening was made to allow the narrow end of a fluted cannula to be inserted. These
tracheal cannulae were manufactured in the heat of a bunsen flame from polythene tubing and
were fluted to maximise air flow. Notches were made at their widest point to hold a ligature
formed from a linen thread that had been previously placed beneath the trachea. From this
stage efforts were made to ensure the trachea remained unobstructed by intermittent suction.
Blood oxygenation was also assisted by directing a gentle jet of humidified oxygen towards
the opening of the tracheal cannula.
An extended laminectomy was then made at vertebral levels T12 to L2 to expose the dura
mater of the lumbar spinal segments Li-L6, that receive an input from the ankle joint area.
This involved removal, by blunt dissection, of the muscle groups attached to the dorsal surface
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of the vertebral column, approximately 2cm either side of the rats most caudal ("floating") rib
which is attached to T13. The exposed bone was cleared of all tissue with a blunt scapel
blade. The rat was then positioned in a stereotaxic frame (Preclinical Veterinary Sciences,
The University of Edinburgh), by means of ear bars and a jaw vice, and six swan neck clamps
were placed under alternate mammillary processes of the exposed vertebrae. The incised skin
was reflected towards the frame and secured to each corner by means of linen thread. The
animals temperature from this point was continually monitored with a rectal probe and
maintained between 36-38°C using a controlled heating system, which consisted essentially of
a metal plate, with inserted controlled heating elements, that partially surrounded the animal
(Preclinical Veterinary Sciences, University of Edinburgh). This was found to be more
satisfactory than commercially available heating blankets which tended to obstruct chest
movement in the spinal frame which was used. The heated plate was controlled by a Devices
control box of the type normally used with heating blankets. Any exposed parts of the rat
were covered with a foil blanket, in particular it was found that heat loss was greatly assisted
by covering the tail. The dorsal vertebrae were removed with micro-rongeurs at the required
segments under a binocular microscope. The edges of the remains of the laminae were lined
with sterile haemostatic gauze (Sterispon) to prevent any subsequent bleeding. A sterile
solution of purified agar in Ringer's solution (4% w/v; Unipath Ltd., UK) was then used to
cover the muscle and nervous tissue beneath and to form a solid pool, into which a window
over the lumbar spinal segments was then made. Following opening of the dural sac with
sterile forceps, the exposed spinal cord was irrigated via a pump and heating jacket with
sterile Ringers' solution at 37°C, continuously throughout the experiment, to prevent drying of
the cord surface and ensure reasonably sterile conditions around the spinal cord. Any excess
fluid was removed by suction at an edge of the opening. Although continuous irrigation
minimised the collection of inflammatory exudates on the surface of the cord, it was often
necessary to remove any small accumulations of fibrinous material from archnoid/ pia
openings with sterile fine forceps and hand controlled suction.
99
CHAPTER 3: General Methodology II: Preparation and
Use of Antibody Microprobes
3.1 STORAGE OF ANTIBODIES AND PEPTIDES
Certain precautions were taken in storage and handling of the antibodies and peptides
employed in the antibody microprobe studies, to ensure that they performed optimally. This is
in contrast to the inorganic compounds commonly employed, which were more robust and
whose storage was more straightforward.
1. ANTIBODIES
The antibodies to dynorphin and CCK, were purchased commercially from Peninsula
Laboratories Europe Ltd. They were supplied in a stable form, Iyophilised from a buffer
solution of 0.1M sodium phosphate buffer (pH7.4), 0.05M NaCl, 0.1 % bovine serum albumin
(BSA), 0.01% NaN3 and 0.1% Triton X-100. In practice it has been found that microprobes
were better made from such preparations if the lysophilisate was reconstituted at double the
concentrations for radioimmunoassay recommended by the manufacturer, with the
recommended diluent. Thus, in these studies, the lyophilised antiserum was reconstituted with
25ml of distilled water and then divided into 250pl and 500(0.1 volumes in Eppendorf tubes.
The resultant aliquots were then stored at -20°C until use. No reconstituted antibodies were
ever refrozen after being thawed, as repeated thawing/ refreezing damages protein structure.
2. PEPTIDES
All peptides used in the antibody microprobe studies described in this thesis, were stored
in Eppendorf tubes treated with Sigmacote (Sigma Chemical, UK). This coating that
minimises the binding of peptides to surfaces, was also (more importantly) employed to coat
the inner surface of the glass microcapillaries, that were used in various stages in the in vitro
and in vivo experiments as a convenient way of incubating the microprobes in small quantities
of the unlabelled and radiolabelled peptides. As with the antibodies, no peptides were ever
refrozen after being thawed from the reconstituted state.
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(i) Unlabelled peptides
These were purchased in freeze-dried form from Peninsula Laboratories or Sigma
Chemical, and reconstituted according to the suppliers recommendations with the appropriate
dilutent, commonly a solution of phosphate buffered saline (PBS) containing 0.1 % sodium
azide. The bulk of the peptide was reconstituted as a 10~4M solution. These were then used
to make up 100p.l dilutions of 1010~7 and 10~9M either at the same time as stock solutions
or as required in the Sigmacoted Eppendorf tubes. All aliquots were stored at -20°C or
-70°C.
(ii) Radiolabelled peptides
Commercially [l25I]-labelled peptides were purchased in a lyophilised form in lOpCi
batches, from Peninsula Laboratories or Amersham International pic, UK. These were
reconstituted immediately on delivery with the recommended dilutent, distilled water for
dynorphin A(l-8) and CCK, then divided into suitable volumes. These aliquots were stored in
a designated, lead screened freezer at -20°C until required. On the day of an experiment a
single aliquot was diluted in a solution of PBS-azide containing 0.5% BSA (Sigma Chemical,
UK) to give a solution with a gamma emission of 2000 counts per minute (cpm) per p.1 and
stored on ice (but not frozen) until required. The BSA serves to block non-specific binding of
the radiolabelled peptide to the microprobe surface. Since [l25I] has a half life of 60 days,
batches of the radiolabelled peptides were usually only used up to approximately 6 weeks after
their specified activity date.
3.2 PREPARATION OF ANTIBODY MICROPROBES
The preparation of the antibody microprobes has changed in various subtle ways
since the most recent detailed published account by Duggan (1992) and indeed since the
work in this thesis was initiated. It is of note that other forms of antibody microprobes
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have been prepared involving evaporative organic aminosilane, polycarbonate or epoxylite
resin-activated charcoal coatings (Waterfall et al, 1994), however these will not be
discussed further in the context of this thesis. The following is the current method of
antibody microprobe production used in our laboratory.
1. SILOXANE POLYMER COATING OF GLASS MICROPIPETTES
Proteins can be immobilised to glass by placing organic groups onto the glass surface
(Weetall, 1970). With the antibody microprobes this is done by reacting a substituted
silane (y-aminopropyltriethoxysilane) with silanol groups and hydroxy! groups of
adsorbed water, on the outer surface of the glass micropipettes. The initial reaction is
shown schematically in figure 8A. The hydroxyl groups interacting with the substituted
silane are shown as part of the glass, but there is evidence that much of the reaction
depends on chemisorbed water molecules. Provided there is sufficient adsorbed water on
the surface of the glass, there is a tendency for a cross-linked polymer to build up. Such a
polymeric coating can be readily visualised under the microscope and assessed for the
quality needed for the future uniform coating with antibodies, which is necessary if any
degree of spatial precision is to be obtained.
(i) Preparation of the glass micropipette
Hollow, non-filament borosilicate capillary glass (GC300-10; Clark Electrochemical
Instruments, UK; external diameter 3mm, internal diameter 1.62mm), was used to
manufacture the glass antibody microprobes. The capillary glass was cleaned thoroughly
before use by incubating it overnight in a container of xylene and then serially in three
different containers of absolute alcohol, for periods of 30 minutes. After drying in a clean
oven, the glass was then stored in covered beakers until required.
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FIGURE 8. Preparation of antibody microprobes. (A) The interaction between 7-
aminopropyltriethoxysilane and the glass surface of a micropipette to produce alkylamine
(siloxane coated) glass. (B) Stages in the preparation of the antibody microprobes. The

































The capillary glass was then drawn out to a very gradual taper by heating in the coil of a
vertical microelectrode puller (Preclinical Veterinary Sciences, The University of Edinburgh).
The coil extends over 10mm of the capillaries, thus ensuring the melting of a large area of
glass. The principles of operation of this type of puller and the factors that influence the
shape of the micropipettes, are illustrated on figure 9A. Figure 9B shows the typical
dimensions of a pulled micropipette used in the studies described in this thesis. Since in these
studies microprobes were inserted 2.25mm into the rat spinal cord, the shape of the
micropipettes had to remain approximately constant up to 5mm from the tip. The pulled
micropipettes were then heat sealed at both ends; the unpulled end in a gas flame and the tip,
by touching it briefly against an electrically-heated coil mounted in a micromanipulator under
a binocular microscope to allow accurate sealing. The resultant micropipettes although very
flexible and fairly resistant to accidental breakage were stored horizontally in specially
prepared grooved metal racks held within covered plastic boxes throughout most of the
production.
The micropipettes (usually in groups of approximately twenty) were then tightly packed
into glass carrying buckets with small perforations in the base, to allow easy handling and
permit draining throughout microprobe preparation during the many washing procedures.
Micropipettes, in buckets, were then immersed in 50% nitric acid for 30 minutes and then
given 3x10 minute washes in distilled water. This is believed to increase the number of free
silanol groups on the glass surface (Weetall, 1970). The buckets of micropipettes were
suspended by their hooked upper ends in a clean oven and dried at 200°C for at least 2 hours,
or until further use. This entire process resulted in clean, dry micropipettes with some degree
of surface etching, on which subsequent chemical reactions could proceed.
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FIGURE 9. Manufacture of glass micropipettes for antibody coating. (A) Principles of
operation of micropipette puller. The capillary glass is suspended between the two holders (a,
b) running through a heated metal coil (c) at mid-length. The lower holder is attached to a
solid metal weight (d) by means of a robust metal cable. As the glass is heated by the coil, it
stretches and the lower holder drops. At a particular distance a switch is activated, which
triggers a strong electromagnetic field (0 , this rapidly pulls the weight down and draws the
molten glass out to a very gradual taper before separating to give two micropipettes. The heat
of the coil, drop distance until magnetic pull triggered and pull force are all factors which
determine microprobe shape. (B) Typical dimensions of antibody microprobes used for

























(ii) Preparation of the reagents
The following method is based on having a measured amount of water in the solution of
substituted silane, in an attempt to control the amount of siloxane polymerisation at the
surfaces of the micropipettes, and hence maximise the coating success rate. Excessive water
in the solution results in excess polymerisation within the bulk of the silane/ toluene solution.
Clean boiling tubes (24/29; Quickfit) were placed in the same oven as the micropippettes
and dried for 2 hours. Whilst still warm the boiling tubes were placed in a fume cupboard and
filled with 30 ml of reagent grade toluene (Aldrich, UK), 10ml aliquots of
y-aminopropyltriethoxysilane (APTES; Aldrich) and 5pl of distilled water The boiling tubes
were then stoppered with polythene caps and vortexed to ensure complete mixing of the
solutions. The toluene had been previously been treated with molecular sieves (4A, 4-8 mesh;
Aldrich) to absorb as much water as possible (150g of molecular sieves are added to a 2.5
litres of the reagent grade toluene and left for at least 24 hours), to control the amount of
water in the substituted silane solution.
(iii) Exposure of the glass micropipettes to the reagents
The buckets of glass micropipettes were carefully removed from the oven with metal
forceps and allowed to cool slightly before each was added to a tube of APTES/ toluene
mixture. The boiling tubes were then restoppered and placed in centrifuge holders, that are
balanced in pairs using lead pieces. The boiling tubes were then placed in a centrifuge and
spun at 4°C, 2000rpm for 1 hour. This centrifugation results in a more even build up of
siloxane polymer on the surface of the micropipettes. This is thought to be due to either
centrifugation of free water away from the tips of the micropipettes or to the removal of small
particles of debris from the solution around the tip, which may act as foci for the
polymerisation reaction. The stoppered boiling tubes were then removed from the centrifuge,
placed in a rack and left to stand overnight in a refrigerator at 4°C. The buckets of
microprobes were then removed from the boiling tubes in a fume cupboard and washed by a
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brief immersion in the toluene solution, after which they were allowed to dry at room
temperature. The APTES/ toluene mixture was then discarded. Sample microprobes from
each bucket were then inspected under a binocular microscope for adequacy of coating. A
satisfactory coat is one that is readily visible and even. If too light, it was necessary to
repeat the above procedure to build up the intensity of the siloxane coat. Once the
micropipettes were deemed to be satisfactorily coated, they were cured, still within the carrier,
in an oven at 200°C for 24 hours. This increased the cross-linking within the polymer and
rendered it insoluble.
(iv) Assessment of siloxane coating
Following curing, each microprobe was checked for evenness of coat by placing in a
micromanipulator mounted beneath a binocular microscope and examined under incident light
at xl2.5 magnification. A good polymer coat on the surface of the microprobes will appear as
a milky deposit, white prior to heat curing and yellowish afterwards. Following curing the
coat should be resistant to a vigorous wiping with a clean soft tissue. It was important to
identify microprobes with uneven or patchy distribution of siloxane coating, which were
disregarded, and also to identify microprobes with small focal aggregations of polymer. In
some cases these 'lumpy' microprobes can be made usable by the wiping procedure.
Microprobes were generally sorted into three groups; those with light, medium and heavy
polymer coating. Although the analysis of microprobes (as will be described in section 3.5) is
performed in such a way as to minimise the effects of coat density on the final result, it was
deemed appropriate to utilise microprobes with similar densities of siloxane.
2. COUPLING OF ANTIBODIES TO MICROPROBES
It takes a minimum of 48 hours for microprobes to be prepared for an in vivo experiment.
Siloxane coated microprobes can be stored indefinitely, but once proteins have been linked
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they probably have relatively short lifespan, and have usually been used within approximately
72 hours of being completed.
There are three stages in the coupling of antibodies to the siloxane coated microprobe.
The basic reagents used at each stage are illustrated figure 8B. Proteins are covalently bound
to the amine groups of the siloxane coated microprobe surfaces via the bifunctional reagent
glutaraldehyde. The antibodies to the neuropeptides studied in this thesis were only available
in polyclonal antiserum, raised by the active immunisation of rabbits to either porcine
dynorphin A(l-8) or CCK-8, and hence full of unwanted proteins. Thus, protein A, a
staphylococcal derived protein which has a high selectivity for the Fc region of some
immunoglobulins of the IgG class (namely those raised in rabbits and guinea-pigs) whilst
leaving the peptide binding site free (Goding, 1978), was used as an intermediate to bind the
required immunoglobulins from a polyclonal antiserum to the surfaces of the microprobes.
(i) Glutaraldehvde treatment
The desired number of siloxane coated microprobes to be used in an experiment, were
selected and placed in clean, siloxane-free glass carrying buckets, their coatings having been
given a final check under the microscope. They were then immersed in a solution of 2.5%
glutaraldehyde (BDH Laboratory Suppliers, UK) in distilled water for 30 minutes. The
buckets of microprobes were then washed for 3 x 10 minute washes in distilled water.
(ii) Glutaraldehvde/ protein A coupling
Under a dissecting microscope, the tips of the glutaraldehyde treated microprobes were
then immediately inserted into 5pl glass microcapillaries (Blaubrand; UK) filled with a
solution of protein A (Staphylococcus aureus; Sigma Chemical, UK). The protein A had been
diluted in PBS-azide solution, to give a final concentration of 0.1 mg ml1. Each microprobe,
capped with a capillary, was placed horizontally in a slot on a perspex rack. When all the
microprobes were treated, the racks were placed in a covered plastic tray and placed in a cold
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room at 6°C for at least 24 hours. Paper towels soaked in PBS-azide were placed in the base
of the tray to minimise evaporation during this period.
(iii) Protein A/ antibody coupling
Following incubation the microprobes were removed from the protein A containing
capillaries and placed in a glass dish containing sodium borohydride 2.5% w/v (Sigma
Chemical, UK) in a borate buffer for 10 minutes. This mixture reacts to produce free
hydrogen, that reduces the Schiff bases, formed by aldehyde coupling to amino groups on the
protein A. The microprobes were then placed in further clean, siloxane-free glass carrying
buckets and given 3x10 minute washes in PBS-azide solution. The microprobes were then
inserted into 20jal glass microcapillaries (Camlab, UK) containing a solution of the antibody
to the neuropeptide under study. The microprobes were then again placed on perspex racks in
covered trays and placed in a cold room at 6°C for a minimum of 24 hours, depending on the
dilution of the antibody.
At least 15 minutes before their use in an experiment, the microprobes were stored in
glass carrying buckets in solutions of PBS-azide, to wash away any excess antibody and allow
the microprobes to acclimatise to room temperature (20 to 23°C).
3.3 IN VITRO TESTING OF ANTIBODY MICROPROBES
In vitro testing of the antibody microprobes occurs both before and periodically
throughout studying the release of a particular neuropeptide in the CNS.
1. PRIOR TO IN VIVO EXPERIMENTATION
Prior to use in vivo the sensitivity and specificity of the antibody microprobes for the
neuropeptide being studied, needs to be determined. When purchasing a new antibody, great
attention is paid to the manufacturers claims regarding the cross-reactivity of the antisera with
other peptides. From such radioimmunoassay data, those antisera displaying the greatest
specificity for the neuropeptide of interest, were initially chosen for testing (see individual
studies for details of specific antiserum). As previously stated these were polyclonal antisera
and hence contained immunoglobulins of a ranging affinity and specificity.
The typical format of an in vitro assay testing both the sensitivity and specificity of
antibody microprobes is illustrated on table 4, using the gamma counter results for
microprobes bearing antibodies to dynorphin A(l-8).
(i) Measurements of antibody microprobe sensitivity and non-specific binding of the
radiolabeled ligand
This involved incubating microprobes in known concentrations of the neuropeptide being
studied. Antibody microprobes (at least five per peptide concentration to be tested, plus an
additional five microprobes which were simply incubated in the radiolabeled peptide) were
prepared as previously described. Approximately 15 minutes prior to use in an assay, the
microprobes were stored in glass carrying buckets in solutions of PBS-azide at room
temperature. Then the majority were inserted into 5pl Sigmacoted capillaries filled with
various concentrations of peptide solution, identified accordingly by colour coding with an
indelible marker pen, and placed for 30 minutes at 37°C in a humidified incubator, to mimic
to some extent the conditions to which comparable microprobes will be exposed to in vivo.
On removal from the incubator the microprobes were placed in a holder and their tips lowered
vertically into a magnetically stirred, ice-cold solution of PBS-azide containing 0.1% Tween
80 (Pierce and Warriner Ltd), for 15 minutes (including those not exposed to any
concentration of peptide solution), to remove any unbound peptide and debris from their
surfaces. After washing the tips, all the microprobes were placed in 5pl Sigmacoted
capillaries filled with the radiolabeled form of the neuropeptide under study, for 24 hours at
6°C.
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TABLE 4. The results of an in vitro assay testing both the sensitivity and specificity of
microprobes bearing antibodies to dynorphin Atl-8). Microprobes mounted on card were
placed in tubes (corresponding to POS no. 1 to no.36) and assessed for amount of radioactive
emission (in cpm) using a Beckmann RIA scintillation well gamma counter. The mean ±
s.e.m. were obtained for microprobes that had been incubated under the same conditions,
using cpm values (or 'counts') that had been corrected for background emissions (cor.cpm).
Microprobes no. 1 to no.5: were not exposed to any concentration of peptide solution but
simply incubated in [I25I]-dynorphin A(l-8). The mean ± s.e.m. of the cor.cpm obtained for
these 'OM' microprobes represent 100% binding of the radiolabelled ligand.
Microprobes no. 6 to no.9: were incubated in a 10"9M solution of dynorphin A(l-8) prior
to [125I]-dynorphin A(l-8). This resulted in an overall suppression of the mean counts
obtained for microprobes no. 1 to 5 (i.e. the total counts) of 36%.
Microprobes no. 10 to no. 15: were incubated in a 10~7M solution of dynorphin A(l-8).
This resulted in an overall suppression of the total counts of 56%.
Microprobes no. 16 to no.21: were incubated in a lO -^M solution of dynorphin A(l-8).
This resulted in an overall suppression of the total counts of 84%.
Microprobes no. 22 to no.26: were incubated in a 10"5M solution of dynorphin A(l-17).
This resulted in an overall suppression of the total counts of 5%.
Microprobes no. 27 to no.31: were incubated in a 10"5M solution of dynorphin A( 1-13).
This resulted in an overall suppression of the total counts of 18%.
Microprobes no. 32 to no.36: were incubated in a 10"7M solution of Leu-enkephalin.
This resulted in no apparent overall suppression of the counts.
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0 1 1 60 914 880.0
0M
0 1 2 60 1422 1396.7
0 1 3 60 1148 1118.0 1105.2
0 1 4 60 1057 1025.4 ±75.4
0 1 5 60 1136 1105.8
0 2 6 60 621 583.0
Dyn A(l-8)
10"9M
0 2 7 60 779 741.0 711.5
0 2 8 60 791 753.0 ±37.4
0 2 9 60 807 769.0 (436%)
0 3 10 60 582 570.3
Dyn A(l-8)
10"7M
0 3 11 60 421 403.0
0 3 12 60 489 473.7 485.5
0 3 13 60 634 596.0 ±31.0
0 3 14 60 433 395.0 (456%)
0 3 15 60 513 475.0
0 4 16 60 208 161.7
Dyn A(l-8)
10"5M
0 4 17 60 316 271.6
0 4 18 60 284 239.1 175.2
0 4 19 60 168 121.1 ±24.7
0 4 20 60 179 152.4 (484%)
0 4 21 60 133 105.0
0 5 22 60 1035 1033.8
Dyn A(l-17)
10'5M
0 5 23 60 1216 1220.1 1046.9
0 5 24 60 819 811.4 ±63.3
0 5 25 60 1010 1008.0 (45%)
0 5 26 60 1151 1161.3
0 6 27 60 875 874.6
Dyn A(l-13)
10"5M
0 6 28 60 983 986.8 908.0
0 6 29 60 945 947.3 ±32.9
0 6 30 60 784 780.1 (418%)
0 6 31 60 989 951.0
0 7 32 60 1266 1191.0
Leu-Enk
10"7M
0 7 33 60 1230 1155.0 1180.44
0 7 34 60 1036 998.5 ±46.4
0 7 35 60 1333 1297.1 (40%)
0 7 36 60 1273 1260.6
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Following incubation in the radiolabeled peptide, the microprobes were again washed for 15
minutes in a magnetically stirred, ice-cold solution of PBS Tween 80. The tips of the
microprobes were then carefully broken off, between a thumb and forefinger, to give a final
length of approximately 15mm. It is important during this procedure that none of the tip is
lost. The distal portions of these microprobes were then mounted on narrow strips of
cardboard by applying a small amount of typist correction fluid (Liquid paper/ Tippex) to the
broken end. These strips of card were then placed in tubes, and the amount of radioactive
emission (in cpm'l) was determined for each tube using a Beckmann RIA scintillation well
gamma-counter.
Autoradiographic images of these in vitro probes were also obtained. This was done by
fixing the strips of card bearing the microprobe tips onto a sheet of paper, again using
correction fluid, and placing it into a standard (non-screen) X-ray film cassette next to a sheet
of monoemulsion X-ray film (CEA, MRB) for up to 7 days.
(ii) Measurements of the specificity of the antibody
Although the antisera used have been examined by conventional radioimmunoassay before
purchase, it is also important to verify some of the manufacturers claims for specificity prior
to commencing in vivo work. Such measurements were carried out at the same time as the
sensitivity and non-specific binding of the radiolabeled ligand was tested and involved
incubating microprobes in equivalent concentrations of those peptides most likely to produce
some cross-reactivity, in an identical manner to that described in (i).
2. CONCURRENT WITH IN VIVO EXPERIMENTATION
Periodically throughout the use of a batch of the radiolabeled peptide, a less intensive
check of the functioning of the antibody microprobes was made. Typically this involved
suppression with only two concentrations of the unlabeled neuropeptide being studied in vivo,
and intermittently that of another peptide had been previously been shown to result in some
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cross-reactivity. This was to confirm that the sensitivity and specificity of the microprobes
being employed were still as determined from the initial in vitro investigations.
3.4 IN VIVO USE OF ANTIBODY MICROPROBES
Before microprobes were inserted into the spinal cord, the suitability of potential
penetration sites in relation to the proposed peripheral stimuli are examined. In the present
experiments this was achieved by recording with a 4M NaCl filled microelectrode, the
excitatory responses of neurones in the deep dorsal horn (approximately 0.6 to 1.0mm from
the dorsal surface of the spinal cord) to light mechanical cutaneous stimuli. All the studies
described in this thesis, involved placement of microprobes into regions of the lumbar spinal
cord that responded to such stimulation of the ankle region. A sketch of the vascular system
on the dorsum surface of the spinal cord exposed was made for future reference of the
microprobe penetration sites chosen. In order to permit microprobe entry into the spinal cord
it was often necessary to remove the pia mater at these sites using sterile fine forceps.
Microprobes were removed from the PBS-azide solution in which they had been stored
immediately prior to use and both of the sealed ends were removed. The unpulled end was
removed by a glass cutter and the tip, by gently bumping it against the surface of a metal coil
under a binocular microscope, to give tip diameters of approximately 10p.m. At this stage
some of the microprobes were filled with potamine sky blue 2% (w/v) in 1,2M sodium acetate
solution to allow easy visualisation of the tips for accurate placement in the cord, and also to
eject dye for future determination of tip placement. Pairs of microprobes were introduced into
the same side of the spinal cord to a depth of 2.25mm from the dorsal surface using two
stepping motor driven micromanipulators. One microprobe was orientated vertically to the
spinal cord surface and the other at 10° from the vertical, both approximately 0.6mm
mediolaterally from the centre of the dorsal vein. When the tips of the microprobes were
visualised as just touching the cord surface, under a binocular microscope, the manipulators
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were re-zeroed, and the microprobes were lowered into the spinal cord. Microprobes were
initially kept in the cord for 5, 15 or 30 minutes, until preliminary analysis could be
performed, to determine the optimum period of time required for that particular release study.
During these periods either no stimulus was applied, the animal was subjected to the
application of a peripheral stimulus, or a drug was given intravenously (see individual studies
for details). On average 24 microprobes were placed in the spinal cord of any one animal.
At the end of each experiment pontamine sky blue was ejected iontophoretically at several
defined sites and depths in the lumbar spinal cord, some of which corresponded to sites of
prior microprobe insertion sites. The spinal cord was then removed and fixed in
paraformaldehyde (10%). This was later sectioned and processed histologically to locate the
resultant dye spots. This data was essential to verify the placement of microprobes during an
experiment, and allow locations on the probes to be related to positions within the spinal cord.
An example of such a spinal cord section is shown in figure 10. On the opposing figure legend
is a schematic drawing depicting the lamination of the spinal cord grey matter of the third
lumbar spinal segment of the adult rat, taken from Molander et al (1984). This can be seen to
bear close resemblance to the spinal cord section illustrated.
Upon removal from the spinal cord, microprobes were washed for 15 minutes in ice-cold
PBS Tween 80, and then incubated for approximately 24 hours at 6°C in Sigmacoted
capillaries containing the radiolabeled form of the peptide under study. Following this period
the microprobes were again washed for 15 minutes in an ice cold solution of PBS Tween 80,
but this time with suction applied to the inside of the microprobes, as a precaution in case the
sealed electrode tips had been broken and any radiolabeled peptide that might have been
transported by capillary attraction into the tip. Suction was obtained by mounting the thick
ends of the microprobes in a sealed perspex block, which was in turn connected to a vacuum
pump. The distal portions (10 to 15mm) of the microprobes were then carefully broken off,
mounted on a sheet of paper and placed in a X-ray film cassette next to monoemulsion X-ray
film for 3 to 5 days for dynorphin study and 5 to 7 days for CCK study, in a manner
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FIGURE 10. Histological section of the rat spinal cord. (A) Transverse 52pm section of the
lumbar region of the rat spinal cord (stained with neutral red) from an antibody microprobe
experiment studying the release of ir-dynorphin A(l-8). To verify the placement of microprobes,
pontamine sky blue was ejected iontophoretically at defined depths near some of the sites of prior
microprobe insertion, which in this particular section was 2.25mm below the surface of the cord
dorsum (marked by an arrow-head). This can be seen in greater detail in (B).
Below is a schematic drawing depicting the lamination of the spinal grey matter of the third
lumbar spinal segment of the adult rat (derived from Molander et al, 1984). This can be seen to
bear a close resemblance to the spinal cord section illustrated opposite. Liss, Lissauer's tract;
LSN, lateral spinal nucleus; IL, intermedio-lateral nucleus; Pyr, pyraminal tract; LG, lateral
group of large cells in the dorsolateral part of the ventral hom; IM, intermedio-medial nucleus;
MG, medial group of large neurones in the intermediate zone; VM, ventro-medial nucleus.
As depicted by the solid vertical line microprobes were inserted approximately 0.6mm






analogous to that previously described for the in vitro tests. At least two films were derived
from each experiment.
A satisfactory X-ray film was considered to be one with unblurred, dark images for all
microprobes, but in which it was clear that exposure was submaximal. In some experiments it
was necessary to expose a second film to the microprobes for a longer time than that used for
the first exposure. Occasionally, single microprobe images would be blurred due to poor
apposition of the microprobes to the film and in this case a minor repositioning of the affected
microprobe was made prior to repeated exposure. The autoradiographs were labelled on each
film with a number corresponding to the order of placement in the spinal cord during the
course of the experiment. An example of such an autoradiographic image is included on
figure 6.4.
3.5 IMAGE ANALYSIS OF ANTIBODY MICROPROBE AUTORADIOGRAPHS
The principles employed in the analysis of the antibody microprobe autoradiographs
obtained, are based on those described by Hendry et al. (1988). Quantitative
microdensitometric analysis was achieved using a computer based image analysis system that
quantifies the microprobe images as changes in image density (or degrees of blackness) along
the microprobe length.
The developed film chosen to represent a particular experiment was cut into small strips
each containing a single microprobe image. Following the removal of any surface dust and
grease by wiping with a clean soft tissue, each was placed in turn onto a microscope stage in a
light proof box and illuminated. Uniform illumination was achieved by a controlled light
source (two 25W microscope halogen bulbs, connected to a Farnell 0.25V power supply),
located beneath the stage, through diffusion plates and a narrow slit, set at a width just larger
than the microprobe image itself. The film was then scanned by a charged coupled device
camera (CCD; Panasonic), using an enlarger lens held in extendable bellows. Although the
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automatic gain control of the CCD camera was deactivated, it was also necessary to restrict
the field of the camera to just that of the microprobe image, to make it a satisfactory
microdensitometer. A constant magnification was maintained throughout the studies described
in this thesis, by setting the distance from the camera lens to the film so that only the last 5mm
of the microprobe tip occupied the monitor screen.
Image analysis of the camera image employed an Imaging Technology PC Vision Plus
frame grabber board operating in an AT based computer (DCS 286e). Using a memory map
of 512 x 512 locations this image board converted the optical density of the video image to an
arbitrary 'greyscale' value over the range of 0 to 255 degrees of brightness recognised by the
CCD camera, where 0 is black and 255 is maximum light. If the light intensity is increased
above 255 no further change in the grey scale reading can be obtained and so linearity is lost.
Thus, to ensure that the entire range of values was being accessed, the light intensity was
maintained at 0 in the absence of any X-ray film and once set, the lighting level for any
particular experimental film was left unchanged, while all the microprobe images on that film
were entered. Since the length of microprobes scanned was 5mm, each memory location in the
image board map corresponded to 5000pm + 512, which has been regarded as 10pm.
The values obtained for the microprobe image were corrected for background. Prior to
scanning the microprobe images from an experiment, a background value for the entire field
had been calculated and stored as a disk file. Due to the particulate nature of X-ray film, this
had been done by scanning 10 times, two different unexposed parts of the X-ray film, and
taking the average sum of the digitalized values obtained for the 512 x 512 pixels. However,
since the object of the image analysis was to quantify the microprobe autoradiographs as
changes in degrees of blackness, a new value was assigned to each pixel from a white to
black 'look-up table', so that 0 now represents maximum light and 255, black. A coloured
image of each microprobe was displayed on the monitor, the corrected intensities having been
converted to 16 false colours by red, green and blue look-up tables.
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Transverse integrations of these background corrected greyscale values were then
performed by the computer, for each vertical column of pixels across the restricted part of the
field which contained the microprobe image. Thus an array of numbers were obtained which
represented image blackness in 10pm intervals. These were then stored in a file on the hard
disc of the computer, together with 37 coded values that represent various details of the
experimental conditions relevant to that microprobe. The coded values which were entered to
define the experimental conditions in the studies of this thesis, are outlined in table 5. Thus,
each file entry for a microprobe image has 549 numbers, 37 for experimental conditions and
512 representing the 5mm of microprobe image length analysed. The integral values obtained
can be displayed graphically as a function of the image density (or grey scale value) changes
along the microprobe length, to a resolution of 10pm (corresponding approximately to the
width of a single pixel). Although in theory the microprobes detect continuously along their
length, the resolution of the method is determined mainly by the scattering of radiation emitted
by bound radioactive molecules, and hence the distance of the source from the detecting film.
This is in turn determined by probe diameter and hence increases with the distance from the
tip. So although the image analysis is performed in 10pm steps, this is beyond the biological
resolution of the microprobe method. This has instead been calculated to be nearer to 100pm,
since 100pm sources of release are readily detected at a distance of 3mm from the tip
(Duggan, 1992). For display purposes the average of three successive integrals was taken to
give a final plotted resolution of 30pm. Such an image density scan is represented on figure
7.1 (n=l). The slope in such a graph results from the progressive increase in probe diameter
starting from the tip. Any inhibition of binding of the radiolabeled peptide (representing
binding of the endogenous peptide) is displayed as areas where the grey scale values are lower
than those at the corresponding points on control microprobes that have only been exposed to
the radiolabelled peptide.
For every microprobe study described in this thesis, the coded values for each microprobe
image were entered into one large file. This enabled a sorting program to retrieve groups of
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TABLE 5. Examples of the coded values entered to define the experimental conditions in the
antibody microprobe studies described in this thesis. These values are used to select groups of
microprobes conforming to a particular experimental criteria from a file of images so that
mean image analyses can be prepared. Some codes (i.e. no.l to no. 17) apply to all
microprobes in an experiment, whereas others (i.e. no. 18 to no.37) vary for each individual
microprobe, in all instances 99 represents non-applicable criteria. Record i.d. numbers 151,
203, 666, 670 are microprobes from the dynorphin study (code 14 = 91, code 26 = 9) and
166, 173 microprobes from the CCK study (code 14 = 80, code 26 = 81).
Microprobe no. 151: was present in the spinal cord of a normal rat (code 18 = 1), for 30
minutes (code 21 = 30), prior to any mechanical stimulation (code 18=1, code 19 = 99).
Microprobe no.203: was not inserted into an animal (i.e. in vitro) but exposed to [I25I]-
dynorphin A(l-8) alone and processed concurrently with those used in vivo (code 18 = 90).
Microprobe no.666: was present in the ipsilateral side of the spinal cord of a rat with
unilateral ankle inflammation (code 18 = 64), during the 30 minute period of noxious
mechanical stimulation (code 18 = 64, code 19 = 6).
Microprobe no.670: was present in the contralateral side of the spinal cord of the same rat that
microprobe no.666 had been inserted (code 18 = 71), for the 35-65 minute period post
compression of the uninflamed ankle (code 18 = 71, code 19 = 99, code 30 = 3).
Microprobe no. 166: was present in the spinal cord of a rat during the third 30 minute period
of the acute intravenous administration (code 18 = 10) of morphine (code 19 = 10), the total
dose given in this time period being 5mg/ kg (code 35 = 5).
Microprobe no. 173: was present in the spinal cord of the same rat that microprobe no. 166
had been inserted during the first 30 minute period post injection (code 18 = 80) of naloxone
(code 19 = 11), the total dose given at the start of this time period being lmg/ kg
(code 35 = 1). However, since this microprobe displayed problems with binding [l25I]-CCK it
was disregarded in any subsequent analysis (code 14 = 99).
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1 Record i.d. number 151 203 666 670 166 173
2 Experimental date: 7 7 17 17 21 21
3 (day/ month/ year) 7 7 5 5 2 2
4 93 93 94 94 95 95
5 Experimental number 18 18 46 46 10 10
6 X-ray film cassette type (screen/ no screen) 2 2 2 2 2 2
7 X-ray film type (monolayer/ bilayer) 1 1 1 1 1 1
8 Hours on film (hours) 96 96 72 72 120 120
9 Microprobe glass (hollow/ solid) 2 2 2 2 2 2
10 Species (rat/ cat) 2 99 2 2 2 2
11 Anaesthetic type (urethane etc.) 3 99 3 3 3 3
12 Intact spinal cord/ spinalised 1 99 1 1 1 1
13 Not paralysed/ paralysed with gallamine 2 99 2 2 2 2
14 Antibody used (type and manufacturer) 91 91 91 91 80 99
15 Antibody dilution 7 7 7 7 7 7
16 Concentration of peptide for in vitro test 7 0 7 7 7 7
17 Method of spinal cord irrigation 3 99 3 3 3 3
18 Stimulus type (none, mechanical etc.) 1 90 64 71 10 80
19 Stimulus parameters (none, pinch, flexion etc.) 99 99 6 99 10 11
20 Probe number within experiment 1 99 3 7 9 17
21 Time in spinal cord (in minutes) 30 99 30 30 30 30
22 Depth of insertion into spinal cord 22 99 22 22 22 22
23 Estimated distance from tip to cord surface 22 99 22 22 22 22
24 Estimated distance of substantia gelatinosa from tip 16 99 16 16 16 16
25 Estimated distance of lamina V form tip 10 99 10 10 10 10
26 Radiolabeled ligand used (type and manufacturer) 9 9 9 9 81 81
27 Wash treatment on removal from cord 2 2 2 2 2 2
28 Incubation time in radiolabeled ligand (hours) 1 1 1 1 1 1
29 Special features of probes/ autoradiographic images 0 0 0 0 0 0
30 Total previous stimuli given 0 99 0 3 3 1
31 Previous noxious stimuli for this patch/ section of cord 0 99 0 0 0 0
32 Age of patch (if applicable) 0 99 0 0 0 0
33 Probe order in patch/ section of cord (1st, 2nd, etc.) 99 99 99 99 99 99
34 Type of antibody on companion probe 99 99 99 99 99 99
35 Drug type and dose 99 99 99 99 5 99
36 Time (minutes) since first dose of drug (any route) 99 99 99 99 99 99
37 Extra comments 99 99 99 99 99 99
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microprobes conforming to a particular experimental criteria, and produce a plot of the mean
grey scale values (± s.e.m.) in 30pm steps. An example of such a mean image density scan is
represented on figure 7.1 (n=30). The mean greyscale values for a particular grouping of
microprobes are plotted out as a solid line graph, with the values of the s.e.m. as dotted lines
on both sides of the mean line. To minimise any differences due to variability in physical
factors such as X-ray film exposure times, the analysis programme has a facility to 'normalise'
the values obtained for each microprobe image scan. This involved determining from the
mean image density scan of the total group of microprobes from a particular study, the mean
grey scale value of a relatively constant 500pm section of the grouped microprobes
(approximating to the width of 50 pixels), located in a region not inserted into the spinal cord.
This was then taken as a standard to calculate a variability constant for each image density
scan, to adjust the coded integral values for each microprobe image that had been previously
entered into a file on the hard disc, and thereafter referred as 'normalised data'. For example
the standard grey scale value of the image density scans for microprobes used to study the
release of ir-dynorphin A( 1 -8), was taken to be 3000 along the 500pm region 2.4 to 2.9mm
from the tip (see figure 11). The readjusted integral values for each microprobe image were
then entered into a new file on the hard disc.
Using this normalised data, the data sorting program was used to compare the differences
between groups and estimate the significance of the differences at each of the 30pm analysis
points using the Students' t-test. This is represented on figure 7.2. Here the 't' statistics,
derived from the differences between the mean image analyses of the two groups, are plotted
in 30pm intervals against a schematic representation of the spinal cord. The cross hatched
areas representing areas where the presence of the neuropeptide under study, in this case
dynorphin A(l-8) was found to be statistically significant at the P < 0.05 level (i.e. t>2). It
should be noted that taking differences between two groups of microprobes (each with the
shape produced by increasing thickness when progressing away from the tip) eliminates the
slope inherent in the plot of each group. There is still the problem however, that a zone of
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FIGURE 11. Determination of a standard grey scale value to 'normalise' the values obtained
for each microprobe image scan in the dynorphin study. This is an example of the type of
mean image density scan of dynorphin A( 1 -8) microprobes used to decide the standard grey
scale value of a relatively constant 500pm section of the grouped microprobes located in a
region distal to that inserted into the spinal cord. The 500pm region 2.4 to 2.9mm from the
tip was chosen, which approximates to a grey scale value of 3000. This was used as a
standard to 'normalise' the values obtained for each microprobe image scan in the dynorphin
study. Such a process serves to minimise any differences between microprobes due to
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complete inhibition of binding near the tip will look smaller than a zone on the thicker part of
the microprobe (the absolute difference is greater with the latter). As the variance in the
difference is smaller near the tip (smaller absolute values), a plot of the t-statistics (in 30p.m
steps) is a better illustration of where significant differences in levels were detected by the two
groups.
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CHAPTER 4: Studies of the Spinal Release of Dynorphin - Effect of
the Development of Peripheral Inflammation
4.1 INTRODUCTION
In 1979 Goldstein isolated a peptide from porcine pituitary that performed so favourably
to other opioid peptides in the guinea pig ileum assay, that he gave it the Greek prefix 'dyn-',
signifying strength or power, describing it as 'an extraordinary potent opioid peptide'
(Goldstein et al, 1979). The peptide isolated, dynorphin A(l-17), is now known to be
prodynorphin 209-225 (Goldstein et al, 1981), derived by the sequential proteolytic cleavage
of the much longer genetically distinct precursor, pre-proDyn, with additional cleavage of this
region resulting in dynorphin A(l-8) (prodynorphin 209-216; Minamino et al, 1980). Other
common dynorphins found in the mammalian nervous system are a-neoendorphin
(prodynorphin 175-184; Kangawa et al, 1981) and dynorphin B( 1 -13) (prodynorphin 228-
240; Kilpatrick et al, 1982).
As indicated in section 1.8, this family of opioid peptides shows dramatic changes in
synthesis and spinal content with inflammation, with increases in dynorphin A(l-8) (Iadarola
et al., 1988a, b; Ruda et al., 1988; Nahin et al., 1989, 1992), dynorphin A(l-17) (Millan et
al., 1985, 1986, 1988; Weihe et al., 1988, 1989) and a-neoendorphin (Przewlocka et al.,
1992) having all been described. Evidence that these rises in neuropeptide levels are preceded
by increases in the mRNA levels for proDyn has also been presented (Iadarola and Draisci,
1988; Ruda et al., 1988; Iadarola et al., 1988a, b; Weihe et al., 1989; Draisci and Iadarola,
1989; Przewlocka et al., 1992).
Early behavioural studies implied a close association of the regulation of these opioid
peptides with sensory alterations, those polyarthritic rats showing the greatest mechanical
hyperalgesia in the paw pressure test displaying the greatest rise in dynorphin
immunoreactivity (Millan et al, 1985). The changes in proDyn synthesis were found to be
localised to the spinal segments receiving the afferent input from the inflamed limbs, occurring
bilaterally in the polyarthritic rats and ipsilaterally in animals with a unilateral inflammation
(Millan et al, 1988). Indirect evidence of the nature of this afferent input was provided by a
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study employing capsaicin neonatally to destroy almost all the unmyelinated (the majority
likely nociceptive), primary afferent fibres (Hylden et al, 1992). These investigators found
dramatic reductions in the number of neurones exhibiting prodynorphin mRNA when a
hindpaw inflammation was induced in the neonatally capsaicin-treated rats in adulthood
compared to those treated neonatally with vehicle alone, implying that dynorphin gene
expression is partially dependent on input from capsaicin sensitive primary afferents. This
could be mono- or poly-synaptic but there is anatomical evidence to suggest that dynorphin
containing spinal neurones are contacted monosynaptically by primary afferents (Cho and
Basbaum, 1989), including putative nociceptive afferents that contain CGRP and substance P
(Takahashi et al., 1988, 1990; Carlton and Hayes, 1989). These neuropeptides were found to
be reduced following neonatal capsaicin treatment (Hammond and Ruda, 1991). It is notable
that although such neonatal capsaicin treatment resulted in some reduction in thermal
sensitivity in normal rats, its lack of effect on FCA-induced oedema and thermal hyperalgesia
implies that the primary afferents affected are not directly involved in the inflammatory
response (Hammond and Ruda, 1989). A close association of the regulation of these spinal
dynorphin containing neurones with sensory processes is also suggested by the finding that the
marked increase in proDyn mRNA expression following injections of carrageenan into the rat
hindpaw was inhibited by the presence of tachykinin receptor antagonists (Parker et al, 1994).
Although an increased RNA message for proDyn could simply be a response to prior
release, it has been proposed that the immediate stimulus to elevated levels of dynorphins is
increased transcription of the prodynorphin gene through immediate early genes, such as c-fos.
As outlined in section 1.8.3, a close temporal link between the increases in c-fos protein (ir-
Fos) and mRNA levels for proDyn has been observed in the spinal cord of the rat on the
induction of a peripheral inflammation (Draisci and Iadarola, 1989), along with evidence to
support the co-localisation of c-fos and the proDyn message within single neurones of the
spinal cord (Naranjo et al., 1991; Noguchi et al., 1991; Lucas et al., 1993). Since the c-fos
protein is expressed by many neurones of the spinal cord in response to the arrival of impulses
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in nociceptive primary afferents, following noxious mechanical (Bullit et al, 1990; Leah et al.,
1992; Cruz et al, 1994), thermal (Hunt et al., 1987; Bullit et al, 1990; Williams et al, 1990;
Naranjo et al, 1991; Evans et al., 1994; Gillardon et al., 1994; Abbadie et al., 1994a; b), and
chemical (Hunt et al., 1987; Menetrey et al, 1989; Cruz et al, 1994) peripheral stimulation, as
well as electrical nerve stimulation at C fibre intensity (Wei and Zhao, 1995; Willcockson et
al, 1995; Herdegen et al, 1991), it is possible that the increased synthesis of dynorphins is a
primary response to this input. Notably inflammation induced increases in c-fos expression
were greatly attenuated by neonatal capsaicin treatment (Hylden et al, 1992). Additional
support for this proposal has been provided by the demonstration that intrathecal pretreatment
with an antisense oligodeoxynucleotides to c-fos mRNA inhibits the increase in the synthesis
ofproDyn by spinal neurones following peripheral inflammation (Hunter et al., 1995).
Although an enhanced spinal release of the prodynorphin derived peptides as inflammation
develops peripherally is implied from these biochemical and immunohistochemical findings,
few studies have been performed to investigate this phenomenon directly. Using spinal cord
isolated from the lumbar region of rats with unilateral induced hindpaw inflammation,
Przewlocki et al (1992) found evidence for an enhancement of both the basal and potassium
evoked release of a-neoendorphin within 12 hours of inoculation, the ability to evoke release
declining thereafter. Such studies, however provide no localisation of the possible sites of
release and little information about the physiological controls of such release. Little is even
known about the mechanisms of the spinal release of dynorphins in normal animals. Reports
concerning the release of the proDyn peptides into artificial CSF fluid superfusing the
subarachnoid space of the spinal cord of the normal rat and cat, have provided evidence that
the levels of dynorphin A in a spinal perfusate are increased by high intensity electrical
stimulation of peripheral nerves (Yaksh et al, 1983; Nyberg et al, 1983), which has been
suggested by some groups as evidence of its central role in the analgesia of high frequency
electroacupuncture (rabbit: Han and Xie, 1984). Studies of the release of proDyn peptides
from spinal cord in vivo (Xie et al, 1986) and in vitro (Przewlocka et al, 1990) of normal rats
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suggest that spinal proDyn neurones are under excitatory (noradrenaline/ adrenoceptor)
and inhibitory (GABA) influences. Additionally, Hutchinson et al (1990) used the antibody
microprobe technique to study the release of dynorphin A( 1-17) in the lumbar spinal cord of
the normal cat. They found a basal presence of ir-dynorphin A( 1-17) in lamina I of the
superficial dorsal hom, which was increased by high frequency (50 to 100Hz) electrical
stimulation of the ipsilateral tibial nerve at C but not A fibre strength. There was also
evidence for the release of ir-dynorphin A( 1-17) deeper in the dorsal hom (laminae V-VI).
However, the effect of more natural stimulation was not investigated. Evoked release in
lamina I was abolished by spinal transection which was interpreted that such release came
from intrinsic neurones activated by supraspinally derived fibres. Possibly relevant to this
proposal are the findings that adding corticotrophin releasing factor to a perfusate of the
isolated mouse cord produced a release of ir-dynorphin A( 1-17) (Song and Takemori, 1992)
and that depletion of 5HT fibres descending from raphe nuclei to the spinal cord by the
intrathecal administration of the neurotoxin 5,7-dihydroxytryptamine dramatically reduced the
expression of prodynorphin mRNA in the superficial dorsal hom (Lucas et al, 1993).
Hence, when I commenced my studies there was a need to determine the adequate stimuli
producing a spinal release of dynorphins under in vivo conditions both in normal animals and
in those with peripheral inflammation and specifically to determine (a) whether dynorphins are
tonically released in both normal and inflamed animals and (b) if such release is increased or
decreased by manipulation of the inflamed tissues. In the experiments described in this thesis
I have employed microprobes bearing immobilised antibodies to dynorphin A(l-8), to study
the release of ir-dynorphin in the spinal cord of normal rats and those with a unilateral ankle
inflammation. Dynorphin A(l-8) was chosen since there is evidence that this peptide is the
major end product of the processing of proDyn in several areas of the central nervous system,
including the spinal cord (Weber et al.,1982; Sweetnam et al., 1986) and it is this form of the
dynorphin molecule which has been most extensively studied in relation to peripheral
inflammation (Iadarola et al, 1988a; b; Rudaetal, 1988; Nahin et al, 1989; 1992)
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4.2 MATERIALS AND METHODS
1. MICROPROBE PREPARATION
Antibody microprobes were prepared as previously described (section 3.2), using a
polyclonal antiserum [Peninsula Laboratories] that had been raised in rabbits against the
COOH-terminus of porcine dynorphin A(l-8). Data supplied from Peninsula Laboratories
indicated that this antiserum had negligible cross reactivity (<0.01%) with the porcine
prodynorphin derived peptides dynorphin AB(l-32), dynorphin A(l-17), dynorphin A(l-13),
dynorphin B( 1 -13), a-neoendorphin and zero cross reactivity for other tested opioid peptides,
porcine |3-endorphin(l-31), Met-enkephalin and Leu-enkephalin-Arg [dynorphin A(l-6)].
2. EXPERIMENTAL PREPARATION
A total of 40 male Wistar rats (weight range 250 to 422g; mean ± s.e.m. = 356±6g) were
used in this study. Twenty-two animals received injections of FCA around one ankle joint (as
outlined in section 2.3) and were used in experiments 3 to 5 days later. An additional six rats
received FCA injections on the morning of the experiment, to allow study of the release ir-
dynorphin A( 1 -8) at an early phase of the inflammatory response.
Anaesthesia was induced, cannulae were inserted and the lumbar spinal cord exposed as
previously described (sections 2.2.2 and 2.5). All microprobes were inserted 2.25mm into the
dorsal spinal cord. Initially, microprobes were kept in the cord for 5, 15 or 30 minutes but as
preliminary analysis indicated that the probability of binding any dynorphin A(l-8) increased
with length of time in the spinal cord, all later experiments employed incubation times of 30
minutes. During these periods either no stimulus was applied or the ankle joint was
mechanically manipulated.
Since the most likely stimulus producing pain from inflamed skin, joints or tendons is that
resulting either from direct physical contact with an environmental object or movement of the
damaged tissues, the ankle joint region was only subjected to mechanical stimulation. A
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typical protocol was 3 minutes of mechanical stimulation followed by 2 minutes of no
stimulation. In the initial experiments the inflamed tissues were compressed laterally, with a
modified strong spring clip. In later experiments this stimulus was quantified by the
application of a pneumatic compression device incorporating a strain gauge for measuring
applied force and employing electronic control of the times of application. The jaws of the
pneumatic compression device were coated in a smooth heat shrink plastic cover to minimise
skin damage. Typically, a force of 14.7N was applied, the surface area of the compression
device contacting the rat ankle being 20mm2. In one series of experiments involving five
animals (three of which had a developed ankle inflammation), the ankle joint area was flexed
by pulling the limb out to near its full extent and then pushing the hindpaw gently until it was
in close apposition to the knee. This flexion of the ankle joint was repeated every 5 seconds
throughout each 3 minute period of mechanical stimulation. In another series of experiments
involving four animals (all of which had a developed ankle inflammation), the laminectomy
was extended to vertebral level T9, the region where the spinal cord which naturally bends
when animal was positioned in the stereotaxic frame used. Following the injection of
Iignocaine (2% solution, total volume of 0.05ml; Xylocaine, Astra, UK) at the proposed site of
incision, the exposed spinal cord was completely transected at this level.
Although inflammation was induced unilaterally, pairs of microprobes were inserted into
both sides of the spinal cord, comparable stimuli being applied to the inflamed and uninflamed
hind limbs. With each side of the spinal cord, periods of no stimulation usually preceded
those of mechanical stimulation to the ipsilateral ankle region but also often followed them.
Due to uncertainty on the persistence of any possibly released ir-dynorphin A(l-8) following
peripheral stimulation, it was usual to perform periods of peripheral stimulation (and
associated periods of no stimulation) only twice, once on each side of the spinal cord. When
in eleven experiments, however, the chosen protocol was carried out more than once on one
side of the cord, a time of at least 2 hours elapsed between periods of stimulation. Blood
pressure, breathing rate and end tidal CO, were monitored throughout.
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After removal from the spinal cord microprobes were washed and then incubated for
approximately 24 hours in porcine [125I]-dynorphin A( 1 -8) [Peninsula Laboratories] and
prepared for analysis as previously described (sections 3.4 and 3.5).
3. IN VITRO TESTS
Prior to use and throughout use in vivo, the sensitivity of the prepared antibody
microprobes were tested (as outlined in section 3.3).
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4.3 RESULTS
A total of 559 microprobes coated with antibodies to dynorphin A(l-8) inserted into the
rat spinal cord form the basis of this analysis. An additional 582 microprobes were used for
in vitro sensitivity tests.
1. IN VITRO TESTS
The counts of total radioactivity of microprobe tips indicated that over 10% of the total
radioactivity in which they had been incubated bound to the microprobes. In vitro tests
indicated that a 10~7M solution of porcine dynorphin A(l-8) suppressed such binding on
average by 55%, with a 10~5M solution resulting on average in 80% suppression. Hence, it
can be assumed that the non-specific binding for these microprobes accounted for less than
20% of the total binding. Information supplied by Peninsula Laboratories on the specificity of
the antiserum was confirmed on microprobes by demonstrating minimum suppression of
binding of [125I]-dynorphin A(l-8) by a range of concentrations of the porcine derived
peptides dynorphin A( 1-17), dynorphin A( 1-13) and Leu-enkephalin [Peninsula Laboratories],
2. BASAL LEVELS OF ir-DYNQRPHIN At 1-81
Since the primary aim of this study was to study the release of ir-dynorphin A(l-8) in
animals with a developed peripheral inflammation, it was necessary to make comparisons
between normal rats and those with unilateral ankle inflammation. In the case of the latter
group the release of ir-dynorphin A( 1-8) was examined in both sides of the spinal cord.
A basal presence of a neuropeptide at a particular site in the nervous system is inferred by
differences between the mean image analysis of microprobes not inserted into the nervous
system but simply incubated in the radiolabelled ligand and that of microprobes placed in the
relevant area for a comparable time but in the absence of any active stimulus. Such
comparisons indicated that ir-dynorphin A(l-8) was present in the spinal cord of normal rats
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and both sides of the spinal cord of those with developed unilateral ankle inflammation under
these 'basal' conditions. As microprobes present in the spinal cord for 5 or 15 minutes failed to
detect ir-dynorphin(l-8) consistently, the data presented below was derived from microprobes
present for 30 minutes in the spinal cord only.
(i) Normal animals
Figure 12A compares the mean image density scan of microprobes (n=77) present in both
sides of the spinal cord of normal rats for periods of 30 minutes and prior to any mechanical
stimulation of the corresponding ankle regions, with that of in vitro microprobes (n=98) that
had only been exposed to [125I]-dynorphin A(l-8) but processed concurrently with those used
in vivo. Figure 12B plots in 30pm intervals the 't' statistics derived from the differences
between the mean image analyses of the two groups. The hatched area indicates where these
differences are significant at the P<0.05 level (t>2) and this is approximately from 0.5 to
1.0mm from the dorsal surface of the spinal cord. Thus, in normal animals extracellular ir-
dynorphin A( 1 -8) was present in zones of both the superficial and deep dorsal horn
approximating to lamina I and laminae IV-V.
(ii) Animals with developed unilateral ankle inflammation: ipsilateral side of the spinal cord
A more extensive basal presence of ir-dynorphin A(l-8) was found in the ipsilateral side
of the spinal cord (58 microprobes) in animals with unilateral ankle inflammation than in
normal animals. When compared with in vitro microprobes significant levels of ir-dynorphin
A (1-8) were found from the dorsal surface of the spinal cord down to 2.0mm from the dorsal
surface (not illustrated). This approximates to the whole of the dorsal horn and ventral horn.
Figure 13 illustrates differences between the mean image analysis of microprobes in this group
and that of microprobes present in the spinal cord of normal animals but without added
stimulation.
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FIGURE 12. Basal presence of ir-dvnorphin AG-8) in the spinal cord of normal rats. (A)
The mean image analyses of two groups of microprobes are plotted with respect to length:
those present in the spinal cord of drug naive animals for 30 minutes in the absence of any
peripheral stimulation (normal rats, no stimulus, n=77) and those which are not inserted into
the spinal cord but simply incubated in [l25I]-dynorphin A(l-8)) (in vitros, n=98). With each
mean image analysis the mean grey scale was determined in 30pm intervals and a line joins
these points. At each analysis point the standard error of the mean (s.e.m.) is also plotted (+)
for no stimulus and (-) for in vitros. (B) A plot of the t statistics derived from the standard
errors of the differences of means at each analysis point in the mean image analyses shown in
(A), is related to an outline of the spinal cord at the area sampled. The hatched areas indicate
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FIGURE 13. Effect of peripheral inflammation on the basal levels of ir-dvnorphin AC1-8) in
the ipsilateral side of the spinal cord. (A) The mean image analysis of 58 microprobes present
for 30 minutes in the ipsilateral side of the spinal cord of rats with a unilateral ankle
inflammation in the absence of any added stimulation (inflamed rats, ipsi side) is compared to
that of microprobes present under similar basal conditions in normal animals (normals, n=77).
(B) The differences between the two groups of microprobes are plotted with respect to depth
in the spinal cord. Since only isolated points attain significance at the P< 0.05 level, there is
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This shows comparable basal levels of ir-dynorphin A(l-8) in the dorsal horn of normal
and inflamed animals but apparently greater levels of this neuropeptide at many sites in the
ventral horn of rats with peripheral inflammation.
(iii) Animals with developed unilateral ankle inflammation: contralateral side of the spinal
cord
The basal extracellular levels of ir-dynorphin A(l-8) in the contralateral side (34
microprobes) of the spinal cords of animals with developed ankle inflammation were found to
be comparable to those present in the ipsilateral side under these basal conditions. Figure 14
illustrates the nearly completely coincident mean image analyses of these two groups of
microprobes.
Attempts to study the influence of supraspinal pathways on the basal levels of ir-
dynorphin A(l-8) found in animals with a developed unilateral ankle inflammation by
spinalising a group of animals, were thwarted due to problems with the condition of the
animals being used at this stage of work. This consisted in the development of 'stiff legs'
during the course of an experiment followed by death. This problem could not be attributed
to the actual spinalisation itself since it also occurred with other non-spinalised animals, both
normals and those with developed ankle inflammation. No satisfactory explanation for this
problem was afforded although a possible contributing factor could have been the use of a
new stereotaxic frame.
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FIGURE 14. Comparable basal presence of ir-dvnorphin A(l-8) in both sides of the spinal
cord of rats with unilateral inflammation. This figure compares the mean image analysis of
microprobes present for 30 minutes in the ipsilateral side of the spinal cord of rats with
unilateral ankle inflammation (ipsilateral side, n=58) to that of microprobes present in the












3. THE EFFECT OF LATERAL COMPRESSION OF THE ANKLE REGION
3.1. Microprobes present in the spinal cord during stimulus application
Although significant basal levels of ir-dynorphin A(l-8) were present both in normal rats
and those with unilateral ankle inflammation, these two groups differed markedly in their
responses to lateral compression of the ankle.
(i) Normal animals
The application of lateral compression to the ankle joint and surrounding tissue of normal
rats failed to increase extracellular levels of ir-dynorphin A( 1 -8) during the period of stimulus
application. No significant differences were found between the mean image density scans of
microprobes (n=33) present in the ipsilateral spinal cord during the application of the
mechanical stimuli and those microprobes (n=67) present in the same animals in the absence
of any prior stimulation, as illustrated in figure 15.
(ii) Animals with developed unilateral ankle inflammation: ipsilateral side of the spinal cord
Lateral compression of the ankle with a developed inflammation, significantly increased
the extracellular levels of ir-dynorphin A( 1 -8) above those found under basal conditions in the
ipsilateral side of the spinal cord. This is illustrated in figure 16A in which the mean image
analysis of microprobes (n=30) present in the ipsilateral side of the spinal cord during the 30
minute period of noxious mechanical stimulation can be seen to be displaced above that of
microprobes (n=47) present for an identical time period prior to this stimulus in the same
animals, but in the absence of any added peripheral stimulation. These enhanced extracellular
levels of ir-dynorphin A( 1 -8) were found to be statistically significant at the P<0.05 level at
nearly all sites sampled from 0.25mm to 2.2mm from the dorsal surface of the spinal cord. As
figure 16B shows, there were three main sites of release. The largest peak was in the deep
dorsal/ upper ventral horn (laminae VI-VII), with further major sites in
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FIGURE 15. Failure to release ir-dvnorphin AG-8") during a period of ankle compression in
normal animals. The mean image analyses of the 33 microprobes present in the spinal cord
for 30 minutes during the application of the mechanical stimuli (lateral ankle compression) is
compared to that of microprobes present in the same animals in the absence of any prior
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FIGURE 16. Release of ir-dvnorphin A( 1 -8) during compression of the inflamed ankle.
(A ) The mean image analysis of 30 microprobes present in the ipsilateral side of the spinal
cord during the 30 minute period of noxious mechanical stimulation (inflamed ankle
compression) is displaced above that of microprobes present in the same side of these spinal
cords for an identical time period prior to this stimulus {no stimulus, n=47). (B) The
differences between the two groups of microprobes are plotted with respect to an outline of the
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(laminae II-V) and the lower ventral hom. No study was made of possible contralateral
release of ir-dynorphin(l-8) during compression of the inflamed ankle.
(iii) Animals with developed unilateral ankle inflammation: contralateral side of the spinal
cord
Equivalent analysis of the effect of ankle compression on the normal side of animals with
unilateral inflammation failed to show any such evoked release of ir-dynorphin A( 1 -8). Thus,
the mean image analysis of microprobes (n=12) present in the side of the spinal cord
contralateral to the peripheral ankle inflammation and during lateral compression of the
normal ankle displayed no significant differences from that of microprobes (n=28) present in
the same side of the spinal cord under basal conditions (not illustrated).
3.2. Microprobes present in the spinal cord following a period of mechanical stimulation
Since there is evidence that some neuropeptides are not rapidly degraded after in vivo
release in the central nervous system (Duggan et al, 1990; Hope et al, 1990b) it was important
to examine the decline of any enhanced presence of extracellular ir-dynorphin A(l-8) after
application of a peripheral stimulus. The mean image analyses of microprobes inserted before
or during prior mechanical stimulation of the ankle joint region were compared to those of
microprobes present for equivalent 30 minute periods, up to one hour and a half after lateral
compression of these peripheral tissues.
(i) Normal animals
No increase in the extracellular levels of ir-dynorphin A(l-8) was observed in the spinal
cord during mechanical compression of the ankle region of normal rats. However, as
illustrated on figure 17, comparisons between the mean image analysis of microprobes
inserted prior to the application of lateral compression (n=56) and that of those present in the
corresponding 30 minute period post-stimulation (n=21), showed elevated levels of the ir-
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FIGURE 17. Release of ir-dvnorphin A(l-8) in the spinal cord following a period of ankle
compression in normal rats. (A) The mean image analysis of 21 microprobes present in a 30
minute period post ankle compression (5-35 min post ankle compression) is displaced above
that of microprobes present prior to the application of this mechanical stimulus {no stimulus,
n=56). (B) The differences between the post ankle compression and no stimulus groups are
plotted with respect to an outline of the spinal cord. The hatched areas indicate where these
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dynorphin A(l-8) in the lower ventral horn after the application of ankle compression. No
analysis of the levels of ir-dynorphin A(l-8) in the period 40-70 minutes post-compression
was made due to insufficient microprobes being present in the spinal cord under such
conditions.
(ii) Animals with developed unilateral ankle inflammation: ipsilateral side of the spinal cord
Figure 18 illustrates extracellular ir-dynorphin A(l-8) in the ipsilateral side of the spinal
cord before, during and for one hour after the lateral compression of the inflamed ankle.
Figure 18B shows that the mean image analysis of microprobes (n=22) present for the first 30
minute period after lateral compression of the inflamed tissues of the ipsilateral ankle joint
was displaced above that of microprobes (n=36) present in the same side of these spinal cords
prior to such peripheral stimulation. No significant differences however were found between
these 'post-compression' microprobes and those present in the spinal cord during this noxious
mechanical stimulation (n=28, not illustrated).
The mean image density scan of microprobes (n=14) present in the spinal cord for the
period 40-70 minutes post-compression was also found to be significantly elevated above that
of microprobes inserted under 'basal' conditions, as illustrated on figure 18C. However, ir-
dynorphin A(l-8) levels in the ipsilateral side of the spinal cord had returned to pre-
stimulation 'basal' levels after a period of two hours, as no significant difference was found
between the mean image density analyses of microprobes (n=8) inserted ipsilaterally in the
absence of any prior or concurrent added stimulation and those microprobes (n=8) inserted
into this side of the cord again after a period of at least two hours (not illustrated).
(iii) Animals with developed unilateral ankle inflammation: contralateral side of the spinal
cord
Equivalent analysis revealed that mechanical manipulation of the normal ankle of animals
with unilateral inflammation had not initiated any effect on the levels of ir-dynorphin A(l-8)
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FIGURE 18. Persistently raised levels of ir-dvnorphin AC 1-8) in the spinal cord following a
period of compression of the inflamed ankle. For (A), (B) and (C) the no stimulus group
represents 36 microprobes present for 30 minutes in the ipsilateral side of the spinal cord of
inflamed rats prior to any added stimulation. In (A) the mean image analysis of this group is
compared with that of 28 microprobes inserted during compression of the inflamed ankle
(,lateral ankle compression)-, in (B) the comparison is with the mean image analysis of 22
microprobes present in a 30 minute period after this noxious mechanical stimulus in the same
side of these spinal cords (5-35 min post ankle compression)-, in (C) the comparison is with
the mean image analysis of 14 microprobes inserted under similar conditions in the same
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FIGURE 19. Failure of compression of the normal ankle to release ir-dvnorphin AG-8) in
the contralateral side of the spinal cord in rats with unilateral ankle inflammation. The mean
image analysis of the 12 microprobes present in the side of the spinal cord contralateral to the
peripheral ankle inflammation for a 30 minute period following lateral compression of the
normal ankle (5-55 tnin post ankle compression) is compared to that of microprobes present
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presence under basal conditions. Thus, as illustrated on figure 19 the mean image analysis of
microprobes (n=12) present in the side of the spinal cord contralateral to the peripheral ankle
inflammation for the first 30 minute period following lateral compression of the normal ankle
displayed no significant differences from that of microprobes (n=20) present in the same side
of the spinal cord of these animals prior to application of this ankle compression.
4. THE EFFECT OF FLEXION OF THE ANKLE REGION
4.1. Microprobes present in the spinal cord during stimulus application
Limited data was obtained on the effect of flexion on the basal levels of ir-dynorphin A(l-
8) in normal animals and those with unilateral ankle inflammation. That available indicated
that flexing the ankles of normal animals (12 microprobes) failed to increase the basal release
of ir-dynorphin A( 1 -8) (9 microprobes) at the spinal cord level in an analogous manner to the
application of lateral compression stimuli (not illustrated).
Moreover, in contrast to compression, flexion of the inflamed tissues around the ankles of
rats with a developed unilateral inflammation (7 microprobes) failed to increase ir-dynorphin
A(l-8) levels (11 microprobes) in the segments of the spinal cord receiving input from the
ipsilateral ankles of these animals. Flexing the non-inflamed ankles (4 microprobes) of these
animals also had no effect on the basal levels of ir-dynorphin A(l-8) (5 microprobes) present
in the contralateral spinal cord (not illustrated).
4.2. Microprobes present in the spinal cord following a period of mechanical stimulation
Again limited data was available on the levels of ir-dynorphin A(l-8) in the spinal cord of
normal rats and those with unilateral ankle inflammation after the application of flexion
stimuli. That available showed no evidence for an increased dynorphin A(l-8) presence.
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The apparent lack of effect of flexion may have been partly due to the comparatively large
basal levels of ir-dynorphin A(l-8) detected in both the normal and inflamed animals to that
found in the rest of the dynorphin study. For example as illustrated on figure 20 the mean
image analysis of microprobes (n=l 1) present under basal conditions in the ipsilateral side of
the spinal cord of rats with a unilateral ankle inflammation that were later used to study the
effect of ankle flexion were found to be significantly displaced above that of microprobes
(n=16) from the same series of experiments that studied the effect of lateral ankle
compression.
5. RELEASE OF ir-DYNORPHIN Afl-8) IN THE SPINAL CORD DURING THE
DEVELOPMENT OF UNILATERAL INFLAMMATION
In view of the temporal analysis performed by other groups (Draisci and Iadarola, 1989;
Iadarola et al, 1988a; b; Iadarola and Draisci, 1990; Lucas et al, 1993; Naranjo et al , 1991)
on the expression of the message for prodynorphin, it was of interest to study the release of ir-
dynorphin A( 1 -8) in the spinal cord at an early phase of the inflammatory response.
Microprobes present in the spinal cord ipsilateral to the injected ankle for 15 or 30 minutes
during the third to the eighth hour after the FCA injections, in the absence of any additional
peripheral stimulation, were compared (a total of 79 microprobes; an average of 15
microprobes being inserted for each hourly period). Comparisons were also made to those in
vitro microprobes that had only been exposed to radiolabelled dynorphin A(l-8) but processed
concurrently with those in vivo (18 microprobes). Analysis of the data from six experiments
provided no evidence that levels of ir-dynorphin A( 1 -8) were significantly enhanced 3 to 8
hours after the FCA injections. For example, as illustrated on figure 21 the mean image
analysis of microprobes (n=19) present in spinal cord ipsilateral to the injected ankle for either
15 or 30 minutes between 7 to 8 hours post-injection, displayed no significant differences from
that of microprobes (n= 16) present in the same side of the spinal cord 3 to 4 hours earlier.
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FIGURE 20. The large basal presence of ir-dvnorphin Ad-81 in the animals used to study
the effect of ankle flexion compared to that present in animals used in the rest of the dynorphin
study. (A) The mean image analysis of I 1 microprobes present for 30 minutes in the
ipsilateral side of the spinal cord of rats with a unilateral ankle inflammation prior to flexion
of the inflamed ankle (pre-ankle flexion) is displaced above that of microprobes present in
animals belonging to this series under the same basal conditions, but prior to compression of
the inflamed ankle {pre-ankle compression, n=16). (B) The differences between the two
groups of microprobes are plotted with respect to an outline of the spinal cord. The hatched
areas indicate where these differences are significant at the P<0.05 level.
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FIGURE 21. Lack of effect of FCA injections on the basal levels of ir-dvnorphin A(l-8) in
the ipsilateral spinal cord up to 8 hours post-iniection. The mean image analysis of the 19
microprobes present for either 15 or 30 minutes in the side of the spinal cord ipsilateral to the
injected ankle between 7 to 8 hours post-injection (7-8hrs post FCA) is compared to that of
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No study was made of the release of ir-dynorphin A(l-8) during the application of
mechanical stimuli to the injected ankle under these acute inflammation conditions, that might
better mimic the development of the inflammation in the conscious animal over the same time
period.
6. SUMMARY OF RESULTS
The present experiments have detected ir-dynorphin A(l-8) in the spinal cord of both
normal rats and those with peripheral inflammation but have found significant differences
between the two groups. In the absence of any active peripheral stimulus, extracellular ir-
dynorphin A(l-8) was found in two areas (lamina I and laminae IV-V) of the dorsal horn of
normal rats but occurred throughout the dorsal and ventral horns of both sides of the spinal
cord in rats with unilateral ankle inflammation. Differences were also seen when the ankle
region was subjected to lateral compression. Ir-dynorphin A( 1 -8) appeared in the ventral horn
not during, but after the period of stimulation in normal animals. With inflamed animals,
compression of the inflamed ankle did result in release of ir-dynorphin A(l-8) during the
period of stimulus application. This produced elevated levels at three main sites in the spinal
grey matter . The largest peak was in the deep dorsal/ upper ventral horn (laminae VI-VII),
with further sites of significant release in the mid dorsal horn (laminae II-V) and the lower
ventral horn. These levels persisted for at least one hour after the period of stimulation.
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4.4 DISCUSSION
The significant results of this study which I will discuss are (a) the presence of ir-
dynorphin A(l-8) in the ventral horn region of the lumbar spinal cord both of normal rats and
those with a developed peripheral inflammation, (b) the bilateral increases in ir-dynorphin
A(l-8) following the development of a unilateral peripheral inflammation, (c) the post-
stimulus appearance of ir-dynorphin A(l-8) in the ventral hom of normal rats, (d) the post-
stimulus persistence of ir-dynorphin A(l-8) in the ipsilateral side of the spinal cord of rats
with a developed unilateral peripheral inflammation.
First however the possible sources of release of dynorphins in the spinal cord of normal
rats and those with a developed peripheral inflammation will be considered. The relevant
structures include primary afferent fibres, intrinsic neurones of the spinal cord and the spinal
terminations of fibres of supraspinal origin.
Localisation of dvnorphin in the spinal cord
In normal animals many radioimmunoassay studies have shown higher levels of ir-proDyn
derived peptides in the dorsal hom compared to the intermediate or ventral horn zones of the
mammalian spinal cord (rat: Botticelli et al, 1981; Zamir et al, 1983 Millan et al, 1984; Pohl
et al, 1990. rabbit: Botticelli et al, 1981. human: Przewlocki et al, 1983).
Immunocytochemical studies in normal animals have localised ir-proDyn derived peptides
mainly in cells and terminals of lamina I-II and lamina IV-VI of the mammalian spinal cord
with moderate concentrations in the area around the central canal, lamina X (rat: Vincent et
al., 1982; Khatchaturian et al, 1982; Cho and Basbaum, 1988; 1989; Leah et al, 1988; Miller
and Seybold, 1987; 1989; Ruda et al., 1988; Weihe et al., 1988; 1989; Nahin et al., 1989;
Fallon and Ciofi, 1990; Kajander et al., 1990; Klein et al, 1991. cat: Cruz and Basbaum,
1985; Basbaum et al., 1986; Miller and Seybold, 1987,1989. monkey: Carlton and Hayes,
1989). In situ hybridisation studies have also located sites of proDyn synthesis in normal rats
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to cells of the superficial and deep dorsal horn (Ruda et al., 1988; Iadaroia and Draisci, 1988;
Weihe et al., 1989; Noguchi et ai, 1991; Przewlocka et al., 1992; Parker et al., 1993; Tolle et
al, 1994; Persson et al, 1994). The induction of a peripheral inflammation has been found to
increase the spinal content of these ir-proDyn derived peptides in studies in the rat employing
radioimmunoassay (Millan et al, 1985; 1986; Iadaroia et al, 1988a; b) or
immunocytochemical techniques (Millan et al, 1988; Ruda et al, 1988; Nahin et al, 1989;
1992; Takahashi et al, 1988; 1990; Weihe et al, 1988; 1989; Noguchi et al, 1991). This
increase in peptide content has been shown to be preceded by an enhancement in the
expression of the RNA message for proDyn (Ruda et al, 1988; Weihe et al, 1989; Noguchi et
al, 1991; Przewlocka et al 1992; Parker et al, 1993; Persson et al, 1994) by cells in the
superficial dorsal horn (laminae I-II) but notably also in deep dorsal horn (laminae IY-VI)
neurones. In addition, under these conditions, neurones dorsolateral to the central canal
(laminae VI, VII and X) have also been observed to contain high levels of proDyn mRNA
(Weihe et al, 1989; Persson et al, 1994).
As indicated in section 1.6.3, the majority of the ir-dynorphin is thought likely to be
present in neurones intrinsic to the cord itself. Despite the presence of ir-dynorphin near the
sites of termination of primary afferents in the dorsal horn there is little evidence to support a
significant presence of dynorphin in primary afferents, particularly in lumbar spinal segments
of the rat. Derivatives of proDyn have been demonstrated to exist immunocytochemically in
colchicine treated animals in sacral DRG of the cat (Basbaum et al, 1986) and various sensory
ganglia of the guinea pig (Weihe et al, 1985; Gibbins et al, 1987), as well as cultured mouse
dorsal root ganglia (Sweetnam et al, 1986) although the levels are believed to be very low and
no detectable levels of mRNA have been demonstrated. Dorsal rhizotomy had little or no
effect on the levels of ir-dynorphin in both the dorsal and ventral horns of the rat spinal cord
(Botticelli et al., 1981; Pohl et al., 1990; Klein et al., 1991). Following unilateral multiple
dorsal rhizotomy of the cat lumbar and sacral DRG, decreases in the numbers of ir-dynorphin
terminals were reported at the sacral but not lumbar level of the spinal cord 10 days later
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(Basbaum et al, 1986), and in the rat lumbar spinal cord at the same time period (Tuchscherer
and Seybold, 1989). However, these changes may be secondary to the loss of primary afferent
neuronal transmission in the spinal cord. Notably no reports of detectable amounts of proDyn
mRNA have been observed in rat DRG neurones by either RNA blot or in situ hybridisation
(as commented upon by Ruda et al, 1995). There is also little evidence to support a
significant presence of dynorphin in the spinal terminals of fibres of supraspinal origin (rat:
Botticelli et al., 1981; Menetrey and Basbaum, 1987).
Evidence for monosynaptic synapses between dynorphin containing neurones and CGRP/
substance P containing presumed primary afferent fibres has been found at both light
microscopic (rat: Takahashi et al, 1988; Cho and Basbaum, 1989) and electron microscopic
(rat: Takahashi et al, 1990; Carlton and Hayes, 1989) level. As indicated in section 1.7.3
there is evidence that certain of these dynorphin neurones are the origin of ascending
projections to the brain that terminate in the diencephalon (rat: Nahin et al, 1987; Leah et al,
1988) or brainstem (rat: Standaert et al, 1986; Nahin et al 1987; 1989; 1992; Leah et al,
1988). Thus it appears that the cells releasing ir-dynorphin A(l-8) in the present studies were
predominantly intrinsic spinal neurones with their cell bodies in the superficial and deep dorsal
horn.
Evidence for a ventral horn release of dvnorphin
In contrast to the majority of above immunocytochemical studies the present
investigations using antibody microprobes have found evidence for a significant presence of
ir-dynorphin A( 1 -8) in fibre terminals in ventral horn. Most of these immunocytochemical
studies, however, used cochicine treated animals and hence favoured detecting presence in cell
bodies. Hence they do not necessarily give information on sites of release particularly if the
relevant neurones have long axons with many branches. Ir-dynorphins have been measured in
the ventral horn of the rat spinal cord by radioimmunoassay (Botticelli et al, 1981; Zamir et
al, 1983; Pohl et al, 1990) and more recent immunocytochemical studies, notably on
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non-colchicine treated animals, have emphasised the finding of ir-dynorphin labelled varicose
fibres surrounding both large and intermediate sized motoneurones (Weihe et al, 1989;
Kajanderet al, 1990; Klein et al, 1991). Klein et al. (1991) found that the rat differs from the
cat and primate in this respect. The location of the cell bodies of these dynorphin containing
varicosities in the ventral horn were not known but it is probable that they were intrinsic
spinal neurones with their cell bodies located more dorsally. Such connections could be inter-
and intra-segmental. Klein et al. (1991) also found that electrical stimulation of the small and
large diameter fibres of the ipsilateral sciatic nerve (1Hz for 20 minutes) depleted ventral horn
ir-dynorphin A(l-8). If such depletion results from prior release then these findings are in
accord with some of observations of the present experiments where release in the ventral horn
in addition to the dorsal horn was a prominent finding.
In antibody microprobe studies a significant extracellular basal presence of a compound
could result from a tonic release from an unknown stimulus, or from a continuous afferent
input in nociceptors and other fibres as a result of the surgery required for these preparations.
A contribution from cells and fibres ruptured during the introduction of microprobes cannot be
excluded although differing basal patterns observed in rats with microprobes bearing
antibodies to different peptides makes it unlikely that this is a significant factor (Lang and
Hope, 1994; Hope et al., 1994; Schaible et al., 1994). Although the similar basal presence of
ir-dynorphin A(l-8) in the dorsal horn of normal and inflamed rats could be the result of
surgery, an enhanced afferent input was almost certainly responsible for the increased levels in
the ventral horns of inflamed rats, particularly as active manipulations of the inflamed ankle
region increased these levels still further. As indicated in section 4.1 a basal presence of ir-
dynorphin A( 1-17) was detected by Hutchison et al (1990) in the spinal cord of the normal cat
using antibody microprobes but the consequences of peripheral inflammation were not
examined.
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Bilateral increases in dvnorphin following the development of a unilateral inflammation
The finding of bilateral increases in ventral horn ir-dynorphin in animals with a peripheral
inflammation, when compared with normal animals, was unexpected particularly as most
studies of the changes in the mRNA levels for proDyn following unilateral inflammation have
found only ipsilateral increases (Iadarola and Draisci, 1988; Iadarola et al., 1988a, b; Ruda et
al., 1988; Weihe et al., 1989; Draisci and Iadarola, 1989; Draisci et al., 1991; Parker et al.,
1993). Przewlocka et al. (1992) however, observed bilateral increases in the proDyn mRNA
in the superficial dorsal horn following unilateral hindlimb inflammation but at relative later
stages (5 and 14 days post-injection). This may involve the induction of immediate early
genes, such as c-fos, contralaterally. As discussed in section 4.1, there is considerable
evidence that the protein products of these genes direct the increased synthesis of proDyn
following a spinal input from peripheral nociceptors. However at these later time points, such
changes in expression may be correlated with the transfer of inflammation to the contralateral
paw, as other groups using similar unilateral models of peripheral inflammation in the rat have
shown to occur (Donaldson et al, 1993; Bileviciute et al, 1993, 1994). Although, in the
present experiments using the dose of FCA and time course of inflammation described in
section 2.3, there was no evidence for such a spread of inflammation to the opposite side. A
simple explanation for our finding of bilateral increases in released ir-dynorphin A(l-8)
associated with peripheral inflammation is that some of the cells containing this neuropeptide
project bilaterally to the ventral horn.
As described in section 1.8.2, the sensitisation of nociceptive primary afferents during the
development of a peripheral inflammation, has been shown to produce long term changes in
the responsiveness of spinal cord neurones including increases in the spontaneous activity,
reduced thresholds and increases in the responsitivity to afferent inputs, as well as expansions
of the cutaneous receptive fields beyond the focus of the inflamed tissue to adjacent ipsilateral
and even contralateral regions. That contralateral changes may occur is also implied by the
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pattern of c-fos protein expression found by some groups following a noxious unilateral input,
immunoreactive labelling being evident to a lesser and more limited extent on the contralateral
side of the spinal cord, as well as ipsilaterally. (Hunt et al, 1987; Gogas et al, 1991; Leah et
al, 1992). Of particular interest to this present study are the findings of Leah et al (1992).
This group describe how the expression of c-fos protein in the ipsilateral side of the spinal
cord of rats following the application of mechanical or chemical stimulation to the
corresponding paw, is significantly increased if either of these noxious stimuli are applied up
to an hour and a half before that to the contralateral hindlimb. This effect was seen to persist
for at least 12 hours and was not produced if the contralateral stimuli were applied to sites
remote from this dermatome, such as the forepaw, indicating both the longevity and specificity
of these presumed centrally mediated changes. Thus it is possible that contralateral neurones
are similarly sensitised as an inflammation develops unilaterally, in this study as could the
spinal neurones in normal animals following the application of noxious mechanical stimuli to
the ankle region (see below). This could occur either via supraspinal loops or the direct
commissural connections, that have been shown to anatomically exist in the spinal cord
(Jacquin et al, 1990).
Post-stimulus appearance of dvnorphin
The de novo synthesis of c-fos proteins could also explain the delayed increase in ventral
horn levels of ir-dynorphin A(l-8) following lateral compression of the ankle of normal rats.
This implies a relatively rapid process (30 to 60 minutes) within which the arrival of an input
in nociceptors is translated into increased expression of a gene and the release of a neuroactive
product of that gene. As discussed section 1.8.3 there is evidence that immediate early genes
encoding Fos and related proteins are up-regulated in the spinal cord within 30 minutes of the
injection of an inflammatory agent into the rat hindpaw (Draisci and Iadarola, 1989; Hunter
et al., 1995). Messenger RNA for proDyn in the spinal cord has been found to be increased
within 4 hours of the peripheral injection of an inflammatory agent (Iadarola et al., 1988a, b;
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Millan et al., 1988; Iadarola and Draisci, 1988; Draisci et al, 1991; Draisci and Iadarola,
1989; Hunter et al., 1995). The present studies of released ir-dynorphin A(l-8) suggest that
the process of synthesis and release is occurring more quickly than can be revealed by indirect
methods relating to release, such as mRNA expression and immunocytochemistry. It is thus
feasible that lateral compression of the normal rat ankle could induce the expression of such
immediate early genes, to result in a delayed appearance of ir-dynorphin A( 1 -8) post-stimulus
in the ventral horn region. This proposal is not invalidated by the finding that no increase in
the basal release of ir-dynorphin A(l-8) was detected up to 8 hours after injection of FCA
around the ankle. Until inflammation developed this procedure gives only a trivial noxious
input (associated with the injection) whereas ankle compression was a severe sustained
stimulus.
Although most of the immunocytochemical studies do not refer to a ventral hom
expression of the Fos protein following noxious stimulation, some investigators point to a
sparse presence (Gogas et al, 1997; Abbadie and Besson, 1992; Abbadie et al, 1992;
Chapman et al, 1995a, b; Wei and Zhou, 1995), and again it should be emphasised that c-fos
locates cell bodies and not axon terminals where release occurs.
Persistence of ir-dvnorphin A( 1-8) post-stimulus
The finding of elevated levels of a neuropeptide both during and after a peripheral
stimulus has been interpreted in previous microprobe studies as indicating a slow degradation
of neuropeptide following release, with the opportunity for diffusion to regions remote from
sites of release. For example, in vitro neurokinin A appears to be remarkably resistant to
enzymes believed to be important in the degradation of substance P (Nyberg et al, 1984;
Hooper et al, 1985; 1987; Theodorsan-Norham et al, 1987). Immunoreactive neurokinin A
has been shown to persist and spread after release in the cat spinal cord following noxious
cutaneous stimulation or the development of peripheral inflammation (Duggan et al, 1990;
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Hope et al, 1990b) in contrast to the relatively focal release of substance P detected during the
application of the same stimuli (Duggan et al, 1988a; Schaible et al, 1990).
The exact metabolism of dynorphin A( 1 -8) following release is not known. As indicated
in section 1.8.3, during the development of a peripheral inflammation, changes in the activity
of certain dynorphin processing enzymes found in the spinal cord and CSF occur (Silberring et
al, 1992; Persson et al, 1992a; b). For example, Silberring et al (1992) demonstrated how the
activity of the dynorphin converting enzyme in rat spinal cord homogenates which cleaves
dynorphin B( 1-13) to generate Leu-enkephalin-Arg^ [or dynorphin A( 1 -6)] is significantly
decreased in the spinal cord on the development of an inflammation in the ipsilateral hindpaw.
Although such processes may occur it is also possible that, as with normal animals, lateral
compression of the ankle in inflamed animals induced further synthesis and release of proDyn
peptides.
Another possible explanation for the apparent persistence of dynorphin A(l-8) could be a
technical one, in that the antibody microprobes are binding metabolites of longer derivatives of
the prodynorphin molecule that do not bind to the microprobes. However, from present
understanding of proDyn processing no such metabolite exists. The dynorphin converting
enzyme mentioned above, has a preference in the rat for dynorphin B over dynorphin A or a-
neoendorphin derivatives of the prodynorphin precursor (Persson et al, 1989), and details from
the manufacturer (Peninsula Laboratories) state that the antibodies raised against the COOH-
terminus of the dynorphin A(l-8) peptide used in this present study have negligible zero cross
reactivity for the Leu-enkephalin-Arg^ product. Although it is possible that Leu-enkephalin
could be formed from proDyn peptides released by the action of processing enymes such as
metalloendopeptidase 24.15, in vitro testing performed indicated that the microprobes
employed would not interact with such a derivative.
172
Possible functions of released dvnorphin
In this study active manipulation of the inflamed tissues was an adequate stimulus for
spinal release of ir-dynorphin. This is an important finding since as reviewed in section 1.8,
much of the recent literature has emphasised the hyperexcitability of spinal neurones
associated with peripheral inflammation and has directed substantial research towards
defining the neurochemical basis of such hyperexcitability.
From a functional viewpoint however, the dynorphins have proven to be enigmatic
neuropeptides to study in spinal cord function. As previously outlined in section 1.7, when
administered systemically, k receptor agonists have been demonstrated to depress some spinal
reflexes, indeed k opioid receptors were first proposed from the effects of EKC on spinal
reflexes in the chronic spinal dog (Martin et al, 1976). Administered iontophoretically both
dynorphin A( 1-13) and U50488H have also been described to depress the excitation of
spinocervical tract neurones of the cat by noxious peripheral stimuli (Fleetwood Walker et al,
1988, Hope et al, 1990a). However, when applied topically to the spinal cord, dynorphin A
and k receptor ligands have produced variable effects (mainly in the superficial dorsal horn)
on neuronal firing with mixed excitatory/ inhibitory actions (Knox and Dickenson, 1987;
Sullivan and Dickenson, 1991; Hylden et al, 1991; Dong et al, 1991; Stanfa and Dickenson,
1994). Additionally dynorphins have been reported to antagonise p. mediated antinociception
in electrophysiological (Dickenson and Knox, 1987) and behavioural (Tulunay et al, 1981;
Schmauss and Herz, 1987) studies.
However, as highlighted in section 1.4, although the dynorphins show some preference for
K opioid receptors, they also display significant affinity for p and 8 sites. There is also
evidence for actions of these peptides at non-opioid sites, such as the NMDA receptor (as
reviewed by Smith and Lee, 1988; Day et al, 1993; Shukla and Lemaire, 1994), with similar
effects being displayed by non-opioid derivatives of dynorphin A, such [des-Tyr']dynorphin
(2-17) (Walker et al, 1982). Thus, activating or blocking the k opioid receptor with specific
ligands may not reveal the full functional role of released dynorphins and administering
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dynorphins in high concentrations may produce effects not present following synaptic release.
Notably dynorphin A( 1-17) has recently been demonstrated to directly modulate excitatory
amino acid induced currents (both NMDA and non-NMDA) in acutely isolated trigeminal
(Chen et al, 1995) and spinal dorsal horn (Kolaj et al, 1995) neurones.
Such factors may be responsible for dichotomy of opinion drawn from
electrophysiological studies, as to the role of dynorphins at the spinal cord level. From the
finding that the topical administration of dynorphin A produced expansions of the receptive
fields of the majority superficial dorsal horn neurones in the spinal cord of normal rats,
resembling those found under conditions of peripheral inflammation (Hylden et al., 1991), it
was proposed that instead of being inhibitory to the hyperalgesia induced by peripheral
inflammation, the enhancement of proDyn expression is directly involved in the expression of
the hyperalgesic states (Dubner and Ruda, 1992). However, systemic naloxone failed to
reverse these receptive field expansions and hence these effects are more suggestive of an
action of the dynorphins at non-opioid binding sites. In contrast, Stiller et al (1993) found that
the prominent effect of the microiontophoretic administration of the k receptor antagonist
nor-BNI was to enhance the firing of spinal neurones in animals with peripheral inflammation.
Significantly firing to manipulation of inflamed peripheral tissues was also enhanced by the K
antagonist suggesting that released dynorphins were acting to inhibit cellular responses.
An inhibitory role of the dynorphins in the expression of pain under conditions of
peripheral inflammation is also implied from the findings of behavioural studies that the
increased sensitivity of the inflamed paw to noxious pressure can be potentiated by the
blockade of k receptors, with either acute administration of MR2266 (a relatively selective k
antagonist) or long term perfusion with a high dose of naloxone, whilst the antagonism of p
and 8 receptors alone is ineffective (Millan et al, 1985, 1986, 1988, 1991). Since these drugs
were given systemically a contribution from peripheral opioid receptors that have been
observed to become functional in inflamed tissues (Stein et al, 1987) cannot be discounted.
Additionally a recent study employing a push-pull cannula, demonstrated how the superfusion
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of dynorphin A(l-8) into the dorsal horn of spinalised rats can inhibit the release of ir-
substance P following noxious thermal stimulation in vivo, which is reversible by norBNI
(Zachariou and Goldstein, 1996), a finding again more in favour of the dynorphins acting to
moderate, not exacerbate, hyperalgesia in peripheral inflammatory conditions.
My finding of both basal and evoked release of ir-dynorphin A( 1 -8) in several areas of the
spinal cord does suggest an involvement of dynorphins in several aspects of spinal processing.
Release in the superficial dorsal horn may be related to antinociception, since these are the
areas of the spinal cord where fine sensory fibres that respond to nociceptive stimuli terminate.
Similar enhancements of proDyn synthesis have been observed after various other types of
intense peripheral stimulus, such as partial injury to peripheral nerves (Kajander et al, 1990;
Draisci et al, 1991; Wagner et al, 1993) and dorsal root section (Cho and Basbaum, 1988;
Caneletti and Ferri, 1995). An upregulation of proDyn peptides also occurs during chronic
stress (Przewlocki et al, 1987) and in late pregnancy/ parturition (Medina et al, 1993)
The prominence of evoked release in the deep dorsal horn together with the ventral hom
could reflect an influence on intemeurones and motoneurones mediating spinal reflexes and
supraspinal control of reflexes. Hindlimb 'flaccid' paralysis figures prominently in early
behavioural studies of intrathecally administered dynorphins (Przewlocki et al., 1983; Faden
and Jacobs, 1984; Herman and Goldstein, 1985; Stevens and Yaksh, 1986). However, the
initial concentrations of the compounds administered by this route are high and the final
concentrations at the receptors are unknown. Instead it has been proposed that these
naloxone-resistant effects relate more to the role of dynorphins in the pathophysiology of
spinal cord trauma and necrosis (Przewlocki et al, 1988; Stewart and Isaac, 1989), via
indirect or direct actions involving NMDA receptors (Caudle and Isaac, 1988; Bakashi et al,
1992; Skilling et al, 1992). However, the results presented in this thesis indicate that ir-
dynorphin A(l-8) is physiologically released in the ventral in addition to the dorsal horns of
the rat by intense peripheral stimulation and hence effects on motor behaviour are likely a
normal action of these neuropeptides.
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Thus, although it is a common assumption by many investigators to discuss the function
of the endogenous opioid peptides at the spinal level primarily with events related to
nociception, there is also considerable evidence to suggest that the dynorphins play an
important role in motor behaviour. Hence changes in opioid systems, especially proDyn, on
the induction of peripheral inflammation are likely to result not only in alterations in neuronal
activity related to the transmission of nociceptive information but also to other processes such
as those controlling motor output from the spinal cord in these pain states. Inhibition of
motor performance is a normal accompaniment of the healing process and this may be an
important component of the spinal actions of dynorphins as inflammation develops
peripherally.
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CHAPTER 5: Studies of the Spinal Release of Cholecystokinin -
Effect of Acute Morphine Administration
5.1 INTRODUCTION
It has been proposed that stimulation of opioid receptors may trigger a progressive
compensatory increase in the activity of CCK containing neurones in the spinal cord (as
discussed in section 1.9), with implications for not only the endogenous modulation of the
analgesic effects of opioids but also the development of tolerant states following the prolonged
administration of opiates. However, only a few studies have been performed to investigate
these CCK-opioid interactions directly, and these have produced a confusing array of data.
Hence, despite considerable research little is known about the level at which this interaction
occurs and the mechanisms involved.
No consistent effect has been observed on the synthesis of CCK in the CNS, following
acute or chronic opiate administration. Whereas early investigators reported alterations in the
levels of ir-CCK determined by radioimmunoassay in certain brain regions (Morley et al,
1986; Faris et al, 1986) and in the spinal cord (Watkins et al, 1985b) following morphine,
later studies found no evidence for such changes (Rosen and Brodin, 1989; Pohl et al, 1992).
Alone these ir-CCK levels are difficult to interpret with regard to the activity of CCK
releasing neurones, since parallel activation of the synthesis and release of CCK might well
result in unchanged tissue levels of ir-CCK. Rises in CCK levels could reflect inhibition of
release. However, studies of proCCK mRNA levels that provide a better index of the
synthesis state of the peptide have likewise given mixed results, with some evidence for
increased synthesis of CCK in certain brain regions following acute and chronic morphine
administration (Zhou et al, 1992; Ding and Bayer; 1993; Pu et al, 1994), including the spinal
cord (Ding and Bayer; 1993), though some investigators find no such effects (Pohl et al,
1992). Although not a complete study (only the cerebral cortex was investigated) no changes
in the CCK-B receptor binding characteristics (both Kd and Bmax) have been shown to occur
in morphine induced tolerant and abstinence states (Welin et al, 1994). Thus, overall the
evidence available, although limited, suggests that the mechanism by which CCK-opioid
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interact at the spinal cord level may involve an increased activity of CCK releasing neurones.
The findings of studies measuring the spinal release of ir-CCK into a surface perfusate
when opioids have been given topically or systemically, are equally far from uniform, and
complex opioid receptor interactions have been proposed to account for the release patterns
observed. In vivo, a naloxone reversible increase in ir-CCK levels has been observed in spinal
perfusates following the administration of analgesic doses of morphine either intrathecally (lp
M; Tang et al, 1984) or subcutaneously (5mg/ kg; Zhou et al, 1993b), this effect declining as
morphine administration continues (Pu et al, 1994). Similar effects were found following
acute and chronic periods of electroacupuncture (Zhou et al, 1993a; Sun et al, 1995).
However, by contrast the acute administration of the selective p opioid receptor agonist
DAMGO (1 pM) has been found to inhibit ir-CCK release into perfusate evoked either by
potassium or by direct high threshold stimulation of the rat sciatic nerve, in a naloxone
reversible fashion (Rodriguez and Sacristan, 1989).
In vitro investigations by Benoliel and co-workers (1991, 1994b) using perfused slices of
the rat dorsal hom appear to confirm these in vivo findings, describing increased ir-CCK
release with lOpM morphine added to the perfusate and an inhibition of the potassium evoked
ir-CCK release with 0.1 to lOpM DAMGO, although the effect of morphine was found not to
be reversed by naloxone but by the selective 8 antagonist ICI154129. Some explanation of
this apparent dichotomy was proposed from further studies analysing the effect of selective 8
and K agonists on ir-CCK release. In contrast to the monophasic inhibitory influences of
DAMGO on CCK release, a concentration dependent biphasic effect was observed with the
selective 8 agonist DTLET, a decrease in ir-CCK release being observed at low concentrations
(0.01 to 3pM), but an increase in ir-CCK release at a high concentration (lOpM). Since both
effects were blocked by selective 8 antagonists naltrindole and ICI154129, it was proposed
that these concentration dependent effects could result from actions on differing receptors or
receptor subtypes, as well as different neuronal populations (Benoliel et al, 1991; 1994b).
Similarly low doses of morphine (0.01 to 0.1 pM) were found to exert inhibitory effects on
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ir-CCK release, and like DAMGO, these were reversed by naloxone. Adding to the
complexity, the k agonist, U50488H was found to produce an inhibitory influence only at a
high concentration (10pM), at lower concentrations (lpM) appearing instead to prevent the
negative influence of 10|aM DAMGO on peptide release. In contrast, no interaction was
apparent between § and k agonists and effects on CCK release. Hence this group have
proposed that, since 10pM morphine likely stimulates all the opioid receptors, the overall
effect observed is that of the 8 receptor, the antagonistic effects of k versus p. receptor
stimulation negating each other (Benoliel et al, 1991, 1994b). A preliminary study by these
investigators on the effect of opioid receptor agonists on the spinal ir-CCK release in
morphine tolerant rats, found that under these conditions only the excitatory influence of
opioids on CCK releasing spinal neurones was observed (Benoliel et al, 1994a). However,
such spinal perfusion studies are unable to localise sites of release within the spinal cord and
the dorsal hom in vitro preparation of Benoliel and co-workers can at best determine release
from the limited neuronal systems remaining operative in this part of the spinal cord.
Hence, when I commenced my studies there was a need for further study to investigate the
interaction between opioid and CCK synthesising neurones at the spinal cord level. Thus, in
the experiments described in this thesis I employed microprobes bearing immobilised
antibodies to CCK to study the release of ir-CCK in the spinal cord of normal rats under both
basal conditions and following acute morphine administration, with a view to study the
phenomenon in animals chronically treated with morphine. However, due to the failure of the
CCK microprobes to continue to perform satisfactorily as assessed by in vitro testing I was
unable to perform such experiments. This was due to a change in the competence of the
antiserum purchased from Peninsula Laboratories. Although several other commercial
sources of CCK antiserum and radioactive peptide were investigated, attempts to resume this
study were not successful (see appendix A.II for details). The data that will now be presented
was from experiments performed using only the antiserum shown to be competent.
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5.2 MATERIALS AND METHODS
1. MICROPROBE PREPARATION
Antibody microprobes were prepared as previously described (section 3.2), using a
polyclonal antiserum (Peninsula Laboratories) that had been raised in rabbits against the
COOH-terminus of desulphated CCK 26-33 [CCK-8(NS)]. Data supplied by Peninsula
Laboratories indicated that this antiserum displayed 100% cross reactivity with porcine CCK-
33, caerulein and human gastrin; 78% reactivity with sulphated CCK 26-33 [CCK-8(S)];
63% reactivity with CCK 27-33; 14% reactivity with CCK 30-33 [CCK-4]; negligible cross
reactivity (<0.1 %) with human pancreatic polypeptide and zero cross reactivity with
vasoactive intestinal peptide (human, porcine rat). No information was available concerning
the affinity of this antibody for Bolton-Hunter CCK-8(S).
2. EXPERIMENTAL PROTOCOL
A total of 10 male Wistar rats (weight range 400 to 460g; mean ± s.e.m. = 417 ± 2g) were
used in this study.
Anaesthesia was induced, cannulae inserted and the lumbar spinal cord exposed, as
outlined in sections 2.2.3 and 2.5. All microprobes were inserted 2.25mm into the dorsal
spinal cord and remained in situ for either 5, 15 or 30 minutes. During these periods no
peripheral stimuli were applied, allowing the basal presence of ir-CCK to be examined in
these animals for modification by morphine and naloxone. To increase the likelihood of
detecting spinal release of CCK with acute administration of morphine:
(a) a total dose of 25mg/kg Morphine HC1 (25mg/ml in Ringers' solution) was administered
intravenously in divided doses over a two hour period, followed immediately by
(b) a single intravenous injection of lmg/kg Naloxone HC1 (lOmg/ml in Ringers' solution),
that was repeated for a second time 30 minutes later to block the action of morphine at opioid
receptors (as described in detail in section 2.4).
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As this study formed the pilot of a proposed series of experiments investigating the effect
of acute and chronic morphine administration (see appendix All), during the administration of
these drugs all microprobes were inserted into the spinal cord for the maximum period used
(30 minutes). Blood pressure, breathing rate and end tidal CO2 were monitored throughout.
Unfortunately due to the limited experiments that were able to be performed using the
competent antiserum, no study was made of the effect of naloxone administration alone on the
basal levels of ir-CCK prior to morphine administration.
After removal from the spinal cord, microprobes were washed and incubated for
approximately 24 hours in [125I]Bolton-Hunter CCK-8(S) [Amersham International] and
prepared for analysis as previously described (sections 3.4 and 3.5).
3. In vitro tests
Prior to use and throughout use in vivo, the sensitivity of the prepared antibody
microprobes were tested as outlined in section 3.3.
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5.3 RESULTS
A total of 138 microprobes coated with antibodies to CCK were inserted into the rat
spinal cord and form the basis of this analysis. An additional 400 microprobes were used for
in vitro sensitivity tests.
1. IN VITRO TESTS
The counts of total radioactivity of microprobe tips indicated that over 10% of the total
radioactivity in which they had been incubated bound to the microprobes. In vitro tests
indicated that CCK-8(NS) suppressed such binding on average by 88%, whilst that of
CCK-8(S) resulted on average in a 69% suppression. Hence, it can be assumed that the non¬
specific binding for these microprobes accounts for less than 20% of the total binding. No
evidence for a significant cross reactivity of the antisera with CGRP was found.
2. BASAL LEVELS OF ir-CCK
As previously described (section 4.3.2), a basal presence of a neuropeptide at a particular
site in the nervous system is inferred by differences between the mean image analysis of
microprobes not inserted into the nervous system but simply incubated in the radiolabeled
ligand and that of microprobes placed in the nervous system for a comparable time but in the
absence of any active stimulus. Using microprobes that had been present in the spinal cord
for either 5, 15 or 30 minutes, such comparisons indicated that ir-CCK was present in the rat
spinal cord under these 'basal' conditions. Since during the administration of the drugs, all
the microprobes were inserted into the spinal cord for 30 minutes, only the data derived from
these microprobes present will be presented below.
Figure 22A compares the mean image density scan of microprobes (n=28) present in both
sides of the spinal cord of normal (drug naive) rats for periods of 30 minutes and that of the in
vitro microprobes (n=32) that had not been inserted into the spinal cord but simply
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FIGURE 22. Basal presence of ir-CCK in the spinal cord of normal (drug naive) rats. (A)
The mean image analyses of two groups of microprobes are plotted with respect to length:
those present in the spinal cord of normal (drug naive) animals for 30 minutes in the absence
of any peripheral stimulation (pre-ntorphine, n=28) and those which are not inserted into the
spinal cord but simply incubated in [l25I]Bolton-Hunter CCK-8(S) (in vitros, n=32). With
each mean image analysis the mean grey scale was determined in 30pm intervals and a line
joins these points. At each analysis point the standard error mean of the mean (s.e.m.) is also
plotted (+) for no stimulus and (-) for in vitros. (B) A plot of the t statistics derived from the
standard error of the differences of means at each analysis point in the mean image analyses
shown in (A), is related to an outline of the spinal cord at the area sampled. The hatched








incubated in [125I]Bolton-Hunter CCK-8(S) and processed concurrently with those used in
vivo. Figure 22B plots in 30pm intervals the't' statistics derived from the differences between
the mean image analyses of the two groups. The hatched area indicates where these
differences are significant at the P<0.05 level (i.e. t>2). This is approximately at nearly all
sites from 0.1 to 2.1 mm from the dorsal surface of the spinal cord with three main zones. The
largest peak was in the mid to deep dorsal/ upper ventral horn (laminae III-VII), with further
major sites in the superficial dorsal horn (lamina I-II) and the mid/ lower ventral horn. Thus,
in normal rats extracellular ir-CCK was present in both the dorsal and ventral horns.
3. THE EFFECT OF ACUTE MORPHINE ADMINISTRATION ON BASAL LEVELS
OF ir-CCK
The acute administration of morphine (25mg/ kg) over a two hour period failed to alter the
presence of ir-CCK found under basal conditions in the rat spinal cord. As illustrated on
figure 23 no significant differences were found between the mean image analyses of all the
microprobes (n=28) present in the spinal cord over the two hours within which morphine was
administered, and that of the microprobes (n=16) present under basal conditions in 7 animals.
4. THE EFFECT OF NALOXONE ADMINISTERED AFTER MORPHINE ON THE
SPINAL RELEASE OF ir-CCK
Despite the surprising lack of effect of morphine, subsequent injections of naloxone
evoked a spinal release of ir-CCK. This is illustrated in figure 24A in which the mean image
analysis of all the microprobes (n=12) present in the spinal cord within two 30 minute periods
of naloxone administration can be seen to be displaced above that of microprobes (n=12)
present over the prior two hour period of morphine administration in these same group of
animals. Since only isolated points attain significance there is no hatching of the't' plot of
figure 24B. This preliminary result indicates that the levels of ir-CCK were
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FIGURE 23. Lack of effect of acute morphine administration on basal levels of ir-CCK.
The mean image analysis of the 28 microprobes present in the spinal cord for 30 minute
periods over two hours of morphine adminstration (during morphine) is compared to that of
microprobes present under basal conditions in the same animals (pre-morphine, n=16).
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FIGURE 24. Release of ir-CCK on naloxone administration following morphine.
(A ) The mean image analysis of 12 microprobes present in the spinal cord during the two
consecutive 30 minute periods of naloxone administration (naloxone) is displaced above that
of microprobes present over the prior two hour period of morphine administration in these
same group of animals (during morphine, n=12). (B) The differences between the two groups
of microprobes are plotted with respect to depth in the spinal cord. Since only isolated points
attain significance at the P< 0.05 level, there is no cross hatching as in other figures.
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significantly elevated in some areas of the mid/ deep dorsal horn and ventral horn. The data
however, was only collected from only 3 animals. As previously indicated no study was made
of the effect of naloxone administration on the basal levels of ir-CCK prior to morphine
administration.
5. RECOVERY FROM THE EFFECT OF NALOXONE ADMINISTERED AFTER
MORPHINE
The evidence for naloxone administration producing a significant increase in the release
of ir-CCK in the rat spinal cord following acute morphine administration would be improved
by higher numbers of microprobes. However, the mean image analysis of microprobes (n=9)
present in the spinal cord for the two consecutive 30 minute periods immediately following
those of naloxone administration, can be seen in figure 25 to be nearly completely coincidental
to that of microprobes (n=7) present under basal conditions in this same group of animals.
This observation of recovery strengthens the case that naloxone evoked a release of ir-
CCK in the spinal cords of rats previously exposed to acute doses of morphine. The briefness
of the effect (i.e. less than 30 minutes) perhaps reflects the relatively short half-life of
naloxone relative to that of morphine.
6. SUMMARY OF RESULTS
The present experiments have detected an extensive presence of ir-CCK in normal (drug
naive) rats involving both the dorsal and ventral horns. The largest peak was in the mid to
deep dorsal/ upper ventral horn (laminae III-VII) with further major sites inthe superficial
dorsal hom (laminae I-II) and the mid/ lower ventral horn. The acute administration of high
doses of morphine intravenously (25mg/ kg over two hours) failed to alter this basal presence
of ir-CCK. However, preliminary data suggests that subsequent injections of naloxone (lmg/
kg) evoked release of ir-CCK in some areas of the ventral hom. This effect is short lived, with
a return to basal levels occurring in less than 30 minutes.
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FIGURE 25. Recovery from the effect of naloxone administered after morphine. The mean
image analysis of the 9 microprobes present in the spinal cord for the two consecutive 30
minute periods immediately following those of naloxone administration (post naloxone, n=9)
is compared to that of microprobes present in under basal conditions in the same animals (pre-
morphine, n—1).
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This study has only examined CCK release following acute morphine administration and
whether CCK release is enhanced or reduced during the development of tolerance to
exogenously administered opiates was not investigated. Never the less I shall attempt to
explain why the release of ir-CCK was increased only when naloxone followed morphine
administration and place this within a hypothesis of CCK as an 'anti-opioid' substance. First,
however, the distribution of possible CCK releasing neurones and CCK receptors in the spinal
cord of the normal animal will be considered and this distribution compared to that found in
the present experiments.
Localisation of CCK and CCK receptors in the spinal cord
Cholecystokinin immunoreactivity has been described to be present to some extent at all
levels of the spinal cord, appearing to be concentrated in fibre terminals in lamina I and II, and
the region around the central canal, lamina X, forming an arc around the lateral edge of the
substantia gelatinosa into laminae III, IV and V (rat: Larsson and Rehfeld, 1979; Loren et al,
1979; Vanderhaeghen et al, 1980, 1982; Jansco et al, 1981; Stengaard-Pederson and Larsson,
1981c; Gibson et al, 1981; Schroeder et al, 1983; Conrath-Verrier et al, 1984; Fuji et al,
1985; Tuscherer et al, 1987; Nahin et al, 1987; Hokfelt et al, 1988; Leah et al, 1988. cat:
Maderdrut et al, 1982. guinea-pig: Stengaard-Pederson and Larsson 1981. man: Chung et al,
1989. monkey: La Motte et al, 1988). Cell body staining though rare has also been observed
more distinctly in some studies in lamina III-V, lamina VII and lamina X of the spinal cord,
notably to a greater extent at the lumbosacral level (Gibson et al, 1981; Vanderhaeghen et al,
1982; Schroeder et al, 1983; Conrath-Verrier et al, 1984; Fuji et al, 1985; Nahin et al, 1987;
Leah et al, 1988; Hokfelt et al, 1988; La Motte et al, 1988). This has been confirmed by
recent in situ hybridisation studies (rat: Cortes et al, 1990; Abelson and Miceyvich, 1991;
Schiffman et al, 1991. guinea-pig: Cortes et al, 1990).
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Early immunocytochemical studies pointed to the existence of CCK in primary afferent
neurones (rat: Lundberg et al, 1978; Dalsgaard et al, 1982; Otten and Lorez, 1983;
Tuchscherer and Seybold, 1985. guinea-pig: Lundberg et al, 1978; Larsson and Rehfeld,
1979; Lindh et al, 1988. cat: Leah et al, 1985; Dockray et al, 1981), which appeared to be
supported by the reduction in ir-CCK found in the superficial laminae of the dorsal horn
following neonatal capsaicin treatment (rat: Jansco et al, 1981; Gibson et al, 1982; Priestly et
al, 1982; Schultzburg et al, 1982; Micevych et al, 1983; Conrath-Verrier et al, 1984) and
dorsal rhizotomy (cat: Maderdrut et al, 1982). Support was also provided by the apparent
similarity in staining with peptides known to be predominantly located in primary afferents,
such as substance P (rat: Gibson et al, 1981; Jansco et al, 1981), with some evidence for the
coexistence of these peptides in spinal ganglia neurones (rat: Dalsgaard et al, 1982; Otten and
Lorez, 1983; Tuchscherer and Seybold, 1985; Tuchscherer et al, 1987. cat: Leah et al, 1985.
guinea-pig: Gibbins et al, 1987), and their apparent parallel reduction in the dorsal hom
following neonatal capsaicin treatment (Jansco et al, 1981; Tuchscherer et al, 1987).
Some investigators, however have found no such reductions in ir-CCK in the dorsal hom
following neonatal capsaicin or rhizotomy treatments when examined in the rat by
radioimmunoassay (Marley et al, 1982; Schultzburg et al, 1982; Gibson et al, 1982; Zouaoui
et al, 1990; Pohl et al, 1990). Such discrepancies are thought likely to reflect differences in
the type of immunoreactive material detected by radioimmunoassay and
immunocytochemistry. Since radioimmunoassays are usually performed with the antiserum
very dilute, only those immunoglobulins from a polyclonal antisera with the greatest affinity
for a given antigen (in this case CCK-8) are likely to be involved compared to
immunocytochemistry, in which a range of immunoglobulins are probably involved
(Schultzberg et al, 1982; Zouaoui et al, 1990). The additional material localised in the
immunocytochemical studies although likely related in sequence to CCK could belong to a
different family of peptides. In fact it has been proposed by Hokfelt and co-workers (Ju et al,
1986, 1987a; Williams et al , 1987; Hokfelt et al, 1988) that the ir-CCK in primary afferents
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could simply reflect a cross reactivity of the COOH-terminally directed antisera commonly
employed with CGRP, that has been demonstrated to be present in many primary sensory
neurones and fibres in the superficial dorsal horn (Rosenfeld et al, 1983; Gibson et al, 1984).
These investigators found primary afferents to only demonstrate immunoreactivity for CCK
only when COOH-terminally directed antisera were used, not polyclonal or monoclonal
antisera directed against any other sequence of CCK molecule, and that all the sensory
ganglion cells displaying such immunoreactivity also stained positive for CGRP. Although
CCK-8 and CGRP-37 exhibit only limited structural homology, sharing a similar COOH-
terminal sequence, Gly-X-X-X-Phe-NH2, this very low degree of identity in crucial positions
may be sufficient to cause cross-reactivity. Ju et al (1986) found that the staining for ir-CCK
was almost completely abolished by pre-absorption with 10~5M CGRP, although it was found
that concentrations up to 10~4M CCK-8 did not influence staining for ir-CGRP. Orazzo et al
(1993) though have since shown that CGRP antisera do react with the COOH-terminus of
CCK. Thus, CCK and CGRP may share similar antigenic determinants and the capsaicin
induced disappearance of ir-CCK from primary sensory neurones could reflect depletion of
CGRP, rather than CCK itself. However, it must be noted that the concentration of CGRP
required to block the CCK staining is very high and it is not certain how this relates to the
situation in vivo. Also Zouaoui et al (1990) found on examination by high pressure liquid
chromatography that the ir-CCK material from rat dorsal horn depleted by neonatal capsaicin
treatment was distinct from both genuine CCK and CGRP.
On the whole this evidence along with recent failure of in situ hybridisation studies to
localise the CCK precursor mRNA within the DRG of the rat (Cortes et al, 1990; Seroogy et
al, 1990; Schiffman et al, 1991; Ghilardi et al, 1992) makes the presence of CCK in primary
afferents in the rat very unlikely. However, it should be noted that although minimal ir-CCK
has been observed in the DRG of normal rats, these levels were considerably increased after
treatment with nerve growth factor (Otten and Lorez, 1983). Likewise the levels of proCCK
mRNA have been found to be low in the DRG of normal rats but considerably increased
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between 2 to 3 weeks after lesioning the sciatic nerve (Verge et al, 1993; Xu et al, 1993).
Thus, it remains possible that a very small population of primary sensory neurones may
synthesise CCK peptides at a very low rate, that is increased by peripheral axotomy. Doubts
as to the presence of CCK in primary afferents has so far been confined to the rat. A
prominent expression of ir-CCK (Lindh et al, 1988; Gibbins et al, 1987) and proCCK mRNA
(Cortes et al, 1990; Seroogy et al, 1990) has been found in the DRG of the guinea pig, as well
as that of the monkey (Verge et al, 1993). It is suggested that perhaps species differences may
exist in the level at which CCK participates in the sensory processing in the normal animal,
with CCK in the rat only showing an involvement after an intensive peripheral insult, such as
nerve injury (Verge et al, 1993). There is also evidence for a CCK presence in motoneurones,
though whether this immunoreactivity represents genuine CCK has likewise been debated by
Hokfelt and co-workers (Ju et al, 1986; Hokfelt et al; 1988). However, other investigators
have found it to be present by immunocytochemistry under normal conditions (rat: Schroder et
al, 1983) and 24 hours following ligation of the sciatic nerve (rat: Cortes et al, 1991), as well
as by in situ hybridisation (rat: Abelson and Micevych, 1991; Schiffman et al, 1991; Cortes et
al, 1990. guinea-pig: Cortes et al, 1990).
Whilst it is likely that the majority of CCK is located in neurones that are intrinsic to the
spinal cord, there is evidence that some may form ascending pathways, particularly those
located in cell bodies around the central canal, in lamina VII and X (Zouaoui et al, 1991),
with an immunoreactive presence being described in neurones of the spinoreticular tract
(Nahin, 1987; Leah et al, 1988), the spinomesencephalic tract (Leah et al, 1988), the
spinosolitary tract (Leah et al, 1988) and the spinothalamic tract (Ju et al, 1987b; Leah et al,
1988). There is also considerable evidence that some of the ir-CCK found at the spinal level
may be of a supraspinal origin, with transections of the rat spinal cord at the upper cervical
but not the lower cervical or thoracic level shown to result in accumulations of ir-CCK in the
rostral side only (Fuji et al, 1985). Projections descending from the periaqueductal grey (rat:
Skirboll et al, 1983), the midbrain nucleus of Edinger Westphal (cat: Maciewiez et al, 1984),
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and the raphe nuclei (rat: Mantyh and Hunt, 1984) have all been described to contain ir-CCK.
The results of a more recent study of the effect of thoracic transection on ir-CCK suggests
that some of these descending fibres may project to lamina II of the dorsal horn (Zouaoui et al,
1991).
Detectable levels of [l25I]-CCK binding have been found in all laminae of the mammalian
spinal cord, with the highest density of binding in lamina I and II of the dorsal horn (Van
Dijik et al, 1984; Hill et al, 1988; Hill and Woodruff, 1990; Ghilardi et al, 1992). The origin
of at least a substantial proportion of these CCK receptors appears to be the primary afferent
neurone itself, since DRG contain moderate densities of receptor sites and neonatal capsain
treatment results in a significant reduction of the density of CCK binding sites in several
laminae (Ghilardi et al, 1992). However as previously indicated (section 1.9.1) species
differences have been shown to exist. The use of selective CCK-A and CCK-B receptor
antagonists have demonstrated that whereas the CCK-B is the prominent receptor subtype in
rat and rabbit spinal cord, that in the monkey cord is the CCK-A receptor despite (like the rat
and rabbit) the CCK-B receptor being the more prominent on DRG neurones (Hill et al, 1988;
Hill and Woodruff, 1990; Ghilardi et al, 1992).
In agreement with these anatomical studies the present study has revealed an extensive
presence of ir-CCK in the normal (drug naive) rat. Despite the poor specificity (i.e. high
degree of cross reactivity) of the polyclonal antiserum employed for the other derivatives of
precholecystokinin plus gastrin and caerulein, this immunoreactive material is likely to
represent sulphated CCK-8, since as indicated in section 1.9.1 it is this form of CCK that
predominates in the vertebrate CNS including the rat spinal cord and gastrin exists in only
significant quantities in the neurohypophysis. As previously considered for the spinal release
of dynorphin (section 4.4), little can be determined about the physiology of a neuropeptide
from its basal presence, since the contributions from the anaesthetic and surgical preparation
are unknown. Under such conditions release is best equated with a significant increase in the
extracellular levels of a peptide following a defined stimulus. Since more detailed
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investigations were unable to be carried out, the relative contribution to this basal presence
from primary afferent fibres, intrinsic neurones and the terminations of fibres of supraspinal
origin are unknown. Due to the extensive nature of the basal levels of ir-CCK found, an input
from descending fibres is probable and similarly a contribution from primary afferents cannot
be discounted. To this purpose it would obviously be of interest to determine the effect of
nerve stimulation at both A(3 and A8/ C fibre intensity on this ir-CCK presence, as well as the
effect of spinal transection at the upper thoracic segments.
An hypothesis of CCK acting as an 'anti-opioid' in the spinal cord
As outlined in section 5.1, both increases and decreases in the basal levels of ir-CCK have
been observed in a surface perfusate following the acute administration of opioids to spinal
tissue. This inconsistency is puzzling. The present study found no effect on ir-CCK detected
with the administration of relatively high doses of morphine. However, the finding that
subsequent injections of naloxone did evoke a spinal release of ir-CCK does suggest that
some of the CCK releasing neurones are under opioid control. Unfortunately no study of the
effect of naloxone administered alone on the basal levels of ir-CCK was performed which
limits any interpretation of the present findings. Since as discussed in section 1.9, CCK
antagonists have been observed to facilitate opioid mediated analgesia acutely, it is likely that
in the normal (drug naive) animal CCK is being tonically released to affect opioid receptor
binding. Whilst it is possible that morphine did have an effect in reducing the tonic release of
CCK, the high basal levels of ir-CCK in the present study may have made such an action
difficult to detect. High basal levels of CCK in normal rats was proposed by Stanfa and
Dickenson (1993) as an explanation for the inability of exogenous CCK-8 to reduce the effect
of morphine on C fibre evoked responses in dorsal neurones, as other investigators had
previously shown (Wiesenfeld-Hallin and Duranti, 1987; Kellstein et al, 1991). Recent
behavioural studies have suggested that release of endogenous CCK is influenced by the
environment to which animal exposed. As previously indicated it has been suggested that
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CCK is released in 'safe' situations to limit the analgesic actions of endogenous opioids
released in contrast by environmental cues in aversive or dangerous situations (Wiertelak et al,
1992; 1994). However, confusingly it has also been reported that CCK receptor antagonists
do not enhance morphine antinociception in rats in 'familiar' situation but do so in animals
exposed to a novel environment, suggesting that CCK release is associated with 'stress'
(Lavigne et al, 1992). Although these results are conflicting, they highlight the plasticity of
the CCK systems. It is thus possible that such factors may play a role in the basal levels of ir-
CCK in the anaesthetised and surgically prepared animals used in these present experiments
and such levels may contribute to the lack of effect of morphine observed on basal ir-CCK
levels. An alternative explanation, however, for the ineffectiveness of the high doses of
morphine administered could be of a more pharmacological nature, due to antagonism at non-
opioid receptor sites by its metabolite morphine-3-glucuronide. Recent studies in Sprague-
Dawley rats have provided evidence that the ratio of this metabolite to morphine in blood
plasma (Smith and Smith, 1995) and cortical extracellular fluid (Barjavel et al, 1995) is
highly inversely correlated with the level of antinociception achievable. However, whether
the build-up of morphine-3-glucuronide in the spinal cord of the Wistar rats used in the
present study was significant compared to the levels of morphine over the two hour time
period involved, and played a factor in the lack of effect of the high doses of morphine
observed on the basal levels of ir-CCK, requires further investigation.
Considering both the findings of this present study and those discussed in sections 1.9 and
5.1, an hypothesis by which CCK may interact with exogenously administered opiates (and
endogenously released opioids) in the spinal cord as an 'anti-opioid' and contributes to the
development of opioid tolerance is presented below (in bold), along with supporting evidence
where this is available from the work of other groups. This hypothesis is outlined
schematically in figure 26(A, B, C).
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FIGURE 26. Schematic representation of an hypothesis of CCK acting as an 'anti-opioid' in
the spinal cord. In (A), (B) and (C) opioid releasing neurones are illustrated as contacting
neurones capable of synthesising CCK. These CCK releasing neurones display both opioid
and CCK receptor sites. In the spinal cord of the normal (drug naive) animal, CCK shows
some tonic release (A). On opioid receptor activation (as in the present study following the
acute administration of morphine) an upregulation of CCK synthesis is proposed (B).
However, this is only observed when the opioid receptor effect is partially removed (as in the
present study following the administration of naloxone and, it is predicted, as tolerance to
opiate effect develops), as illustrated in (C). This proposed hypothesis is described in detail








It is proposed that:
(1) Some central neurones have the ability to synthesise and release CCK in
response to opioid receptor occupancy. Some evidence for this exists at the level of the
hypothalamic neurohypophyseal axis where CCK has been described to be colocalised with
oxytocin within the magnocellular neurosecretory neurones of the hypothalamus
(Vanderhaeghen et al, 1981). These neurones are subject to regulation by opioids at the level
of cell bodies and at the terminals in neural lobe to reduce the release of oxytocin into the
blood (as recently reviewed by Russel et al, 1995).
(2) These neurones possess receptors for CCK along with opioid receptors on
their cell bodies and axon terminals (as illustrated on figure 26A). As previously indicated
there is evidence that both CCK receptors (Ghilardi et al, 1992; Zhang et al, 1993) and opioid
receptors (La Motte et al, 1976; Gamse et al, 1979; Fields et al, 1980; Besse et al; 1990) are
present on dorsal root ganglion cells. Notably a recent study involving whole-cell patch-clamp
recordings of acutely isolated rat dorsal root ganglion neurones demonstrated that the
depressive effect produced by the selective (I agonist, ohmefentanyl, on voltage gated Ca2+
currents, could be readily reversed by CCK-8 through CCK-B receptors located on the same
neurone, and that this effect was not mediated by a reciprocal action on the same Ca2+
currents (Liu et al, 1995), although CCK may mobilise intracellular stores of Ca2+ (Wang et
al, 1992). It has also been proposed that CCK and opioid receptors may belong to the same
complex (Hudson et al, 1992).
(3) With acute morphine administration (as illustrated on figure 26B), CCK
synthesis is increased but is not released while the acute action of the opiate (inhibition of
firing) is undiminished (no tolerance). As indicated in the introduction to this section,
although there have been limited investigations of CCK synthesis under such conditions there
is some evidence to support such an effect (Zhou et al, 1992; Ding and Bayer, 1993; Pu et al,
1994).
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(4) Only when the opioid receptor-mediated inhibitory influence is partially removed
will this CCK be released (figure 26C). As in the present study where the administration of
naloxone is seen to result in the release of CCK.
(5) Released CCK can access opioid receptors on both axon terminals and cell
bodies, having little effect per se, but acting as a specific 'anti-opioid' compound to
reduce the effect of opioid receptors. As outlined in section 1.9 this may occur either by an
uncoupling of the opioid receptor-effector systems ('desensitisation') or by the internalisation
of the opioid receptors themselves ('down- regulation'). Whilst early studies reported that
CCK-8 did not inhibit opioid binding directly (Stengaard Pedersen and Larsson, 198 la), more
recent reports have indicated that CCK-8 does appear to affect the binding characteristics of
opioid receptors in neonatal (Johnson et al, 1987), and adult rat brain (Wang et al, 1989)
indirectly via actions on CCK receptors. Another binding study found that whilst CCK-8 was
very effective in suppressing the binding of [3H]-DAMGO to p. receptors and [3H]U69593 to
K receptors, no effect was observed on the binding of [3H]DPDPE to 8 receptors in the rat
brain (Wang and Han, 1990). Similarly electrophysiological (Magnuson et al, 1990) and
behavioural (Wang et al, 1990) investigations have determined that CCK-8 preferentially
antagonises the analgesia mediated by p and k opioid receptors respectively, but not that of 8
receptors. Since a remarkable lack of cross tolerance has been demonstrated among p, 8 and
K receptor agonists, such findings may partly explain the results of Benoliel and co-workers
(1991; 1994a; b), that imply a significant role for the 8 receptor in the morphine induced
release of ir-CCK at the spinal cord level. Such effects may also be mediated by allosteric
interactions between opioid and CCK receptors in which the conformational state of an opioid
receptor could be modified, as proposed from the finding of a recent study in rat hippocampal
slices (Miller and Lupica, 1994).
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From such an hypothesis it would be predicted:
(6) With chronic morphine administration, as tolerance develops, small amounts
of CCK will be released, which by slightly removing the opiate inhibition of release
will act as a positive feed-back process to eventually result in complete tolerance.
It should be noted, however, that such an hypothesis could not be proposed if the
morphine administered was found to be ineffective at the opioid receptors due to antagonism
by a significant build-up of its morphine-3-glucuronide metabolite or if naloxone alone was
found to have an effect on ir-CCK basal levels in the absence of prior morphine
administration. Further studies are required.
Overall the findings from behavioural investigations into role of CCK in opioid analgesia
have supported an involvement of CCK releasing neurones in the development of tolerant
states only (as discussed in section 1.9), with no evidence for a role in either the development
or expression of physical dependence. This was also confirmed more recently by Pournaghash
and Riley (1991), who demonstrated the failure of even high doses of CCK (up to 40ng/ kg) to
precipitate withdrawal in morphine dependent rats as naloxone (10mg/ kg) was able to do.
Thus, CCK studies imply that the mechanisms that underlie tolerance and dependence states
are not identical and may be differently regulated depending on the system and species studied.
It is possible that the involvement of other anti-opioid peptides, for example neuropeptide FF.
(Malin et al, 1990a; b) may play more of a defined role in the development of physical
dependence upon opiates. To this purpose it would be obviously be of interest to study the
release of ir-CCK under conditions of tolerance to and dependence upon opiates.
As to the potential therapeutic use of CCK receptor antagonists. Whilst there is evidence
that CCK-opioid interactions occur in humans, proglumide enhancing the analgesia induced
by morphine (Price et al, 1985; Lavigne et al, 1989), studies in rats have indicated that
compensatory alterations may develop during chronic CCK blockade which may limit the
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clinical effectiveness of CCK antagonists as useful adjuvants in the management of chronic
pain (Kellstein and Mayer, 1990), the long term administration of proglumide and lorglumide
appearing to result in a loss of facilitation (after 8 days) or a reduction (at 22 days) of
morphine antinociception.
Although not dealt with in the context of this thesis, it has been proposed that adaptive
changes in the functional activity of spinal CCK systems are responsible for alterations in the
potency of morphine at the spinal level observed in chronic pain states (Stanfa et al, 1994).
Namely enhanced spinal levels of CCK may be responsible for opiate insensitivity of
neuropathic pain observed in animal models (Xu et al, 1993) and in the clinic (Arner and
Meyerson et al, 1985; Portenoy et al, 1991), whilst reduced spinal levels may explain the
observed enhancement of the inhibitory effects of intrathecal morphine on the C fibre evoked
responses of dorsal horn neurones in animals with a peripheral inflammation (Stanfa and
Dickenson, 1993). Further studies however, are required to determine the basal release of
CCK in these different pain states.
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CONCLUDING REMARKS
Following the discovery of the endogenous opioid peptides, it was anticipated that many
new insights into the understanding of opiate drug action would be gained, ultimately resulting
in the development of new analgesics with enhanced potency but reduced side effects,
including a lower abuse potential. However, despite considerable research and accumulating
knowledge of the opioid peptides and their actions, especially at the cellular level (as reviewed
in the introduction of this thesis), the isolation of the opioid peptides has not resulted in
effective improvements to opiate therapy. Indeed the significant advances to opiate therapy in
recent years have been pharmacokinetic in nature, involving the synthesis of opiate drugs with
a range of duration of actions, the development of patient controlled analgesia, and the
widespread use of opiates by epidural and intrathecal routes either intraoperatively or for the
treatment of chronic pain. This may be a reflection of our lack of understanding of the
physiology of opioid peptides in chronic pain states.
An example of this is the dichotomy of opinion which has evolved in recent years as to the
role of the endogenous opioids, in particular the dynorphins, in the hyperexcitabilty of spinal
cord neurones following the development of a peripheral inflammation. This has resulted in
an apparent shift in emphasis from viewing the opioid peptides as inhibitory to the changes
induced in the spinal cord under such conditions, exerting a modulatory influence on the
processing of nociceptive information, to one in which a direct contribution to the formation of
the hyperalgesic states is implied (Dubner and Ruda, 1992). These two opposing views need
further data to come to a complete overview of how nociceptive information is processed
centrally under inflammatory conditions, and the role the opioid peptides play within these
evolving processes. My studies clearly show that within the time period studied, dynorphins
are released when inflamed peripheral tissues are manipulated. Since this release is
widespread involving both dorsal and ventral horns, an involvement of these opioid peptides in
several aspects of spinal function is implied. From my reading of the literature and from my
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results I have proposed that the released dynorphin exerts an inhibitory role on the
transmission of nociceptive information under normal and inflamed conditions, and also likely
plays a role in motor function, perhaps setting the level at which simple reflexes are operative
at the spinal cord level.
The opioid field has grown increasingly complex with multiple opioid peptides exerting
their effects via multiple opioid (and possibly non-opioid) receptors to impart a number of
short and long term effects on neuronal function. Additionally the opioid systems are known
to be widely distributed throughout the CNS and to influence many functions other than those
pertaining to the processing of nociceptive information. Although in no instance is a full
description of a central 'opioid event' available, knowledge of opioid events could be
considerably improved by further studies aimed at determining the opioid receptor sites
functionally active in response to a particular stimulus and which opioid peptides mediate
these effects. To this end further antibody microprobe studies (or other release studies
capable of significant spatial localisation) and electrophysiological studies involving the
administration of selective opioid receptor antagonists, are imperative. The recent cloning of
the opioid receptors has significantly added to the range anatomical and behavioural
techniques by which the functions of the opioid systems can be investigated and these are
likely to provide further insight into the functions of the opioid systems at the spinal level.
From a more holistic viewpoint the opioid systems have been proposed to be important in
the modulation of basic survival instincts involving reward and the reinforcement of
behaviours, such as food and water intake, and sexual activity (Terenius, 1992). Acute pain
is also recognised as being essential for survival enabling suitable avoidance/ protective
responses to be leamt and autonomic responses activated, hence preventing excessive tissue
damage. Acute pain, however, is not a protean benefit, since the disruption to motor
performance produced by pain may prevent an adequate escape from a threatening
environment. The interplay of a hypersensitive pain system and an inhibited pain system
('stress-induced analgesia'), indicates the need to regulate the central processing of nociceptive
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information. It is not surprising therefore that the opioid systems themselves also appear to be
highly regulated. Cholecystokinin has been proposed to impart such a role in the certain CNS
systems, thus acting as an 'anti-opioid' peptide. My studies perhaps indicate an association
between CCK and opioid systems, with the suggestion perhaps of an increased availability of
this neuropeptide for release at the spinal level after only an acute exposure to an opiate drug.
However, additional experiments investigating the effect of naloxone alone and lower doses of
morphine on ir-CCK basal levels need to be performed to strengthen the evidence for such an
interpretation. Based on the plethora of studies performed, there is strong evidence to support
such a release of CCK in the development of tolerant states to exogenously administered
opioids. To this end, as previously indicated, it would of considerable interest to extend the
studies described in this thesis to determine the release of CCK in opiate tolerant and
dependent states. Additionally since it has been proposed that the spinal levels of CCK may
be instrumental in the creation of opioid insensitive (neuropathic) and hypersensitive
(inflammatory) pain states (Stanfer et al, 1994), it would also be informative to use the
antibody microprobe technique to examine CCK release in animal models involving nerve
damage or tissue injury.
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APPENDIX: Technical Considerations of the Antibody
Microprobe Technique
A.I GENERAL
Although (as outlined in section 1.10) the antibody microprobe technique has been
successfully employed for the detection of many neuropeptides in the CNS, this has not been
true for all neuropeptides studied. In recent years in our laboratory problems have been
encountered during the in vitro testing of galanin, endothelin, dynorphin A, met-enkephalin
and as indicated in section 5 of this thesis, cholecystokinin. Some of these problems have
been overcome allowing the studies to proceed successfully, however in other instances the
problem has appeared to be more of a fundamental nature, particularly with the competency of
the antiserum purchased, and have not been resolved. Problems have presented as: (a) a
failure of the immobilised antibodies to bind adequate amounts of the radiolabelled peptide
('tracer'); (b) poor sensitivity (characterised by the least concentration of unlabelled peptide
able to suppress binding of tracer to immobilised antibodies)/ and or specificity (characterised
as extent of cross reactivity of immobilised antibodies with peptides other than that used to
raise the antiserum) of microprobes for the neuropeptide being studied; and (c) inadequate
suppression of tracer binding to microprobes by a high concentration (i.e. 10~5M) of
unlabelled peptide.
There are many possible explanations why antibody microprobes can fail to perform
satisfactorily on in vitro testing (described in section 3.3). Some of these will be now
outlined, and then considered more specifically in appendix A.II in relation to the problems
encountered with CCK microprobes.
(i) Problems with the attachment of the radiolabel to the peptide
Two approaches are commonly employed to label peptides with the radioisotope l25I. In
one the iodide is oxidised, for example by chloramine T (Greenwood et al, 1963), to form
iodine, which substitutes onto the aromatic side-chain of tyrosine residues of the peptide (as
illustrated on figure 27A for [l25I]CCK-8(desulphated)). At low levels of specific activity
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FIGURE 27. Different methods used for iodination of CCK-8. (A) [l25I]CCK-8
(desulphated) is prepared by the iodination of tyrosine residue on NH2-terminal of the
peptide. This is achieved as illustrated (in box) by the substitution of 125I onto the aromatic
side-chain of tyrosine in the presence of the oxidising agent, chloramine T. (B) [l25I]CCK-8
(sulphated) is prepared by the conjugation of the NH2-terminal of CCK-8 with the iodinated






























(defined as the radioactivity in Curies [Ci] per unit mass or mole of ligand) the majority of
substitutions are single, only at higher levels is diiodotyrosine formed. The other approach
involves the conjugation of the peptide to a molecule that can be labelled with iodine, such as
the Bolton-Hunter reagent [N-succinimidyl 3-(4-hydroxyphenyl)propionate] (Bolton and
Hunter, 1973), which includes a phenol group capable of iodination, and a carboxyl group
which can be directly coupled to free amino groups on lysyl or NH2-terminal residues of the
peptide (as illustrated on figure 27B for [l25I]CCK-8(sulphated)). Which approach is chosen
is often dependent on the availability of suitable tyrosine residues (if any present) on the
neuropeptide of interest, namely tyrosine residues that if iodinated will not alter the binding
characteristics of the peptide. The specific activities of the iodinated peptides purchased for
the purpose of the studies described in this thesis were in the range of 1000 to 2000 Ci/
mmole.
The occurrence of low '0M' microprobe counts (i.e. those microprobes not exposed to any
concentration of unlabelled peptide solution but simply incubated in the radiolabeled peptide)
could be due to poor iodination of the peptide purchased, or a rapid dissociation of the
radiolabel from the peptide after purchase ('deiodination'), or damage to the peptide structure
(for example, by the iodination process itself)- To accurately determine the iodination status
of the tracer purchased and assess the integrity of the peptide structure, requires some degree
of chemical assessment of the components of a sample of the tracer after separation for
example by gel filtration chromatography. This has not been pursued to any great extent in
our laboratory.
It is of note that for the purpose of the antibody microprobe technique, low counts alone
do not pose an irreconcilable problem, as long as the microprobes display a satisfactorily level
of sensitivity and specificity in vitro for the particular neuropeptide being investigated. The
main drawback is the length of time in which the microprobes must be placed next to an
X-ray film to obtain satisfactory autoradiographic images (perhaps more than a month) which
obviously slows down the progress of a study.
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(ii) Problems with the binding of the radiolabeled peptide to the immobilised antibodies
IgG molecules are the most abundant immunoglobulins found in the serum of a number of
species including rabbits, in which most polyclonal antisera to neuropeptides are raised by
artificial immunisation. The structure of an IgG molecule is illustrated in figure 28A. As
indicated in section 3.2.2 the process of immobilisation of these antibodies to the siloxane
coated microprobes involves the coupling of the Fc region (illustrated in figure 28B) of the
IgG molecules in a polyclonal antiserum via glutaraldehyde/ protein A. It is possible for IgG
molecules raised to certain neuropeptides that this coupling may cause alterations in the
antigen binding site or affect the ability of the antigen binding domain to interact with
particular conformations of the peptide, perhaps by limiting movement of the 'hinge' region of
the immunoglobulins. Different coupling methods may be overcome some of these problems,
but this has still to be investigated fully. Such problems may present themselves as
background or low 'OM' microprobe counts resulting from either a complete failure or poor
ability of the immobilised antibody to bind the radiolabeled peptide.
To check that the IgG molecules have not been seriously damaged in the antigen binding
domain during the manufacturing process, the prepared microprobes can be incubated in
capillaries containing radiolabeled F(ab)2 fragments of antibodies directed against Fc region
of the IgG molecules of the host species (usually rabbit) in which the polyclonal antisera had
been raised (as illustrated on figure 28C). These microprobes can then be processed as
described in section 3.3 for in vitro testing, the ability or not to detect radioactivity on these
probes determining whether antibodies capable of binding F(ab)2 fragments are actually bound
to the microprobes and how uniformly bound. It is also possible that the iodination of the
peptide itself may place a conformational constraint on the peptide and limit the extent to
which it may interact with the IgG binding sites, as well as possibly causing a steric hindrance
to binding due to the position of the radiolabel on the peptide. If the tracer is not suspected of
being damaged or poorly iodinated, then the performance of a radioimmunoassay may be
informative of the competency of the 'free' (i.e. non-immobilised) antiserum.
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FIGURE 28. The structure of the IgG molecule. (A) This consists of four peptide chains
linked by disulphide bonds; two 'heavy' and two 'light' chains. (B) Limited enzyme digestion
by the protease papain, splits the IgG molecule into three domains; two of which are identical
and form the arms of the 'Y' (known as 'Fab' fragments as contain the antigen binding sites),
the third domain forming the base of the 'Y' and the effector region of the antibody (known as
the 'Fc' fragment because it can be crystallised). The region between the Fab and Fc
fragments is known as the 'hinge', since it allows lateral and rotational movement of the two
antigen binding domains to enable them to interact with a large number of different antigen
conformations. (C) Treatment with the protease pepsin can be used to release the two antigen





(iii) Problems with the competency of the polyclonal antiserum
In the course of the immune response to a particular injected neuropeptide, large numbers
of IgG molecules are produced with slightly variable antigen binding site regions, some of
which fit the neuropeptide very closely and thus have a high affinity, others less closely and
are of a lower affinity. It is suspected that often the reason for the failure of antibodies to
perform adequately as part of antibody microprobes may be due to a high proportion of the
immunoglobulins in particular batch of antiserum purchased being of a low affinity nature,
with great variability between different batches (of different lot number) of antiserum being
sometimes encountered. Microprobes do not allow simultaneous competition between ligands
for binding to available sites but rather the unlabelled (or endogenous peptide) is allowed first
access and the radiolabelled peptide follows. For this to succeed it is important that the
antibody have a high affinity, such that the radiolabelled peptide does not displace the
previously bound unlabelled form. This may be indicated by the 'titre' of the antiserum
purchased or ICi0 value (although this information is not always provided by the
manufacturer). Such problems may present as low sensitivity and or/specificity of the
prepared microprobes for the neuropeptide being studied, as well as poor suppression of the
binding of the tracer to microprobes by the unlabelled peptide. Although the use of
monoclonal antibodies or more NH2-terminally directed antisera could provide the answer to
such problems, monoclonal antibodies are not available for most neuropeptides and the use of
NFF-terminally directed antisera is often limited by the availability of COOH-terminally
radiolabelled peptides.
A high percentage of low affinity antibodies may not necessarily affect the performance
of the polyclonal antiserum in radioimmunoassay and immunocytochemical procedures for
which they have been usually prepared, since both the labelled and unlabelled forms of the
peptide are allowed to compete. Many procedures to improve sensitivity and specificity of a
polyclonal antiserum are not applicable under conditions of antibody microprobe technique,
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which involves immobilisation of IgG molecules and incubation times limited by their ultimate
use in vivo.
(iv) Problems with non-specific binding
With certain peptides (both labelled and unlabelled) it has been suspected that losses may
occur due to the binding of the peptide to the inner surfaces of glass microcapillaries,
effectively lowering their concentrations in the capillary. Sigmacote treatment of these
surfaces appears to have limited this problem but it is important to reassess the possibility that
this may be occurring when a problem with low 'OM' microprobe counts or poor suppression
of tracer binding by the unlabelled peptide is found. Non-specific binding sites on the
microprobe surface to which the radiolabeled peptide could bind is minimised by using an
excess of a general binding agent, such as bovine serum albumin (BSA), in the tracer solution.
Although for the purpose of antibody microprobe studies BSA has commonly been used, other
binding agents such as gelatin and casein, have sometimes proved more effective (as will be
discussed in A.II), perhaps causing less steric hindrance to peptide-antibody interactions. The
use of such substances also serves to reduce the effect of any contamination in the tracer
solution.
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A.II CHOLECYSTOKININ IN VITRO ASSAY
As indicated in section 5.1 the original intentions of the cholecystokinin study were not
completely fulfilled due to the failure of the CCK microprobes to continue to perform
satisfactorily, as assessed by in vitro testing. The following account chronicles the 'history' of
the CCK in vitros performed, indicating the problems encountered and offering explanations
where possible. In total a 1091 microprobes were employed!
(i) Failure of immobilised antibodies from Amersham antiserum to bind rl25I1Bolton-Hunter
CCK-8(sulphated).
The first antibodies for CCK tested in vitro were purchased from Amersham International
[N1591; Lot no. 11445], The polyclonal antisera had been raised in rabbits against the
COOH-terminus of sulphated CCK 26-33 [CCK-8(S)] covalently conjugated to BSA for use
in radioimmunoassay (RIA). An iodinated form of CCK was also purchased from Amersham
International. This was [l25I]Bolton-Hunter CCK-8(S), prepared by the conjugation of the
NH2-terminal of the sulphated form of CCK-8 with iodinated Bolton-Hunter reagent, as
illustrated in figure 27B. Table 6 displays the results of an in vitro assay on microprobes
prepared using this source of antibody and tracer and following the protocol described in
section 3.3. The counts (cor.cpm) obtained for these microprobes were at background level.
This was not due to a failure to immobilise the antibodies onto the microprobes since high
counts were obtained when anti-rabbit 125I-IgG F(ab)2 fragments were incubated with these
same microprobes, as also illustrated on table 6. Instead, it appeared that the radiolabeled
tracer had not bound to the immobilised antibody.
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TABLE 6. The failure of immobilised antibodies from Amersham CCK(RIA) antiserum to
bind rl25I1BoIton-Hunter CCK-8(sulphated). The counts (cor.cpm) obtained for microprobes
prepared using this antiserum were at background level. This is in contrast to those obtained
following the incubation of the microprobes in anti-rabbit 125I-IgG F(ab)2 fragments.
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(ii) Success obtained using microprobes prepared with Peninsula antiserum.
The next source of antibodies were purchased from Peninsula Laboratories [RAS 7181;
Lot no. 005790]. This polyclonal antisera that had been raised in rabbits against the COOH-
terminus of desulphated CCK 26-33 [CCK-8(NS)], again for use in radioimmunoassay. On
in vitro testing, microprobes prepared with this antiserum consistently displayed high counts
for the unsuppressed binding of the tracer to the microprobes, and good suppression of tracer
binding by the unlabelled peptide. An example of the results of such an in vitro assay
performed, is illustrated on table 7A. Since in this assay the same [125I]Bolton-Hunter CCK-
8(S) tracer was employed as for those employing the Amersham antiserum, it can be
concluded that the tracer being used was competent and that any problems were likely due to
the antiserum employed (at least when immobilised onto the microprobes).
(iii) BSA vs. gelatin conditions tested.
As indicated in A.I(iv) BSA (bovine serum albumin) is usually present in the tracer
solution to occupy any non-specific binding sites on the microprobe surface and to reduce the
effect of any contamination in the tracer solution. However, other general binding agents have
been tried such as gelatin and casein. Notably casein is presently being employed instead of
BSA in a microprobe study of the release of neuropeptide Y in the rat spinal cord by Mark et
al.
In the information supplied with the antiserum from Amersham it was stated that gelatin
should be used in the radioimmunoassay buffer in preference to BSA since:
"spurious results may be obtained with certain preparations of BSA".
Hence, in vitro assays were performed to determine whether gelatin had any effect on the
failure of immobolised antibodies from Amersham International to bind [12SI]Bolton-Hunter
CCK-8(S), as described in (i).
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TABLE 7. Success and then failure of microprobes prepared with Peninsula antisera. The
results of in vitro assays testing the unsuppressed ('OM') and suppressed (unlabelled sulphated
and desulphated CCK-8) binding of [125I]Bolton-Hunter CCK-8(sulphated) to microprobes
prepared with Peninsula antisera. (A) Microprobes bearing immunoglobulins from RIA-1
antiserum show high counts (cor.cpm) for the unsuppressed binding of the tracer to the
microprobes, and good suppression of tracer binding by 10~6M CCK-8 (sulphated and
desulphated). (B) The counts obtained for the 'OM' microprobes in comparison using the
RIA-2 antiserum are low, and are not dramatically suppressed by prior incubation in
unlabelled peptide.
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A CCK-8 IN VITRO \26/1/ 951 - PENINSULA CCK (RIA-1) ANTISERUM
PROBE TYPE COR.CPM COR.CPM
[CCK] [l25I]BH CCK-8 (S) MEAN±S.E.M.
1090.5
1180.1














B CCK-8 IN VITROS -\25/ 5/ 951 AND T5/ 6/ 951
PENINSULA CCK (RIA-1) PENINSULA CCK (RIA-2)
ANTISERUM [25/ 5/ 95] ANTISERUM [5/ 6/ 95]
PROBE TYPE COR.CPM COR.CPM COR.CPM COR.CPM
[CCK] [l25I]BH CCK-8 (S) MEAN±S.E.M. [l25I]BH CCK-8 (S) MEAN+S.E.M.
2237.4 533.9
1893.4 345.4





CCK-8 (S) 386.7 619.2 ±62.1 364.2 296.5 ±31.5




CCK-8 (S) 374.7 442.0 ± 84.0 216.4 270.5 ±25.6
105M 707.2 (-177%) 348.1 (432%)
218.5
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As can be seen from table 8, the finding of such an in vitro assay revealed that although
when gelatin was used in the PBS-azide solution to make up the tracer, the counts obtained for
'0M' microprobes bearing Amersham antibodies were slightly higher than background, poor
suppression of these counts was obtained by the unlabelled peptide. This was also true for
microprobes bearing Peninsula antibodies. The reason for this is unknown.
(iv) Failure of the CCK microprobes to continue to perform satisfactorily.
A replacement batch of antiserum from Peninsula Laboratories failed to perform
satisfactorily on in vitro testing. This was of a different lot number [021294-1], Table 7B
compares the findings from in vitros employing the same batch of radiolabeled ligand but
these different lot numbers of Peninsula antisera. Unfortunately the remainder of the initial
batch (RIA-1) of antiserum was exhausted before the second batch (RIA-2) arrived, and so a
direct comparison between the antiserum in the same assay could not be made. It can be seen
that the counts obtained for the '0M' microprobes using the RIA-2 antiserum are low, and are
not dramatically suppressed by prior incubation in unlabelled peptide. This is in comparison
to those microprobes employing the RIA-1 antisera, which show high counts and good
suppression under comparable conditions. Since the replacement antiserum had an IC50 of 38
pg/ ml, compared to the previous one of 3.4 pg/ ml, it was possible that this antiserum
contained a higher proportion of low affinity immunoglobulins, binding both the unlabelled
and radiolabelled peptide poorly, and this was responsible for its failure to perform
satisfactorily by the antibody microprobe technique.
Attempts were made to obtain another batch of CCK antiserum from Peninsula
Laboratories of the same original lot number, but since this was not possible other lot numbers
of CCK antiserum available were tested. This consisted of another polyclonal antiserum
prepared for use in radioimmunoassays [RAS 7181; Lot no. 020187-1], and one prepared for
use in immunocytochemistry (ICC) [RAS 7181N; Lot. no GO 19531 -1 ] all raised in under the
same conditions as RIA-1 and RIA-2. Neither antiserum however, performed satisfactorily
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TABLE 8. Comparison of the use of BSA vs. gelatin in radiolabeled peptide solution. The
results of an in vitro assay to determine whether gelatin in the tracer solution instead of BSA
had any effect on the failure of immobolised antibodies from Amersham to bind [125I]Bolton-
Hunter CCK-8(sulphated) are shown. Although the counts (cor.cpm) obtained for 'OM'
microprobes radioactive emission were slightly higher than that of background, poor
suppression of these counts was obtained by incubation in 10~7M sulphated CCK-8. This was
also true for microprobes bearing Peninsula antibodies.
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CCK-8 IN VITRO \24/ 4/ 951 - AMERSHAM CCK (RIA) ANTISERUM
- PENINSULA CCK (RIA-1) ANTISERUM
PROBE OM CCK-8 (S)
TYPE 10"7M
COR.CPM COR.CPM COR.CPM COR.CPM
[l25I]BH CCK-8 (S) MEAN ± S.E.M. [l25I]BH CCK-8 (S) MEAN ± S.E.M.
-6.1 10.3





PENINSULA 800.6 691.3 ±70.3 344.9 320.5 ± 23.6





AMERSHAM 179.7 100.3 ±20.7 34.0 87.1 ±34.0





PENINSULA 518.3 1293.6 ±228.3 954.0 1097.5 ±92.8




on in vitro testing. The ICC antiserum did show higher unsuppressed counts than the RIA
antisera but there was poor suppression of the binding of the tracer by the unlabelled peptide
and great 'scatter' amongst the counts obtained. This is illustrated on table 9. No
improvement was found by using gelatin or casein in the tracer buffer.
(v) Investigations into the lack of competency of replacement batches of Peninsula antiserum.
As indicated in appendix AI there are many possible explanations why antibody
microprobes can fail to perform satisfactorily on in vitro testing. Although the competency of
the replacement batches of Peninsula antisera was suspected, it was tested whether:
a) The radiolabelled peptide was binding non-specifically (either to the inner surfaces of
the glass microcapillaries or to non-antibody sites on the microprobes). This was
investigated by counting the radioactive emission of the capillaries following incubation of the
microprobes in tracer made up with BSA, gelatin or casein. No evidence for tracer binding to
the inner surfaces of the microcapillaries was found. That the radiolabelled peptide was also
not binding to the microprobe surface, which would result in an apparent poor suppression by
unlabelled peptide, was revealed by the failure of the tracer to bind microprobes in the absence
of immobilised antibodies, and the failure of non-related peptides such as substance P and
CGRP to cause any suppression of binding.
b) The presence of the iodinated Bolton-Hunter reagent on the NH2-terminus of CCK-
8(S) was interfering with the binding of the radiolabelled peptide to the immobilised
antibodies. Although the antiserum purchased from Peninsula Laboratories (as stated in
section 5.2.1) displayed only 14% cross reactivity with CCK-4, it is possible that the
antibodies could be recognising more the NH7-terminus of CCK-8. Thus, so if the antiserum
contained a higher proportion of low affinity immunoglobulins this could greatly effect the
ability of the tracer to bind to the immobilised antibodies and to apparently suppress the
binding of the unlabelled peptide. To test this an iodinated form of CCK was purchased
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TABLE 9. Investigations into the lack of competency of replacement batches of Peninsula
antiserum. The results of an in vitro assay testing the unsuppressed ('OM') and suppressed
(10_6M sulphated and desulphated CCK-8) binding of [l25I]Bolton-Hunter CCK-8(sulphated)
to microprobes prepared with either RIA-2 or ICC Peninsula antisera. Neither antiserum
performed satisfactorily.
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CCK-8 IN VITRO \22! 6/ 951 - PENINSULA CCK (ICC) ANTISERUM
A PENINSULA CCK (RIA-2) B PENINSULA CCK (ICC)
ANTISERUM ANTISERUM
PROBE TYPE COR.CPM COR.CPM COR.CPM COR.CPM
[CCK] [125I]BH CCK-8 (S) MEAN±S.E.M. [l25I]BH CCK-8 (S) MEAN±S.E.M.
486.4 1182.9
293.2 1038.8





CCK-8 (NS) 161.8 293.0 ±58.4 663.1 706.9 ±95.5




CCK-8 (S) 264.8 273.5 ±38.3 994.9 798.6 ±65.7
10"6M 281.4 (427%) 863.2 (432%)
120.6 831.2
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from Peninsula Laboratories prepared by the direct substitution of radioisotope l25I onto the
aromatic side-chain of the Tyr2 residue of desulphated CCK-8, as illustrated in figure 27B.
However, no improvement of the unsuppressed or suppressed binding of the tracer to any of
the antisera purchased from Peninsula was evident by in vitro testing.
That these antisera likely contained a high proportion of low affinity immunoglobulins and
this was the main reason for their poor performance on in vitro testing was supported by the
finding that if the microprobes were incubated in the concentration of unlabelled peptide for
longer periods of time more satisfactory suppression of tracer binding was achieved, as shown
in table 10 using the Peninsula ICC antisera and [l2<iI]CCK-8(NS) tracer.
(vi) Other sources of antiserum tested.
As well as the antisera already stated, other sources of antiserum selective for the COOH-
terminai of cholecystokinin were purchased and tested in vitro as described. These were from
Biogenesis Ltd., UK [2050-0309; Lot no. 950726C] and Affinity Research Products Ltd., UK
[CA 1127; Lot no. Z00049]. Both had been raised in rabbits against the COOH-terminus of
sulphated CCK-8 covalently conjugated to BSA prepared for use in radioimmunoassay.
When these antibodies were immobilised onto microprobes however, like those purchased
from Amersham International, they failed to bind either the Amersham or Peninsula
radiolabelled tracer.
(vii) Findings from radioimmunoassays.
Although the antibody microprobes technique follows the same basic principles of that of
the radioimmunoassay technique, as indicated in appendix A.I, there are differences, and
hence it is useful to check the performance of an antiserum by conventional
radioimmunoassay. This was done for the antisera described in this appendix for CCK
following the 'double-antibody' separation procedure outlined by Peninsula Laboratories. In
this the antibody-radiolabelled peptide complex is precipitated by an antibody directed
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TABLE 10. Investigation of prolonged incubation times on the success of unlabelled CCK to
suppress tracer binding. Increasing the contact desulphated CCK-8 with microprobes bearing
immobolised antibodies from Peninsula ICC antisera resulted in a more satisfactory
suppression of [125I]CCK-8(desulphated) binding.
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CCK-8 IN VITRO \2\! 8/ 95] - PENINSULA CCK (ICC) ANTISERUM
PROBE TYPE COR.CPM COR.CPM








































against the bound antibody (in this instance those present in normal rabbit serum), the 'second'
antibody being specific to the immunoglobulins of the species in which the bound 'first'
antibody was raised (in this instance those present in goat 'anti-rabbit' IgG serum).
It was found that the antisera purchased from Peninsula appeared to perform satisfactorily
under these conditions with good suppression of either tracer binding with a 10~8M solution of
the unlabelled peptide (both sulphated and desulphated). Interestingly, the antibodies present
within the RIA antisera purchased from Amersham International, Biogenesis Ltd. and Affinity
Research Products Ltd., although failing to bind the tracer purchased from Peninsula,
[l25I]CCK-8(NS), did bind that from Amersham, [125I]BoIton-Hunter CCK-8(S), as indicated
in table 11. This is curious since such a distinction had not been found when these antibodies
had been immobilised to microprobes.
(viii) Future studies
It is possible that sources of CCK antiserum could be found that will perform
satisfactorily when immobilised onto the microprobes, or that the manufacturers of the
antiserum indicated in this appendix may produce antiserum containing a greater proportion of
high affinity antibodies to CCK-8. Alternatively the use of gastrin antibodies should be
considered, since such antibodies will bind equally the COOH-terminus of CCK-8, and as
indicated in section 1.9, gastrin itself displays a very limited distribution in the CNS.
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TABLE 11. In vitro testing of antisera by radioimmunoassay. Comparison made between a
radioimmunoassay performed using (A) [l25I]CCK-8(desulphated) and (B) [l25I]Bolton-
Hunter CCK-8(sulphated), in both instances 10~6M desulphated CCK-8 was used to suppress
tracer binding.
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689.2+ 13.9 268.2 ±31.9
(4. 62%)




4644.2 ± i 15.6 1593.7 ±66.1
(4- 66%)




202.6 ± 18.2 230.9 ± 18.5
(4- 0%)




194.7 ±6.0 214.6 ± 13.1
(1 0%)




221.5 ± 16.6 189.1 ± 11.6
(4- 15%)
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Abstract
Microprobes bearing immobilised antibodies to dynorphin A(l_8) were used to study the basal and evoked release of this prodynorphin
derived peptide in the spinal cord of urethane anaesthetised normal rats and those with a peripheral inflammation. In the absence of any
active peripheral stimulus the antibody microprobes detected immunoreactive (ir)-dynorphin A(1_g) in two areas (lamina I and laminae
IV-V) in the dorsal horn of the spinal cord of normal rats. With the development of unilateral ankle inflammation over 3 to 5 days
following subcutaneous injections of Freund's complete adjuvant, a basal presence of ir-dynorphin A(]_8) was found in both the dorsal
and ventral horn regions of both sides of the spinal cord. Lateral compression of the ankles of the normal animals did not release
ir-dynorphin A(l_8) during the period of stimulation, but this neuropeptide was detected in increased amounts in the ventral horn
following the stimulus. By contrast, compression of inflamed ankles produced elevated levels of ir-dynorphin A(1_g) during the period of
stimulus application at three major sites in the ipsilateral spinal grey matter. The largest peak was in the deep dorsal horn/upper ventral
horn (laminae VI-VII), with further sites of significant release in the mid dorsal horn (laminae II—V) and the lower ventral horn. The
observation that ir-dynorphin A(1_g) is physiologically released in the ventral and deep dorsal in addition to the superficial dorsal horn of
the rat suggests an involvement of dynorphins in several aspects of spinal function.
Keywords: Dynorphin A(,_g); Peripheral inflammation; Spinal cord; Release; Antibody microprobe
1. Introduction
When inflammation develops peripherally, alterations
occur in the synthesis and release of neuropeptides in the
spinal cord. Such release has been studied directly with a
variety of techniques and an enhancement has been shown
for compounds contained within primary afferent fibres
such as substance P (SP) [18,57,65], neurokinin A [26],
and calcitonin gene related peptide (CGRP) [18,66], These
studies have revealed significant differences in the timing
of the enhanced release of these neuropeptides as inflam¬
mation develops, suggesting that there are evolving pro¬
cesses influencing the spinal processing of nociceptive
information.
There are no reports of altered spinal release of the
prodynorphin derived peptides as inflammation develops
peripherally and this is a significant omission, as it is this
Corresponding author. Fax:
awd@labO.vet.ed.ac.uk
(44) (131) 650-6576; e-mail:
family of neuropeptides which shows the greatest changes
in synthesis and spinal content with inflammation. Such
increases have occurred with dynorphin A(1_g) (prody¬
norphin 209-216) [34,35,51,52,63], dynorphin A(I_17)
(prodynorphin 209-225) [44,46,47,79,80] and a-neoen-
dorphin (prodynorphin 175-184) [61]. Preceding these rises
in neuropeptide levels, the messenger RNA levels for
prodynorphin in spinal neurones have also been found to
be increased [12,13,25,34-36,58,61,63,79],
An increased RNA message for prodynorphin could
simply be a response to prior release. It has been proposed,
however, that the immediate stimulus to elevated levels of
dynorphins is increased transcription of the prodynorphin
gene through cellular immediate early gene products, such
as c-fos. There is a close temporal link between the
increases in c-fos and messenger RNA levels for prodynor¬
phin observed in the spinal cord of the rat on the induction
of a peripheral inflammation [12,42,53] and the co-locali¬
sation of c-fos and the prodynorphin message within single
neurons of the spinal cord [42,53,56], Since the gene for
c-fos is expressed by many neurones of the spinal cord in
0006-8993/96/S15.00 © 1996 Elsevier Science B.V. All rights reserved
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response to the arrival of impulses in nociceptive primary
afferents [1,7,17,19,20,28,33,41,55,56], it is possible that
the increased synthesis of dynorphins is a primary re¬
sponse to this input and not a homeostatic secondary
response following prior release. Supporting this proposal
is the finding of synapses between dynorphin containing
spinal neurones and CGRP and SP containing presumed
primary afferent fibres [4,9,73,74], and more recently from
the demonstration that intrathecal pretreatment with an
antisense nucleotide to c-fos mRNA synthesis inhibits the
increase in the synthesis of prodynorphin by spinal neu¬
rones following peripheral inflammation [29].
Such considerations indicate the need to determine the
adequate stimuli producing a spinal release of dynorphins
under in vivo conditions both in normal animals and in
those with peripheral inflammation. Specifically, are
dynorphins tonically released in both normal and inflamed
animals and is such release increased or decreased by
manipulation of the inflamed tissues? The present experi¬
ments have employed microprobes bearing immobilised
antibodies to dynorphin A(1_g) to study the release of
immunoreactive (ir)-dynorphin A(1_g) in the spinal cord of
normal rats and those with a unilateral ankle inflammation.
We chose dynorphin A(1_8) since there is evidence that
this peptide is the major end product of the processing of
prodynorphin in several areas of the central nervous sys¬
tem, including the spinal cord [72,77], and it is this form of
the dynorphin molecule which has been most extensively
studied in relation to peripheral inflammation
[34,35,51,52,63],
2. Materials and methods
2.1. Microprobe preparation
Antibody microprobes for the detection of ir-dynorphin
A(1_g) were prepared following the technique previously
described [14,15], Briefly, conventional glass micropipettes
were heat sealed at both ends and incubated for up to 24 h
in a 10% solution of y-aminopropyltriethoxysilane in
toluene. This procedure produced a fine, granular siloxane
polymer with free amino groups on the outer surface of
each microprobe to which protein A (Sigma Chemical,
UK) was immobilised with glutaraldehyde. Protein A, is a
staphylococcal derived protein which binds to the Fc re¬
gion of some subclasses of IgG antibodies and this prop¬
erty was utilised to bind immunoglobulins present in a
polyclonal antiserum raised in rabbits against the C termi¬
nus of dynorphin A(1_8) (Peninsula Laboratories Europe
UK), to microprobes.
2.2. Animal preparation
A total of 35 male Wistar rats (weight range 250 to 422
g; Charles River, UK) were used in this study.
2.2.1. Induction ofperipheral inflammation
Eighteen animals received 4 subcutaneous injections of
Freund's complete adjuvant (FCA, Sigma Chemical, UK,
1.0 mg/ml, total volume of 0.15 ml) around one ankle
joint, either under diethyl ether or halothane anaesthesia,
3-5 days before being used in an experiment. Throughout
this time the animals were monitored for the development
of any secondary swellings at other peripheral sites, and
the circumferences of both ankles were measured on the
day of the experiment. These injections resulted in a
swelling of the ankle region, from an average diameter in
normal animals of 2.7 cm to 4.0 cm. Previous histological
studies by other groups [22] have shown that the inflamma¬
tion resulting from this procedure involves both the joint
and periarticular tissues (connective tissue, tendons and
overlying skin). Injected animals showed little or no appar¬
ent discomfort, gait impairment or weight alteration. An
additional six rats received FCA injections on the morning
of the experiment, to allow study of the release of ir-dy-
norphin A(1_8) at an early phase of the inflammatory
response.
2.2.2. Surgical procedure
Anaesthesia was induced by a single intraperitoneal
(i.p.) injection of 1 g/kg urethane (25% solution). Cannu-
lae were then inserted into the trachea, a carotid artery and
an external jugular vein, to aid unobstructed breathing, and
to permit direct measurements of arterial blood pressure
and the intravenous injection of substances respectively.
The depth of the anaesthesia was continually assessed by
monitoring blood pressure and ensuring that the corneal
blink and hindpaw withdrawal reflexes remained absent.
Further injections of urethane were given i.p. when neces¬
sary to maintain a satisfactory level of anaesthesia. Blood
oxygenation was assisted by directing a gentle jet of
humidified oxygen towards the opening of the tracheal
cannula. The animals body temperature was monitored
with a rectal probe and maintained between 36-38°C using
a controlled heating system.
An extended laminectomy was made at vertebral levels
Tjo—L2 to expose the dura mater and the lumbar spinal
cord (spinal segments L[-L6) receiving input from the
ankle joint area. The animal was supported in a metal
frame and six swan neck clamps were positioned under
alternate mammillary processes of the exposed vertebrae.
'A solid agar pool was formed at the site of the laminec¬
tomy into which a window over the lumbar spinal seg¬
ments was made. Following opening of the dural sac with
sterile forceps, the exposed spinal cord was irrigated with
sterile Ringer's solution at 37°C continuously throughout
the experiment. Any excess fluid was removed by suction
at an edge of the opening. Although continuous irrigation
minimised the collection of inflammatory exudates on the
surface of the cord, it was often necessary to remove any
small accumulations of fibrinous material from pia open¬
ings with sterile fine forceps and hand controlled suction.
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2.3. Experimental protocol
Before microprobes were inserted into the spinal cord,
the suitability of potential penetration sites was examined
by recording (with a 4 M NaCl filled microelectrode) the
excitatory responses of neurones in the deep dorsal horn
(approximately 0.6 to 1.0 mm from the dorsal surface of
the spinal cord) to light mechanical cutaneous stimuli. In
order to permit microprobe entry it was often necessary to
remove the pia mater at these sites using sterile fine
forceps. Microprobes were broken back to give tip diame¬
ters of approximately 10 p.m and some were filled with
Pontamine sky blue 2% (w/v) in 1.2 M sodium acetate
solution to allow easy visualisation of the tips for accurate
placement in the cord. Pairs of labelled microprobes were
introduced into the same side of the spinal cord to a depth
of 2.25 mm from the dorsal surface using two stepping
motor driven micromanipulators. Initially, microprobes
were kept in the cord for 5, 15 or 30 min but as prelimi¬
nary analysis indicated that the probability of binding any
dynorphin A(I_g) increased with length of time in the
spinal cord, all later experiments employed incubation
times of 30 min. During these periods either no stimulus
was applied or the ankle joint was mechanically manipu¬
lated.
Since the most likely stimulus producing pain from
inflamed skin, joints or tendons is that resulting either
from direct physical contact with an environmental object
or movement of the damaged tissues, the ankle joint region
was only subjected to mechanical stimulation. A typical
protocol was 3 min of mechanical stimulation followed by
2 min of no stimulation. In the initial experiments the
inflamed tissues were compressed laterally, with a modi¬
fied strong spring clip. In later experiments this stimulus
was quantified by the application of a pneumatic compres¬
sion device incorporating a strain gauge for measuring
applied force and employing electronic control of the times
of application. Typically, a force of 14.7 N was applied,
the surface area of the compression device contacting the
rat ankle being 20 mm2.
Although inflammation was induced unilaterally, pairs
of microprobes were inserted into both sides of the spinal
cord, comparable stimuli being applied to the inflamed and
uninflamed hind limbs. With each side of the spinal cord,
periods of no stimulation usually preceded those of me¬
chanical stimulation to the ipsilateral ankle region but also
often followed them. Due to uncertainty on the persistence
of any possibly released ir-dynorphin following peripheral
stimulation, it was usual to perform periods of peripheral
stimulation (and associated periods of no stimulation) only
twice, once on each side of the spinal cord. In six experi¬
ments, however, the chosen protocol was carried out more
than once on one side of the cord and a time of at least 2 h
elapsed between periods of stimulation.
At the end of each experiment Pontamine sky blue was
ejected iontophoretically at several defined sites in the
spinal cord. The cords were then removed, fixed and
sectioned to determine the location of the resultant dye
spots. These data were essential to allow locations on the
probes to be related to positions within the spinal cord.
2.4. Treatment of microprobes and data analysis
Upon removal from the spinal cord, microprobes were
washed for 15 min in ice-cold phosphate-buffered saline
(PBS) containing 0.1% Tween-80 (Pierce and Warner Ltd,
UK) and then incubated for approximately 24 h at 6°C in
capillaries (treated with Sigmacote to prevent binding of
peptides to glass) containing [125I]dynorphin A(1_g)
(porcine; Peninsula, UK) diluted in a PBS azide solution
containing bovine serum albumin (0.1%). The final dilu¬
tion of the radiolabelled peptide resulted in approximately
2000 counts min 1 fiL1. After a final 15 min wash in ice
cold PBS Tween-80 (0.1%) solution, the distal portions of
the microprobes were broken off, mounted on a sheet of
paper and placed in a cassette next to monoemulsion X-ray
film (Kodak NMB) for 3-5 days. At least two films were
derived from each experiment. The resultant microprobe
autoradiographs were analysed with a computer based
image analysis system employing an Imaging Technology
PC Vision Plus frame grabber board operating in a DCS
286e (AT based) computer, as previously described [23], A
charged coupled device camera scanned each image start¬
ing at the tip, and following background subtractions, a
transverse integration of optical density on a scale of
0-255 was performed for each microprobe at defined
intervals. With the resolution of the analysis system used,
this gave a 10 p.m interval between each integration.
However, since this was beyond the biological resolution
of the microprobe method (see Duggan [14]), the average
of three successive integrals was taken to give a final
plotted resolution of 30 ^m. For each microprobe, the
resultant plot of integrated optical density (grey scale) with
respect to length together with coded information which
described the experimental and stimulus conditions for that
particular microprobe, were stored in a computer file.
Regions of bound endogenous ir-dynorphin A(1_g) along
the length of each microprobe have been equated with
relative deficits in the tracer binding, that are represented
graphically as comparatively low grey scale values. A
sorting program was then used to retrieve defined groups
of these microprobes and produce for each group a plot of
the mean grey scale values ( + S.E.M. in 30 /xm steps)
with respect to depth within the spinal cord. Differences
between groups were determined, the significance of the
differences at each of the 30 pm analysis points being
estimated using the Student's r-test. Release was equated
with increased extracellular levels produced by a stimulus.
It should be noted that with mean image analyses of results
from several microprobes, the location of sites of release is
less precise than with individual microprobes. Although all
microprobes were inserted 2.25 mm into the spinal cord,
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the relationship of spinal laminae to distance to the tip will
vary slightly between animals and with distance from the
midline within any one animal.
2.5. In vitro tests
The antiserum used was polyclonal and directed against
the C-terminus of dynorphin A(1_g) (porcine). The manu¬
facturer stated that this antibody had negligible cross reac¬
tivity (< 0.01%) for the prodynorphin derived peptides
prodynorphin (209-240), dynorphin A(1_17), dynorphin
A(i_i3), dynorphin B(1_]3), a-//3-neoendorphin and zero
cross-reactivity for other tested opioid peptides, e.g.,
Leu/Met enkephalins. In parallel with the present experi¬
ments, the sensitivity of the prepared antibody microprobes
was regularly assessed by incubating a small number either
directly in [125I]dynorphin A(1_8) or a range of concentra¬
tions (10~5 to 10~y M) of unlabelled dynorphin A(1_g)
(Peninsula) in vitro at 37°C for 30 min prior to the
incubation in a solution of [l2:T]dynorphin A(1_g) (porcine)
for approximately 24 h at 6°C. Following washing in
PBS/Tween-80, the distal portion of these microprobes
were broken off, mounted on small pieces of cardboard
and placed in tubes for processing by a gamma counter.
X-ray images of these in vitro probes were also obtained.
The counts of total radioactivity of microprobe tips
indicated that over 10% of the total radioactivity in which
they had been incubated bound to the microprobes. In vitro
tests indicated that a 10~7 M solution of dynorphin A(1_g)
(porcine) suppressed such binding by greater than 55%,
with a 10~5 M solution resulting in greater than 80%
suppression. Hence, it can be assumed that the non-specific
binding for these microprobes accounts for less than 20%
of the total binding. Information supplied by the manufac¬
turer on the specificity of the antiserum was confirmed on
microprobes by demonstrating negligible or zero suppres¬
sion of binding of [125I]dynorphin A(1_g) by a range of
concentrations of the peptides dynorphin A(1_17), dynor¬
phin A(1_13) and Leu-enkephalin (Peninsula).
3. Results
A total of 496 microprobes coated with antibodies to
dynorphin A(1_g) inserted into the rat spinal cord form the
basis of this analysis. An additional 572 microprobes were
used for in vitro sensitivity tests.
3.1. Basal levels of immunoreactive (ir) dynorphin A<1_8)
Since the primary aim of this study was to study the
release of ir-dynorphin A(1_g) in animals with a developed
peripheral inflammation, it was necessary to make compar¬
isons between normal rats and those with unilateral ankle
inflammation. In the case of the latter group, the release of
ir-dynorphin A(1_g) was examined in both sides of the
spinal cord.
A basal presence of a neuropeptide at a particular site in
the nervous system is inferred by differences between the
mean image analysis of microprobes not inserted into the
nervous system but simply incubated in the radiolabeled
ligand, and that of microprobes placed in the relevant area
for a comparable time but in the absence of any active
stimulus. Such comparisons indicated that ir-dynorphin
A(i_g) was present in the spinal cord of normal rats and
both sides of the spinal cord of those with developed
unilateral ankle inflammation under these 'basal' condi¬
tions. As microprobes present in the spinal cord for 5 or 15
min failed to detect ir-dynorphin(1_8) consistently, the data
presented below were derived from microprobes present
for 30 min in the spinal cord only.
3.1.1. Normal animals
Fig. 1A compares the mean image density scan of
microprobes (n = 77) present in both sides of the spinal
cord of normal rats for periods of 30 min and prior to any
mechanical stimulation of the corresponding ankle regions,
with that of in vitro microprobes in — 98) that had only
been exposed to radiolabelled dynorphin A(1_g) but pro¬
cessed concurrently with those used in vivo. Fig. IB plots
in 30 /urn intervals the 't' statistics derived from the
differences between the mean image analyses of the two
groups. The hatched area indicates where these differences
are significant at the P < 0.05 level (r>2) and this is
approximately from 0.5 to 1.0 mm from the dorsal surface
of the spinal cord. Thus, in normal animals extracellular
ir-dynorphin A(1_g) was present in zones of both the
superficial and deep dorsal horn approximating to laminae
I and 1V-V.
3.1.2. Animals with developed unilateral ankle inflamma¬
tion - ipsilateral side of the spinal cord
A more extensive basal presence of ir-dynorphin A(1_g)
was found in the ipsilateral side of the spinal cord (58
microprobes) in animals with unilateral ankle inflamma¬
tion than in normal animals. When compared with in vitro
microprobes (not inserted into animals) significant levels
of ir-dynorphin A (1_g) were found from the dorsal surface
'of the spinal cord down to 2.0 mm from the dorsal surface
(not illustrated). This approximates to the whole of the
dorsal horn and ventral horn. Fig. 2 illustrates differences
between the mean image analysis of microprobes in this
group and that of microprobes present in the spinal cord of
normal animals but without added stimulation.
This shows comparable basal levels of ir-dynorphin
A(1_g) in the dorsal horn of normal and inflamed animals
but significantly greater levels of this neuropeptide at
many sites in the ventral horn of rats with peripheral
inflammation.
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3.1.3. Animals with developed unilateral ankle inflamma¬
tion - contralateral side of the spinal cord
The basal extracellular levels of ir-dynorphin A(1_g) in
the contralateral side (34 microprobes) of the spinal cords
of animals with developed ankle inflammation were found
to be comparable to those present in the ipsilateral side
under these basal conditions. Fig. 3 illustrates the nearly
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Fig. 1. Basal presence of ir-dynorphin A(1_g) in the spinal cord of normal
rats. A: the mean image analyses of two groups of microprobes are
plotted with respect to length: those present in the spinal cord of normal
animals for 30 min in the absence of any peripheral stimulation (normal
rats, no stimulus, n = 77) and those which are not inserted into the spinal
cord but simply incubated in [125I]dynorphin A(1_g) (in vitros, n = 98).
With each mean image analysis the mean grey scale was determined in
30 /rm intervals, a line joining these points. At each analysis point the
standard error mean (S.E.M.) is also plotted, (+) for no stimulus and (-)
for in vitros. B: a plot of the t statistics derived from the standard error of
the differences of means at each analysis point in the mean image
analyses shown in A, is related to an outline of the spinal cord at the area
sampled. The hatched areas indicate the sites where these differences are
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Fig. 2. Effect of peripheral inflammation on the basal levels of ir-dy-
norphin A(1_g) in the ipsilateral side of the spinal cord. A: the mean
image analysis of 58 microprobes present for 30 min in the ipsilateral
side of the spinal cord in rats with a unilateral ankle inflammation in the
absence of any added stimulation (inflamed rats, ipsilateral side) is
compared to that of microprobes present under similar basal conditions in
normal rats (normals, n = 77). B: the differences between the two groups
of microprobes are plotted with respect to depth in the spinal cord. Since
only isolated points attain significance at the P < 0.05 level, there is no
hatching as in Fig. 1.
3.2. The effect of lateral compression of the ankle region
3.2.1. Microprobes present in the spinal cord during stim¬
ulus application
Although significant basal levels of ir-dynorphin A(1_g)
were present in both normal rats and those with unilateral
ankle inflammation, these animals differed markedly in
their responses to lateral compression of the ankle.
3.2.1.1. Normal animals. The application of lateral com¬
pression to the ankle joint and surrounding tissue of nor¬
mal rats failed to increase extracellular levels of ir-dy-
norphin A(,_g) during the period of stimulus application.
No significant differences were found between the mean
image density scans of microprobes (n = 29) present in the
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Fig. 3. Comparable basal presence of ir-dynorphin A(1_8) in both sides of
the spinal cord of rats with unilateral inflammation. This figure compares
the mean image analysis of microprobes present for 30 min in the
ipsilateral side of the spinal cord of rats with unilateral ankle inflamma¬
tion (ipsilateral side, n = 58) to that of microprobes present in the
contralateral side of the same animals in the absence of any added
stimulation (contralateral side, n = 34).
ipsilateral spinal cord during the application of the me¬
chanical stimuli and those microprobes (n = 56) present in
the same animals in the absence of any prior stimulation,
as illustrated in Fig. 4.
3.2.1.2. Animals with developed unilateral ankle inflamma¬
tion - ipsilateral side of the spinal cord. Lateral compres¬
sion of the ankle with a developed inflammation, signifi¬
cantly increased the extracellular levels of ir-dynorphin
A(1_g) above those found under basal conditions in the
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Fig. 4. Failure to release ir-dynorphin A(1_8) during a period of ankle
compression in normal animals. The mean image analyses of the 29
microprobes present in the spinal cord for 30 min during the application
of the mechanical stimuli (lat. ankle compression, n = 29) is compared to
that of microprobes present in the same animals in the absence of any
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Fig. 5. Release of ir-dynorphin A(l 8) during compression of the in¬
flamed ankle. A: the mean image analysis of 30 microprobes present in
the ipsilateral side of the spinal cord during the 30 min period of noxious
mechanical stimulation (inflamed ankle compression) is displaced above
that of microprobes present in the same side of these spinal cords for an
identical time period prior to this stimulus (no stimulus, n = 47). B: the
differences between the two groups of microprobes are plotted with
respect to a diagram of the spinal cord. The hatched areas indicate where
these differences are significant at the P < 0.05 level.
5A in which the mean image analysis of microprobes
(n = 30) present in the ipsilateral side of the spinal cord
during the 30 min period of noxious mechanical stimula¬
tion can be seen to be displaced above that of microprobes
(n = 47) present for an identical time period prior to this
stimulus in the same animals, but in the absence of any
added peripheral stimulation. These enhanced extracellular
levels of ir-dynorphin A(1_g) were found to be statistically
significant at the P < 0.05 level at nearly all sites sampled
from 0.25 mm to 2.2 mm from the dorsal surface of the
spinal cord. As Fig. 5B shows, there were three main sites
of release. The largest peak was in the deep dorsal/upper
ventral horn (laminae VI-VII), with further major sites in
the mid dorsal horn (laminae II-V) and the lower ventral
horn. No study was made of possible contralateral release
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of ir-dynorphin(1_8)
ankle.
during compression of the inflamed A o -i
3.2.1.3. Animals with developed unilateral ankle inflamma¬
tion - contralateral side of the spinal cord. Equivalent
analysis of the effect of ankle compression on the normal
side of animals with unilateral inflammation failed to show
any such evoked release of ir-dynorphin A(1_8). Thus, the
mean image analysis of microprobes (n = 12) present in
the side of the spinal cord contralateral to the peripheral
ankle inflammation and during lateral compression of the
normal ankle displayed no significant differences from that
of microprobes (n = 28) present in the same side of the
spinal cord under basal conditions (not illustrated).
3.2.2. Microprobes present in the spinal cord after the
application of mechanical stimuli
Since there is evidence that some neuropeptides are not
rapidly degraded after release in the central nervous sys¬
tem [16,26], it was important to examine the decline of any
enhanced presence of extracellular ir-dynorphin A(1_g) af¬
ter application of a peripheral stimulus. The mean image
analyses of microprobes inserted before or during prior
mechanical stimulation of the ankle joint region were
compared to those of microprobes present for equivalent
30 min periods, up to 1.5 h after lateral compression of
these peripheral tissues.
3.2.2.1. Normal animals. No increase in the extracellular
levels of ir-dynorphin A(1_g) was observed in the spinal
cord during mechanical compression of the ankle region of
normal rats. However, as illustrated in Fig. 6, comparisons
between the mean image analysis of microprobes inserted
prior to the application of lateral compression (n = 55) and
that of those present in the corresponding 30 min period
post-stimulation (n = 21), showed elevated levels of the
ir-dynorphin A(1_g) in the lower ventral horn after the
application of ankle compression.
3.2.2.2. Animals with developed unilateral ankle inflamma¬
tion — ipsilateral side of the spinal cord. Fig. 7 illustrates
extracellular ir-dynorphin A(1_g) in the ipsilateral side of
the spinal cord before, during and for 1 h after the lateral
compression of the inflamed ankle. Fig. 7B shows that the
mean image analysis of microprobes (n — 21) present for
the first 30 min period after lateral compression of the
inflamed tissues of the ipsilateral ankle joint was displaced
above that of microprobes (« = 36) present in the same
side of these spinal cords prior to such peripheral stimula¬
tion. No significant differences however were found be¬
tween these 'post-compression' microprobes and those
present in the spinal cord during this noxious mechanical
stimulation (n = 28, not illustrated).
The mean image density scans of microprobes (n = 14)
present in the spinal cord for the period 35-65 min
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Fig. 6. Release of ir-dynorphin A(|_8) in the spinal cord following ankle
compression in normal rats. A: the mean image analysis of 21 micro¬
probes present in the 30 min period post ankle compression (5-35 min
post ankle compression) is displaced above that of microprobes present
prior to the application of this mechanical stimulus (no stimulus, n = 55).
B: the differences between the post ankle compression and no stimulus
groups are plotted with respect to a diagram of the spinal cord. The
hatched areas indicate where these differences arc significant at the
P < 0.05 level.
vated above those placed under 'basal' conditions, as
illustrated in Fig. 7C. However, ir-dynorphin A(l_g) levels
in the ipsilateral side of the spinal cord had returned to
pre-stimulation 'basal' levels after a period of 2 h, as no
significant difference was found between the mean image
density analyses of microprobes (n = 8) inserted ipsilater-
ally in the absence of any prior or concurrent added
stimulation and those microprobes (n = 8) inserted into
this side of the cord again after a period of at least 2 h (not
illustrated).
3.2.2.3. Animals with developed unilateral ankle inflamma¬
tion - contralateral side of the spinal cord. Equivalent
analysis revealed that mechanical manipulation of the nor¬
mal ankle of animals with unilateral inflammation had not
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initiated any effect on the levels of ir-dynorphin A(1_g)
presence under basal conditions. Thus, the mean image
analysis of microprobes (n = 10) present in the side of the
spinal cord contralateral to the peripheral ankle inflamma¬
tion for the first 30 min period following lateral compres¬
sion of the normal ankle displayed no significant differ¬
ences from that of microprobes (n = 20) present in the
same side of the spinal cord of these animals prior to
application of this ankle compression.
3.3. Release of ir-dynorphin A(l_8) in the spinal cord
during the development of unilateral ankle inflammation
In view of the temporal analysis performed by other
groups [12,34-36,42,53] on the expression of the message
for prodynorphin, it was of interest to study the release of
ir-dynorphin A(1_g) in the spinal cord at an early phase of
the inflammatory response. Microprobes present in the
spinal cord for 15 or 30 min during the third to the eighth
hour after the FCA injections, in the absence of any
additional peripheral stimulation were compared (a total of
79 microprobes; an average of 15 microprobes being in¬
serted for each hourly period). Comparisons were also
made to those in vitro microprobes that had only been
exposed to radiolabelled dynorphin A(1_g) but processed
concurrently with those in vivo (18 microprobes). Analysis
of the data from six experiments provided no evidence that
levels of ir-dynorphin A(1_8) were significantly enhanced
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Fig. 7. Persistently raised levels of ir-dynorphin A(1_8) in the spinal cord
following compression of the inflamed ankle. For A, B and C the
no-stimulus group represents 36 microprobes present for 30 min in the
ipsilateral side of the spinal cord of inflamed rats prior to any added
stimulation. In A, the mean image analysis of this group is compared with
that of 28 microprobes inserted during compression of the inflamed ankle
(lateral ankle compression); in B, the comparison is with the mean image
analysis of 21 microprobes present in the first 30 min period after this
noxious mechanical stimulus in the same side of these spinal cords (5-35
min post ankle compression); in C, the comparison is with the mean
image analysis of 14 microprobes inserted under similar conditions in the
same experiments but present in the second 30 min period post ankle
compression (35-65 min post ankle compression).
4. Discussion
The present experiments have detected ir-dynorphin
A(1_8) in both normal rats and those with peripheral
inflammation, but have found significant differences be¬
tween the two groups. In the absence of any active periph¬
eral stimulus, extracellular ir-dynorphin A(1_g) was found
in the dorsal horn of normal rats but occurred throughout
the dorsal and ventral horns of both sides of the spinal
cord in rats with unilateral ankle inflammation. Differences
were also seen when the ankle region was subjected to
lateral compression. Ir-dynorphin A(1_8) appeared in the
ventral horn not during, but after the period of compres¬
sion in normal animals. With inflamed animals, compres¬
sion of the inflamed ankle did result in release of ir-dy¬
norphin during the period of stimulus application. This
produced elevated levels at three main sites in the spinal
grey matter. The largest peak was in the deep dorsal/up¬
per ventral horn, with further sites of significant release in
the mid dorsal horn and the lower ventral horn.
In order to consider the possible significance of our
findings, it is first necessary to consider the possible
sources of release of dynorphins in the spinal cord of
normal rats and those with peripheral inflammation. The
relevant structures include primary afferent fibres, intrinsic
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neurones of the spinal cord and the spinal terminations of
fibres of supraspinal origin. In normal animals many ra¬
dioimmunoassay studies have shown higher levels of ir-
prodynorphin derived peptides in the dorsal horn compared
to the intermediate or ventral horn zones of the mam¬
malian spinal cord (rat [3,45,60,81], rabbit [3], human
[62]). Immunocytochemical studies in normal animals have
localised ir-prodynorphin derived peptides mainly in cells
and terminals of lamina I—II and lamina IV-VI of the
mammalian spinal cord with moderate concentrations in
lamina X (rat [8,9,37,38,48,49,52,63,76,79,80], cat
[2,11,48,49]). It should be noted that most of these studies
have used colchicine treated animals and hence favour
detecting presence in cell bodies. Moreover, studies of
mRNA for prodynorphin only locate sites of synthesis
within cell bodies, and in normal rats these have been
found mainly in the superficial and deep dorsal horn
[36,58,59,61,63,79], The induction of a peripheral inflam¬
mation has been found to increase the spinal content of
these ir-prodynorphin derived peptides in studies in the rat
employing radioimmunoassay [34,46,47,63] and immuno¬
cytochemical techniques [44,51,52,63,73,74,79,80]. This
increase in peptide content has been shown to be preceded
by an enhancement in the expression of the RNA message
for prodynorphin [58,59,61,63,79] by cells in the superfi¬
cial dorsal horn (laminae I—II), but notably also in deep
dorsal horn (laminae IV-VI) neurons. In addition, under
these conditions, neurons dorsolateral to the central canal
(laminae VI, VII and X) have also been observed to
contain high levels of prodynorphin mRNA [59,79],
Despite the presence of ir-dynorphin near the sites of
termination of primary afferents in the dorsal horn, there is
little evidence to support a significant presence of dynor-
phin in primary afferents, particularly in lumbar segments
[2,72,78]. Dorsal rhizotomy has had little or no effect on
the levels of ir-dynorphin in both the dorsal and ventral
horns of the spinal cord [3,38,60], There is also little
evidence to support a significant presence of dynorphin in
the spinal terminals of fibres of supraspinal origin [3,43],
Thus it appears that the cells releasing ir-dynorphin(1_g) in
the present studies were predominantly intrinsic spinal
neurones with their cell bodies in the superficial and deep
dorsal horn. It needs to be emphasised, however, that
where dynorphins are released will depend on the projec¬
tions of these dynorphin-containing cells.
It has been suggested that some dynorphin-containing
spinal neurones project to supraspinal areas [40,50-52,69],
More recent immunocytochemical studies, notably on
non-colchicine treated animals, however, have emphasised
the finding of ir-dynorphin labelled varicose fibres sur¬
rounding both large and intermediate sized motoneurones
[37,38,79]. Klein et al. [38] found that the rat differed from
the cat and primate in this respect. The location of the cell
bodies of these dynorphin containing varicosities in the
ventral horn were not known, but it is probable that they
were intrinsic spinal neurones with their cell bodies lo¬
cated more dorsally. Such connections could be inter- and
intra-segmental. Klein et al. [38] also found that electrical
stimulation of the small and large diameter fibres of the
ipsilateral sciatic nerve (1 Hz for 20 min) depleted ventral
horn ir-dynorphin A(1 g). If such depletion results from
prior release then these findings are in accord with some
observations of the present experiments, where release in
the ventral horn in addition to the dorsal horn was a
prominent finding.
In antibody microprobe studies, a significant basal pres¬
ence of a compound could result from a tonic release from
an unknown stimulus, or from a continuous afferent input
in nociceptors and other fibres as a result of the surgery
required for these preparations. A contribution from cells
and fibres ruptured during the introduction of microprobes
cannot be excluded, although differing basal patterns ob¬
served in rats with microprobes bearing antibodies to
differing peptides makes it unlikely that this is a signifi¬
cant factor [27,39,66], Although the similar basal presence
of ir-dynorphin A(1_8) in the dorsal horn of normal and
inflamed rats could be the result of surgery, an enhanced
afferent input was almost certainly responsible for the
increased levels in the ventral horns of inflamed rats,
particularly as active manipulations of the inflamed ankle
region increased these levels still further. In the normal cat
a basal presence of ir-dynorphin A(1_17) was detected by
Hutchison et al. [30] using antibody microprobes, but the
consequences of peripheral inflammation were not exam¬
ined. The finding of bilateral increases in ventral horn
ir-dynorphin in animals with a peripheral inflammation,
when compared with normal animals, was unexpected,
particularly as most studies of the changes in the messen¬
ger RNA levels for prodynorphin following unilateral in¬
flammation have found only ipsilateral increases
[12,13,34-36,58,63,79], Przewlocka et al. [61], however,
observed bilateral increases in the prodynorphin mRNA in
the superficial dorsal horn following unilateral hindlimb
inflammation but at relative later stages (5 and 14 days
post-injection). An alternative explanation for our finding
of bilateral increases in released ir-dynorphin A(]_8) asso¬
ciated with peripheral inflammation is that some of the
cells containing this neuropeptide project bilaterally to the
ventral horn.
There is evidence that immediate early gene products,
such as c-fos, are responsible for the increased synthesis of
prodynorphin following a spinal input from peripheral
nociceptors (see Section 1). The delayed increase in ven¬
tral horn levels of ir-dynorphin A(1_8) following lateral
compression of the ankle of normal rats may have resulted
from such a mechanism. This implies a relatively rapid
process (30 to 60 min) within which the arrival of an input
in nociceptors is translated into increased expression of a
gene and the release of a neuroactive product of that gene.
Messenger RNA blot analysis has revealed a rapid and
pronounced elevation in immediate early genes encoding
c-fos and related proteins in the spinal cord within 30 min
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of the injection of an inflammatory agent into the rat
hindpaw [12,28,29], Messenger RNA for prodynorphin in
the spinal cord has been found to be increased within 4 h
of the peripheral injection of an inflammatory agent
[12,13,29,34,35,44], Our studies of released ir-dynorphin
A(1_8) suggest that the process of synthesis and release is
occurring more quickly than can be revealed by indirect
methods relating to release, such as mRNA expression and
immunocytochemistry. Our finding of elevated levels of a
neuropeptide both during and after a peripheral stimulus
we would normally interpret as indicating a slow degrada¬
tion following release, with the opportunity for diffusion to
regions remote from sites of release [16,64], This may still
occur with dynorphin A(1_g), but it is possible that lateral
compression of the inflamed ankles induced further synthe¬
sis and release of this neuropeptide.
Active manipulation of the inflamed tissues was an
adequate stimulus for spinal release of ir-dynorphin in the
present experiments. This is an important finding, since
much of the recent literature emphasises the hyperex-
citability of spinal neurones associated with peripheral
inflammation [21,24,31,54,67,68] and has directed much
research towards defining the neurochemical basis of such
hyperexcitability. Although the effects of topically admin¬
istered dynorphins led Hylden et al. [32] to propose these
compounds as producing hyperexcitability of spinal neu¬
rones, Stiller et al. [71] found that the k opiate antagonist
nor-binaltorphamine enhanced the firing of spinal neurones
in animals with peripheral inflammation. Significantly,
firing to manipulation of inflamed peripheral tissues was
also enhanced by the k antagonist, suggesting that re¬
leased dynorphins were acting to inhibit cellular responses.
It appears that when inflammation develops peripherally, a
complex response occurs in the spinal cord that involves
both inhibitory [5,55,70] and excitatory neuroactive com¬
pounds [6,10,16,65,75].
Our finding of both basal and evoked release of ir-dy¬
norphin, ,_8) in several areas of the spinal cord does sug¬
gest an involvement of dynorphins in several aspects of
spinal processing. Release in the superficial dorsal horn
may be related to antinociception. The prominence of
evoked release in the deep dorsal horn together with the
ventral horn could reflect an influence on interneurones
and motoneurones mediating spinal reflexes and
supraspinal control of reflexes. Thus effects on motor
behaviour, perhaps related to immobility and healing, are
possible.
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